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Abstract 
 
The role of cell-cycle phase in cytokine-induced lineage production has long 
been a point of debate. The main shortcomings in todays’ research are the lack of live 
cell-cycle observation in primitive primary cells and a fast yet robust read-out that 
allows detection of all lineages in vitro. Furthermore, a clonal ex vivo/in vitro culture 
would be favorable to current analyses that are mostly performed on a population 
scale since by doing so, a direct effect can be detected and potential influences and 
contaminations from other cells can be excluded.  
 
The data I present in this thesis provides answers to these questions by employing 
high-throughput methods that overcome all of these hurdles. Through use of a live 
cell-cycle reporter combined with time-lapse imaging at single-cell resolution, cell-
cycle durations and transitions were quantified in hematopoietic stem cells (HSCs) 
over multiple generations. I demonstrate a strongly heterogeneous behavior of highly 
purified primitive stem cells, allowing me to assess the influence of cell-cycle on 
lineage production upon cytokine administration by use of optimized culture 
conditions and live antibody staining.  
 
Here, evidence is provided that HSCs that produce all myeloid lineages not only 
are more frequently found in G1-phase upon cytokine administration but also have a 
longer G1-phase, which can be observed over multiple generations. Strikingly, when 
cytokines were administered to daughter cells the same phenomenon could be 
observed, showing the reoccurrence and reversibility of this feature. To test whether 
this is a cell-intrinsic effect rather than an effect of cytokine administration, HSCs 
were enriched for G1-phase using cell-cycle inhibitors. Indeed, this resulted in an 
overall higher yield of G1-phase cells that produced all myeloid lineages, despite 
increased toxicity. In contrast, further administration of GM-CSF resulted in a 
reduced clonal production of all myeloid lineages. Together with preliminary data that 
shows signaling pathway activity, these data form a stepping-stone to identify the 
molecular prerequisites for multlineage production and highlight the involvement of 
cell-cycle phase in multilineage production from hematopoietic stem cells. 
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Further in-depth analysis of cell lifetimes in HSC subsets was performed in 
NUP98-HOXA10homeodomain (NA10hd) overexpressing HSCs, known to increase 
HSC expansion in vitro. However, to date little is known about the behavior of these 
cells and the mechanism(s) underlying this effect remains elusive. The use of time-
lapse imaging resulted in the novel identification of HSC subsets with distinct cell 
lifetimes in NA10hd-overexpressing cells. Both slow- and fast-dividing cells were 
generated from the same ancestry, gradually leading to exhaustion of slow dividing 
NA10hd cells. Through co-culture with non-transduced HSCs NA10hd was 
unexpectedly found to have a paracrine effect, strongly affecting lineage marker 
expression and increasing the prevalence of a fetal liver phenotype in these cells, 
which could not be detected when co-cultured with mock-infected control cells. These 
phenomena require in-depth follow-up and could help understanding the mechanism 
of HSC expansion, with great impact on the clinical setting.  
 
Co-culture with stromal cells (PA6) that can maintain HSC stemness over 
multiple generations revealed an increase in motility and cell lifetime for NA10hd-
positive HSCs, which was dependent on cell-cell interactions. Indeed, it may well be 
the case that reduced NA10hd HSC proliferation upon transplantation is a direct 
effect of cell-cell signaling in the in vivo niche, yet this requires future work for 
further elucidation. Together, these results elicit new NA10hd-induced behavioral 
features, which could have implications in deciphering the mechanism behind HSC 
expansion.  
 
In summary, the data I present here sheds new light on the mechanisms of HSC 
expansion, self-renewal and multilineage production with important clinical 
applications.  
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1 Introduction 
 
1.1 Hematopoietic stem cells 
 
Were it not for the early 17th century Dutch pioneers, we probably would not 
be at our current state of knowledge of blood cells and their function. With the 
invention of the first compound microscope in the late 16th century, Jan 
Swammerdam and Antoni van Leeuwenhoek were the first naturalists who described 
and drew the structure of red blood cells, “red corpuscles”. Until then, blood was only 
seen from a holistic perspective, following Hippocrates’ and Aristotle’s antique and 
classic theorem. However, even today blood is considered one of the most complex 
tissues in the human body. Comprising growth factors, hormones and important 
nutrients such as fatty and amino acids, sugars and oxygen, it is simultaneously 
providing a gateway for metabolic waste products and carbon dioxide to ensure 
optimal physiologic homeostasis in our body.  
  
The blood cells involved in all these actions are originally derived from 
hematopoietic stem cells (HSCs). HSCs form a very rare subpopulation (~1 in 20,000 
bone marrow cells in young adult mice (Warr, Pietras et al. 2011)), and fulfill two 
characteristics: they can self-renew life-long and have the potential to differentiate 
into every blood lineage. The first experimental evidence of the existence of HSCs 
dates back to 1963, when Becker, Till and McCulloch discovered that a clonogenic, 
transplantable marrow cell that fulfilled these characteristics could form spleen 
colonies. (Becker, McCulloch et al. 1963). In homeostasis, HSCs on top of the 
hematopoietic hierarchy (Figure 1.1-1), are thought to be in a dormant state 
(quiescent) with a very low in vivo cell division rate, ranging from two to four months 
in mice (Chesier, Morrison et al. 1999; Sudo, Ema et al. 2000). Upon activation, 
HSCs transit into cell-cycle and can have either self-renewing divisions, e.g. 
providing progeny with the same HSC characteristics, differentiate into (committed) 
multipotent progenitors, or are often hypothesized to have asymmetric cell divisions 
that sustain HSC numbers whilst simultaneously providing fast proliferating 
multipotent progenitor cells that eventually differentiate and produce all blood 
lineages (Akashi, He et al. 2003; Takano, Ema et al. 2004; Giebel, Zhang et al. 2006; 
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Beckmann and Scheitza S 2007; Wu, Kwon et al. 2007; Knoblich 2008). 
 
 
Figure 1.1-1: Hematopoietic hierarchy 
Simplified overview of hematopoiesis, containing the key components of the hematopoietic system. 
HSC (hematopoietic stem cell), MPP (multipotent progenitor), CMP (common myeloid progenitor), 
CLP (common lymphoid progenitor), CMLP (common myeloid lymphoid progenitor), GMP 
(granulocyte-macrophage progenitor), MEP (megakaryocyte-erythrocyte progenitor), dendritic cells 
and osteoclasts are not shown. 
 
In recent years it has become evident that this long-accepted hierarchical 
system may have bypasses and even the existence of certain progenitor populations 
has been disputed. HSCs can also be biased towards specific lineages (Müller-
Sieburg, Cho et al. 2002; Sieburg, Cho et al. 2006; Dykstra, Kent et al. 2007; Challen, 
Boles et al. 2010; Benz, Copley et al. 2012), posing the question again: what really 
defines hematopoietic stem cells? 
 
The factors and mechanisms controlling cell fate have been extensively 
studied but are still poorly understood. The in vivo HSC pool is very small and not 
readily accessible due to its primary location in the bone marrow, a tissue that is in 
itself poorly understood in term of anatomical, cellular and molecular architecture. 
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Studies on HSC function furthermore struggle with classic in vivo read-outs that can 
take up to two years for completion. Ex vivo (e.g. in vitro) studies require cell culture 
techniques. Although ultimately only partially mimicking physiological conditions, 
they allow us to study the behavior of these cells, manipulate them and directly read-
out the effect of different conditions. For many progenitor types that are often found 
at different locations in the body, depending on the state of activity and 
developmental stage, this is common practice and has led to the discovery and 
characterization of many genetic and molecular fingerprints. 
 
HSCs cannot be kept in culture long-term. They either undergo apoptosis or 
lose their multipotency or self-renewal capacity after even short culture. Taking these 
cells out of their highly structured microenvironment, the so-called niche, signaling 
pathways are changed and disrupted and the physiologic conditions are altered, 
eventually leading to a loss of quiescence and activation of HSCs. It is for this reason 
that many studies are focusing on mimicking the in vivo niche by optimizing culture 
conditions with cytokines and growth factors, co-cultures and media perfusion in 
order to retain quiescence or induce self-renewal divisions.  
 
On the other hand, a great interest lies in the in vitro large-scale production of 
specific lineages. Many patients with blood disorders cope with a depletion of mature 
lineage subsets. Platelets that initiate wound healing are derived from megakaryocytes 
and pathological defects in their maturation cause severe bleeding. Erythrocytes are 
crucial for oxygen transport within the body and their differentiation and maturation 
are often impaired by leukemic cells or by genetic defects causing anemia. Both cell 
types are descendants of megakaryocyte-erythrocyte progenitor cells (MEPs), yet it 
remains unclear what exactly causes these cells to differentiate in either lineage. 
When foreign bodies enter our circulation, as is the case during e.g. injury or 
infection, granulocytes and macrophages act first to clear our system and together 
form our innate immune system. Although it has recently become clear that cytokines 
can instruct lineage choice in their common ancestor, granulocyte-macrophage 
progenitor (GMP) (Rieger, Hoppe et al. 2009), still little is known about the 
hierarchical level at which this decision can occur and the potential of lineage priming 
is still a point of debate (Luc, Buza-Vidas et al. 2008; Ng, Yoshida et al. 2009; 
Heffner, Clutter et al. 2011).  
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Together, GMPs, MEPs and their mature progeny form the myeloid 
compartment with the hematopoietic system. The lymphoid compartment, which 
contains T-cells, B-cells and natural killer cells (NKs) forms the adaptive immune 
system. These cells are much more effective and efficient in eradicating foreign 
bodies and cooperate through opsonization by the complement system. Although 
these cells require more time to develop, they are also long-term retained in the body 
in order to respond quickly during future relapse.  
 
Developing culture methods to boost the efficiency of this production not only 
satisfies this high clinical demand, but also provides deeper knowledge and 
understanding about the critical pathways that are involved. Cytokine function and 
pathway activation have been established for many progenitor populations (Rieger, 
Hoppe et al. 2009), but a direct effect or a direct targeting of specific lineage 
production at the HSC level is still difficult. For many cytokines, little is known about 
how they affect individual cell fates. Since most studies have been performed in bulk 
populations, important information about apoptosis, proliferation, differentiation and 
activation had been lost or could not be directly assessed. Furthermore, now that the 
existence and potential of different cell populations as common myeloid progenitors 
(CMP), common lymphoid progenitors (CLP) and even different stages of multipotent 
progenitors (MPP) are disputed due to recent findings that the hematopoietic system 
may have bypasses (Wilson, Laurenti et al. 2008; Gekas and Graf 2013; Yamamoto, 
Morita et al. 2013), more than ever, the effect of cytokines on the cell fate of more 
primitive HSCs needs to be assessed. In order to distinguish proliferation and 
apoptosis rates and prevent cross-contamination from cells with distinct potential, 
these read-outs are best performed continuously, clonally and at single-cell resolution 
to reveal individual cell fates caused by cytokine addition. 
  
1.2 The concept of the HSC niche 
 
During development, HSCs journey through different locations in the body. 
From the early yolk sac (Yoder, Hiatt et al. 1997) to the aorta-gonad-mesonephron 
(AGM) (Bertrand, Chi et al. 2010) and then fetal liver (Rebel, Miller et al. 1996), they 
eventually migrate towards the bone marrow shortly before birth (Moore and Metcalf 
1970). Whereas HSCs have a highly active cell-cycle state in the fetal liver, they are 
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deeply quiescent in the bone marrow (Bowie, McKnight et al. 2006; Bowie, Kent et 
al. 2007). There is substantial evidence that the microenvironment forms a highly 
specialized tissue controlling the state of the HSC (Schofield 1978; Calvi, Adams et 
al. 2003; Zhang, Niu et al. 2003). Inside the bone marrow, most of the HSCs are 
found at the endosteal niche, periosteal region or vascular niche, where they are in 
indirect contact with the blood circulation and are subjected to minimal oxidative 
stress by keeping them in a required hypoxic state (Kiel, Yilmaz et al. 2005; Jang and 
Sharkis 2007; Mendez-Ferrer, Michurina et al. 2010; Rehn, Olsson et al. 2011; Arai, 
Hosokawa et al. 2012; Ding, Saunders et al. 2012; Ding and Morrison 2013). The 
bone marrow niche comprises many cell types, most of them of osteoblastic and 
endothelial lineage, which secrete cytokines and extracellular matrix proteins (ECM) 
important for HSC function. 
 
Although still a matter of debate, many factors have been shown to play 
crucial roles in HSC function. The bone morphogenetic protein 4 (BMP4) is 
important for engraftment and stem cell activity and its transforming growth factor-β 
(TGF-β) related receptor mediates hibernation through lipid raft clustering and 
SMAD activation (Goldman, Bailey et al. 2009; Yamazaki, Iwama et al. 2009). TGF-
β has also been linked to HSC bias. After brief culture with TGF-β, HSCs show an in 
vivo bias towards the myeloid compartment. The concomitant up-regulation of p18 
and p19, both repressing cell-cycle progression (Latres, Malumbres et al. 2000; 
Larson, Singer et al. 2009; Challen, Boles et al. 2010), indicates the potential 
importance of cell-cycle regulators in cell fate regulation. 
 
Another factor derived from the osteogenic lineage is stromal derived factor-1 
(SDF-1 or CXCL12), a chemokine ligand involved in homing and recruitment of 
HSCs at the endosteal surface (Sugiyama, Kohara et al. 2006). Cells expressing its 
receptor, CXCR4, are found to be either directly at the endostium or surrounded by 
sinusoidal endothelial cells, which postulates heterogeneity within the HSC niche, 
possibly related to their function (Kiel, Yilmaz et al. 2005; Omatsu, Sugiyama et al. 
2010; Nagasawa, Omatsu et al. 2011; Ding and Morrison 2013; Greenbaum, Hsu et 
al. 2013). Furthermore, the adrenergic nerve system has been shown to be capable of 
reducing CXCL12 expression in target cells that are present in the HSC niche. Upon 
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ablation of neurotransmitters, HSCs were found to mobilize outside of their niche, 
implicating a role of the sympathetic nerve system in HSC regulation, to add to the 
already highly complex microstructure (Katayama, Battista et al. 2005; Mendez-
Ferrer, Battista et al. 2010). 
 
Other factors such as angiopoietin-1, Tie-2 and osteopontin have also been 
suggested to maintain quiescence of HSCs at the endosteal bone surface (Arai, Hirao 
et al. 2004; Nilsson, Johnston et al. 2005). Moreover, the extensively studied classical 
Wnt and Notch-1 signaling pathways have been shown to be indispensable at the 
endosteal niche for maintaining quiescence and self-renewal of HSCs (Stier, Cheng et 
al. 2002; Reya, Duncan et al. 2003; Fleming, Janzen et al. 2008; Schaniel, Sirabella et 
al. 2011). Taken together, all these tightly regulated interactions point towards a 
highly complex signaling network, rather than a sole master pathway regulating in 
vivo HSC fate. 
 
 Although much is known about the structure and function of the hematopoietic 
niche, many findings remain ambiguous. Ex vivo imaging has been employed to 
visualize HSC niche dynamics using real-time detection and has made a great step 
forward into functional characterization by tracking cell dynamics and kinetics (Xie, 
Yin et al. 2009). Former models that postulate HSC activity correlates with a dynamic 
cross-talk between different HSC niches (Wilson and Trumpp 2006) as well as future 
models can now be tested in a more reliable manner, providing answers to a field still 
coping with many unsolved questions and lacking a thorough understanding of what 
determines HSC fate. All these signaling pathways together form a very complex 
network of HSC extrinsic factors. The majority of this signaling is lost or disrupted 
upon HSC isolation. However, the great advantage of in vitro cultivation lies in the 
fact that this provides a controllable system. Not only can medium or stromal co-
culture conditions exactly be determined, their effect on cell fate can be directly read-
out in terms of e.g. survival, proliferation and differentiation and conditions can be 
adjusted as such. Combining this with further measurement of signaling pathway 
activation, essential mechanisms for survival or self-renewal as well as cell intrinsic 
mechanisms may be unraveled. Furthermore, lineage potential and multipotency can 
be measured and lineage production could be directed more effectively. Together, the 
signaling pathways that are activated in vivo can be selectively re-established or 
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manipulated. The effect of cell-cell or receptor-ligand signaling can be studied to 
explore the direct effect of many molecules on cell fate and determine whether these 
are sufficient or essential to establish or sustain known pathway activity and cell-
cycle progression. It is for this reason that simplified models are mostly preferred in 
in vitro cultures, using only one or few co-culture cell types and using minimal 
essential medium to reduce variables, providing a highly controllable factorial system 
while minimizing compensatory mechanisms that exist in vivo.  
 
1.3 HSC isolation methods 
 
HSCs are one of the best-characterized stem cell-types and can be isolated 
with high purity. The first achievement in the quest for HSC purification was in 1961 
by Becker, Till and McCulloch, where they developed the spleen colony assay to 
assess the potency of hematopoietic cells (see Table 1.3-1). In this assay different 
numbers of bone marrow cells were transplanted in lethally irradiated mouse 
recipients. The nodules that were formed in the spleen after 8 to 12 days were 
equivalent to the number of bone marrow cells transplanted and were derived from a 
single cell with self-renewal capacity although the majority were later found to be 
multipotent progenitors rather than HSCs. Hodgson and Bradley developed an 
improvement of this method in 1979, when 5-fluoroacil was used to ablate cycling 
cells and increase the yield of cells with more self-renewal and differentiation 
capacity through HSC mobilization (Hodgson and Bradley 1979). Although better 
results were obtained, this crude method still resulted in low purities of HSCs.   
Much better results were obtained after the discovery of Sca-1 (stem cell 
antigen, Ly6A/E) (Spangrude, Heimfeld et al. 1988; Okada, Nakauchi et al. 1992) and 
c-kit (CD117) (Okada, Nakauchi et al. 1991; Ikuta and Weissman 1992). This 
population of lineage marker negative, Sca-1/c-kit positive (LSK) cells comprises 
both HSCs and non-committed progenitor cells and transplantation of 100 LSKs was 
sufficient to repopulate a sublethally irradiated recipient mouse. Alternatively, similar 
results were obtained using dye efflux and the purification of a side-population (SP) at 
the low end of the distribution, following the theory that HSCs show a stronger dye 
efflux due to active ABC-transporter expression, providing a self-defense mechanism 
(Goodell, Brose et al. 1996).  
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It was long assumed from the human counterpart that murine HSCs had to be 
CD34 positive, until a CD34 monoclonal recombinant antibody showed that the HSC 
compartment was CD34 negative (Osawa, Hanada et al. 1996; Ogawa, Tajima et al.). 
The lineage hierarchy between HSC and common myeloid progenitors (CMP) was 
further characterized by use of Thy-1.1 and CD11b (Morrison, Wandycz et al. 1997), 
but even more so by the identification of Flk-2 as a MPP marker that provides higher 
HSC purity and a better classification of the MPP population and downstream 
progenitors (Adolfsson, Borge et al. 2001; Christensen and Weissman 2001). 
Following combined purification methods that led to increasing levels of 
purity (Matsuzaki, Kinjo et al. 2004), HSC purification in the 21st century has taken a 
leap further with many more antibodies to isolate both HSC and MPP subsets. Further 
addition of antibodies against a family of signaling lymphocytic activation molecules 
(SLAM), CD150 and CD48 increased HSC purity up to almost 60% (Kiel, Yilmaz et 
al. 2005). Similar results were obtained when substituting lineage depletion and c-kit 
for endothelial protein C receptor (EPCR, or CD201), drastically reducing effort and 
antibody requirement whilst maintaining efficiency and purity (Kent, Copley et al. 
2009). It is plausible that HSCs from different sorting regimes show similar co-
expression of marker subsets and combinations of these could further increase HSC 
purity and could provide a deeper understanding of functionality. With the current 
high isolation purities, it is also of interest to study the correlation between different 
sorting schemes and surface marker expression with a potential related functional 
difference. Such a direct comparison between different isolation methods and 
combinations has not yet been performed in vivo using single cell transplantations. 
Given that HSCs are in direct contact with their niche, the hypothesis that they 
would therefore express cell adhesion molecules such as integrins has been proposed. 
However, CD49b was shown not only to be exclusively expressed in short-term HSCs 
and progenitors, its expression also correlated with faster cell-cycle division rates in 
vitro (Benveniste, Frelin et al. 2010). Aside from providing new surface markers to 
further characterize and distinguish the HSC compartment, this also supported 
previous studies that found that a slow cell-cycle or late cell-cycle entry correlated 
with HSC purity when compared with MPPs (Nygren, D et al. 2006) and leads the 
way to assess the influence of other surface molecules and integrins in the future.  
! 9!
Although MPPs possess self-renewal potential and are multipotent, they do 
not have HSC potential. For this reason, optimizing HSCs purification methods have 
played a central role in studies aiming for higher HSC yield and expansion for clinical 
therapies. The potential to induce an HSC phenotype in multipotent progenitor cells 
has been poorly studied. Combining purification schemes with a time-lapse 
microscopy read-out therefore posed the question whether slow cell-cycle could not 
only be used as a method to assess overall HSC purity, but also whether this 
correlated with in vitro multipotency or lineage production. The slow cell-cycle or 
late cell-cycle entry could furthermore point to extended cell-cycle phase durations or 
heterogeneity thereof. Furthermore, it is unknown whether these phenomena exist 
during in vitro culture in subsequent generations, i.e. progeny after division, and 
whether lineage production can be directed or limited prior to reaching a multipotent 
progenitor stage. To date, these questions have not yet been answered due to the lack 
of tools that allow both continuous non-invasive assessment of cell-cycle phase and 
detection of lineage commitment without losing starting cell identity.  
Table 1.3.1. provides a chronological overview of improvements in HSC purification.  
Table 1.3.1: History of HSC purification  
Purification method Read-out HSC Purity Author Year 
Nucleated WBM CFU-S 0.01% Becker 1963 
5-fluoroacil CFU-S / CRU 0.02% Hodgson 1979 
Ly6A/E CFU-S / LDA 2.5% Spangrude 1988 
Ly6A/E, CD117 (LSK) CFU-S / CRU 2.5-12% Okada 1991 
Hoechst Rhodamine (SP) LDA 3% Goodell 1996 
LSK CD34 LDA 21% Osawa 1996 
LSK Thy-1.1 CD11b CD4 LDA / 2° 10-20% Morrison 1997 
LSK Flk-2 CRU 8-20% Christensen 2001 
LSK CD34 SP Single-cell > 90% Matsuzaki 2004 
LSK CD150 CD48 (SLAM) Single-cell 47% Kiel 2005 
EPCR SLAM (E-SLAM) Single-cell 56% Kent 2009 
LSK SLAM CD49b Sinlge-cell 29% Benveniste 2010 
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The development and improvement of different purification techniques. WBM (whole bone 
marrow), CFU-S (spleen colony forming unit), CRU (competitive repopulating unit), LDA 
(limiting dilution assay), LSK (lineage- Ly6A/E+ CD117+). Peripheral blood counts were used 
to determine donor contribution. 
 
1.4 HSC assays 
 
Following half a century of HSCs characterization and defining their 
phenotype, the conclusion must be drawn that despite large improvements, a uniform 
HSC marker or combination thereof has not yet been discovered. With purities 
ranging from 50 to potentially 90 percent (Matsuzaki, Kinjo et al. 2004), 
heterogeneity has been much reduced. However, stem cell potential, i.e. having both 
life-long self-renewal capacity and the potential to differentiate into every blood 
lineage, vary.  
 
The gold standard to measure potency is transplantation. While in early days 
the in vivo lineage contribution was assessed after 8 to 12 days, now 16 weeks to 32 
weeks or longer is required to prove HSC potency, including secondary and even 
tertiary transplants. Moreover, initially bulk bone marrow transplants were performed, 
in contrast to today where single-cell transplants are the norm. To date, an in vitro 
assay to read-out HSC potential unfortunately does not exist. However, many 
important questions regarding cell fate such as self-renewal, survival, apoptosis and 
even multipotency can be read-out in vitro. With recent studies proving the existence 
of HSCs that are biased towards specific lineages, which can also vary with age 
(Dykstra, Kent et al. 2007; Gekas and Graf 2013), more than ever assays are required 
to not only assess lineage potential but also to address the question of how these cells 
behave and how cell fate decision is orchestrated. This is difficult to attain in vivo. To 
define their behavior in terms of migration, division rate and survival, continuous 
observation and monitoring is required, which is limited in living and moving 
animals. Furthermore, in vivo imaging of HSCs requires deep-tissue penetration, 
which limits both temporal and spatial resolution for single-cell quantification. Other 
methods such as genetic manipulation and use of tissue sections, often leads to 
unwanted effects on both the microenvironment and hematopoietic hierarchy and 
leaves uncertainties about exact localization of other cell types in many cases, 
respectively.  Thus, an in vitro assay to read-out both cell fate and cellular behavior 
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would form a desirably faster, more robust and more controllable alternative for the 
laborious and time-consuming and complicated in vivo read-out. 
 
Colony assays have been performed in semi-solid media, with a mixture of 
cytokines and growth factors, for almost fifty years (Bradley and Metcalf 1966). They 
directly reveal the clonal potential of cells, but despite the detection of blast (non-
differentiated) cells and self-renewal through serial re-plating it cannot assess HSC 
potential.  However, this assay does serve the purpose of assessing multipotency by 
allowing detection of clonal lineage production. Since behavior cannot be defined due 
to the lack of single-cell resolution, early cell fate decisions cannot be measured and 
correlated.  
 
Methods not directly driving differentiation, such as co-culture techniques for 
long-term culture initiating cells (LTC-IC) (Sutherland, Lansdorp et al. 1990), cobble-
stone formation (Ploemacher, Sluijs et al. 1989; Song, Bahnson et al. 2010) or 
retention of HSC numbers using premature feeder layers (Moore, Ema et al. 1997; 
Nolta, Thiemann et al. 2002) also allow classification of multipotency while 
preserving clonal identity. Single-cells can still be distinguished and cell behavior 
such as motility or division rate can be measured. The remaining bottleneck of HSC 
visualization under stromal co-culture conditions, which impairs detection due to loss 
of optical clarity, focus and contrast, requires further improvements and can be 
overcome when further optimizing culture conditions by developing a stroma free 
liquid culture assay. 
 
Attributing cell behavior to lineage potential would not only provide a 
functional correlation to molecular and gene expression, but would ultimately allow 
to predict cell fate, lowering the need for long-term assays. Benveniste et al. showed 
that CD49b- and CD49b+ HSCs showed a significant difference in initial cell-cycle 
division rates. While both cell types developed chimerism in recipient mice, the 
former would sustain multilineage contribution much longer and this correlated with a 
profoundly longer cell-cycle in vitro (Benveniste, Frelin et al. 2010). CD49b is an 
integrin and as such is involved in cell adhesion. It is therefore quite possible that 
other features such as cell adherence, motility, cell size or morphology could further 
characterize this HSC subset. However, the difference in initial cell-cycle division 
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rates not only points to heterogeneity with respect to cell-cycle entry, but also to 
potential differences in cell-cycle phase durations. Since the in vivo long-term 
repopulation assays revealed marked distinctions in chimerism, it would be of key 
interest to assess whether in vitro lineage potential correlates with cell-cycle transit in 
early divisions. The lack of continuous cell-cycle data and the ability to continuously 
read-out cell fate on a single-cell resolution are the main problems that have made it 
yet impossible to prove this correlation. With the development of advanced 
technology such as continuous time-lapse imaging, many of these hurdles have been 
overcome, yet need to be adjusted to specific needs and cell types and is not yet 
readily available. 
 
1.5 Cell-cycle 
 
Cells have different fates they can adopt. They can e.g. differentiate, migrate, 
proliferate, be quiescent, senescent, necrotic or apoptotic. These states can occur 
during different active cell-cycle phases. Quiescence is the only state reserved for 
non-cycling cells, such as HSCs and post-mitotic differentiated cells. This phase is 
depicted as the G0-phase. From this resting phase, HSCs can be activated and transit 
into cell-cycle.  
 
During replication, two major checkpoints exist that secure DNA integrity and 
under normal conditions prevent tumorigenesis by controlling division rate. Hence, 
the first checkpoint is encountered before DNA is replicated, the so-called G1-phase 
(gap1) (Figure 1.5-1). The key factors that drive G1-phase progression are cyclin D 
and retinoblastoma (Rb). The cyclin family had been first identified in yeast by 
Hartwell in the 1970`s, after which Nurse and Hunt discovered analogs and further 
characterized their function in xenopus and human, for which they were awarded the 
NobelPrize in 2001 (Hartwell, J et al. 1970; Lee and P 1988; Hunt 1989). Cyclin D 
levels (1 from over 15 family proteins from cyclin A to Y) regulate the 
phosphorylation state of Rb. Upon binding its complementary cyclin-dependent 
kinases 4-6 (CDK4-6), it forms an active complex that phosphorylates Rb. p16 
(INK4a) and p18 (INK4c), G1-phase-specific cell-cycle inhibitors, can block this 
activity and since in HSCs levels of p18 in G0-phase are often found to be high and 
cyclin D levels are minimal, Rb resides in an unphosphorylated state. However, 
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during quiescence p130, part of the Rb family, and p18 have a more prominent role in 
retaining the quiescent state since p16 and p19 are actively repressed through bmi1 
(Lessard and Sauvageau 2003; Park, Qian et al. 2003; Passegue, Wagers et al. 2005). 
When homeostasis is disrupted, cyclin D levels can be triggered, overcoming this 
threshold and putting retinoblastoma in a hypophosphorylated state.  
 
In late G1-phase stage, cyclin E has a more prominent role and together with 
its complementary CDK2 it can further phosphorylate retinoblastoma. The cell-cycle 
inhibitors repressing CDK2 activation are p21 and p27, part of the Cip/Kip family. 
These inhibitors are also found in low levels on the active CDK4-6 complex, but are 
displaced and bind CDK2 upon increasing concentrations of cyclin D. Similarly, 
higher concentrations of p21 and p27 result in CDK2 inhibition. If levels of cyclin E 
are sufficiently high, CDK2 activation completes the phosphorylation state of 
retinoblastoma, which releases and activates the E2F transcription factors that 
orchestrate the DNA replication machinery.  
 
 
Figure 1.5-1: Cell-cycle 
Simplified cell-cycle progression. CDK (cyclin-dependent kinase), Rb (retinoblastoma), R (restriction 
point, Cdc (cell division cycle). 
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At this stage, synthesis (S-phase) has started and is further driven by cyclin A 
in early S-phase. Between synthesis and mitosis (M-phase), the G1-phase equivalent 
checkpoint is found in G2-phase (gap2). Up-regulation of Cdc25 by G2-phase specific 
cyclin B, activates mitosis promoting factor. However, when DNA damage occurs, 
Ataxia telangiectasia mutated (ATM) kinase degrades Cdc25 and therefor prevents 
transition into M-phase, leading to cell-cycle arrest or induced apoptosis and forming 
the second major checkpoint. The cell then continues mitosis by condensing the 
chromatin structure, building of the spindle and separation of the centrosomes 
(prophase), degradation of the nuclear membrane, chromosome alignment and 
polarization (metaphase), chromatin separation (anaphase) and eventually lengthening 
of the cell and nuclear membranes are established (telophase), after which the cell 
separates into two daughter cells (cytokinesis). This process is highly complex and 
occurs within a very short time frame, relative to the other phases of the cell-cycle. 
 
The name and function of retinoblastoma are derived from a type of cancer in 
children that arises when gene mutations in both alleles occur, causing defects in the 
retinoblastoma protein (Herwig and Strauss 1997). Furthermore, its importance in 
both embryo development and hematopoiesis has been supported by studies in which 
a Rb double knockout caused embryonic lethality through the absence of mature 
erythrocytes and impaired neuronal growth (Clarke, Maandag et al. 1992). Together 
this shows that Rb not only forms an important tumor suppressor in controlling cell 
proliferation, but also is essential for differentiation. This was further underlined in 
studies that showed modified Rb in tumor cells causes a differentiation block and fails 
to provide mature blood lineages (Santamarina, Hernandez et al. 2008). The 
differential Rb expression at distinct stages in hematopoietic lineage production 
(Szekely, Jiang et al. 1992) together with the fact that Rb mainly drives G1- to S-
phase progression, led to the hypothesis that cell-cycle phase may play an important 
role in lineage production i.e. posed the question whether different cell-cycle phases 
have opposing cell fates or lineage potential upon cytokine addition.  
 
Although not yet proven to date, this hypothesis does not seem farfetched 
since previous studies have shown a reversible differential gene expression pattern 
throughout different cell-cycle phases (Lambert, Liu et al. 2003). During replication, 
chromatin is modulated and access for different transcription factors is enabled. 
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However, despite evidence that shows diverging cell fates of daughter cells after one 
cell-cycle division (Suda, T et al. 1984), it is still unknown whether this yields a cell 
intrinsic or extrinsic mechanism.   
 
The binding of Rb to myeloid transcription factors as CEBP/a, is mostly found 
in a hypophosphorylated state, which supports a role of early G1-phase in providing a 
time-frame for differentiation. Furthermore, this indicates that the involved signaling 
pathways may be cell-cycle phase dependent (Herwig 1997; Lipinski 1999; Zhang 
1999). p16, known to repress phosphorylation of Rb by blocking cyclin D function, is 
expressed in undifferentiated cells but is rapidly downregulated during lineage 
maturation (Furukawa, Kikuchi et al. 2000). Overexpression of p16 reduces both 
proliferation and differentiation in hematopoietic stem and progenitor cells (Bergh 
2001) and indeed, a double knock-out of p16 leads to tumorigenesis (Sharpless, 
Bardeesy et al. 2001). However, a clear role of Rb could not be detected, probably 
due to in vivo compensatory mechanisms by the family pocket proteins p130 and 
p107 (Santamarina, Hernandez et al. 2008). Low-level expression of late G1-phase 
regulators of p21 and p27 have been shown to facilitate the production of erythroid 
lineages. Even lineage-specific expression of cell-cycle regulators could be revealed, 
however only in mature cell types (Furukawa, Kikuchi et al. 2000; Hsieh 2000; Tamir 
2000; Bergh 2001). This further supports the hypothesis that the key regulators of G1-
phase progression also form a crucial role in determining cell fate.  
 
To date, real evidence to prove a role of cell-cycle phase in determining cell 
fate in hematopoiesis is still missing. While most studies have been performed on cell 
lines or cultures of tumor cells, studies that have used primary cells are primarily 
based on bulk population assays that read-out total lineage production but not single 
cell fates. Furthermore, the existence of differential gene expression patterns and even 
cell-cycle regulators in distinct differentiated populations, does not prove the point 
that these cell-cycle phases and regulators play a role in lineage decision and cell fate 
in upstream cells, i.e. ancestor cells that did not yet express lineage specific 
differentiation markers. To add to the complexity, overexpression and genetic 
modification are tools that mostly possess an invasive character that could alter or 
influence the observed effect on cell fate. Together, a read-out is required that could 
prove the influence of cell-cycle phases in multipotent cells rather than lineage 
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restricted and differentiated cells. An in vitro read-out would provide a controllable 
system and allows clonal assessment of cell fate. By doing so, different cytokine 
combinations that are known to direct lineage production can be added during 
different cell-cycle phases in order to reveal a cell-cycle dependency in cell fate. 
 
The difficulty in studying the influence of cell-cycle in cytokine induced 
differentiation lies in (1) providing a clean read-out that allows quantification and 
determination of lineage commitment on a single-cell level and (2) providing a 
method that allows measuring cell-cycle phase whilst keeping the cells viable and 
without perturbing intracellular signaling pathways. The former has been achieved by 
both classic colony assays and LTC-IC assays and cell fate can be easily determined 
using a snapshot-based read-out at different time-points. Using lineage tracing or 
specific viral integration patterns (barcoding), culture and in vivo read-outs can be 
initiated with different starting cell numbers since lineage contribution can be 
assessed without loss of ontogeny (Lu, Neff et al. 2011; Kretzschmar and Watt 2012). 
The latter however is much more difficult to obtain since current methods to measure 
cell-cycle mostly require fixation and (immuno-) staining.  
 
In a 2007 study by Quesenberry et al. cell-cycle of quiescent hematopoietic 
stem and progenitor cells (HSPCs) was indirectly measured based on bulk population 
propidium iodide quantification using flow cytometry. Although cell-cycle phase 
prevalences at various time-points were reproducible, cell-cycle phases between cells 
were never fully synchronous. In addition, since genealogy was lost, uncertainties 
existed whether cells after 32 and 48 hours had yet divided in vitro. Nevertheless, 
building on this assumption, the influence of different cytokines was assessed, leading 
to the interesting hypothesis that certain cytokines may increase the yield of 
megakaryocytic lineages, when added in the right cell-cycle phase or at the right time 
(Colvin, Dooner et al. 2007). Indeed, despite generating data based on bulk culture 
and cell-cycle phase probabilities, they found that cytokine change during early S-
phase increased the total production of megakaryocytes, whereas cytokine addition 
during G1-phase increased the yield of granulocytes. However, when performing 
clonal analysis, their data showed inconsistencies. It might well be that in bulk culture 
cell-cell contact occurs with a higher frequency and secreted molecules are more 
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abundant, raising the question what formed the major component in orchestrating 
different lineage production? 
 
1.6 Cytokines in lineage production 
 
Since the emergence of in vitro culture of hematopoietic cells, medium 
optimization to promote maintenance, proliferation or differentiation has become of 
key interest. The following cytokines have been used to study the influence of cell-
cycle in cytokine induced lineage production and maintenance of multipotency. 
 
Stem cell factor 
Culture and maintenance of HSCs ex vivo is a complex and difficult 
procedure. After isolation they eventually undergo apoptosis without the proper 
growth factors. Found as one of the first crucial cytokines for ex vivo HSC 
maintenance stem cell factor (SCF), also known as steel factor or c-kit ligand, is 
indispensable for prolonging survival of HSCs in vitro. SCF binds its CD117 (c-kit) 
receptor and represses apoptosis through PI3K and Erk signaling and Wnt inhibition. 
However, culture of HSC in SCF alone does not yield self-renewal divisions but only 
transient survival and maintenance of multipotency can be achieved, as shown by 
studies on proliferation kinetics and colony assays (Li and Johnson 1994; Keller, 
Ortiz et al. 1995). Although this points to SCF involvement in G1-phase progression, 
other studies have shown that its target receptor CD117 is expressed through all cell-
cycle phases (Lambert, Liu et al. 2003; Passegue, Wagers et al. 2005; Dooner, Colvin 
et al. 2008). Since SCF is indispensible for in vitro HSC survival through all cell-
cycle phases (Zhang and Lodish 2008), its effect on lineage production with cell-cycle 
phase correlation has not yet been revealed. 
 
Thrombopoietin 
Known for its function in megakaryocyte production, thrombopoietin (TPO) 
not only helps maturation and development of proplatelets (Kaushansky 1995) but 
also and synergistically with SCF stimulates both survival and proliferation of in vitro 
cultivated HSCs (Matsunaga, Kato et al. 1998). Binding its receptor Mpl, TPO 
activates amongst other pathways PI3K signaling, which stimulates and directs the 
cell to transit into cell-cycle. In concert with SCF, addition of TPO in ex vivo cultures 
!18!
can (to a limited extent) even induce self-renewal as well as multilineage 
differentiation of HSCs (Ku, Yonemura et al. 1996; Ramsfjell, Borge et al. 1996; 
Yagi, Ritchie et al. 1999; Ema, Takano et al. 2000). Its importance for HSC 
maintenance is further illustrated by the fact that in vivo TPO knock-out and Mpl 
receptor blocking through neutralizing antibodies show hematopoietic deficiencies 
(Kimura, Roberts et al. 1998; Fox, Priestley et al. 2002; Qian, Buza-Vidas et al. 2007; 
Yoshihara, Arai et al. 2007). In addition, CD34- HSCs show an increased expression 
of Mpl when compared with CD34+progenitors, which may point to the necessity of 
TPO signaling in both in vivo and in vitro of HCS function (Morita, Ema et al. 2010). 
A potential cell-cycle phase dependency of TPO with respect to lineage production 
was hypothesized after the discovery that TPO induces PI3K signaling which can 
stabilize cyclin D while simultaneously repressing transcriptional activity of p21 and 
p27 (Massague 2004). Indeed, in accordance, TPO signaling during G1-phase has 
been shown to increase the potency to produce megakaryocytes (Colvin, Dooner et al. 
2007). Taken together, the role of TPO in HSC fate remains ambiguous, being 
involved in survival, cell-cycle, self-renewal and differentiation. 
 
Interleukin-3 
Produced by activated T-cells and mast cells, interleukin-3 (IL-3) can not only 
suppress induced apoptosis but, upon binding its receptor, also orchestrate myeloid 
lineage development and stimulate proliferation (Miyajima, Mui et al. 1993; 
Kinoshita, T et al. 1995). In progenitors, increased levels of IL-3 can direct 
megakaryocyte differentiation and functions synergistically with the receptor 
homologue of granulocyte-macrophage colony-stimulating factor (GM-CSF) 
(Hoffman, R et al. 1990; Briddell and JE Brandt 1992). However, upon addition of 
interleukin-6, this co-stimulation leads to a loss of megakaryocytes and an increase in 
granulocyte macrophage progenitors (GMPs). For both, the exact mechanism 
including potential cell-cycle phase relevancy still needs to be elucidated. 
 
Granulocyte macrophage colony-stimulating factor 
Originally defined as a growth factor specific for neutrophils and 
macrophages, granulocyte macrophage colony-stimulating factor (GM-CSF) has been 
shown to be important for maturation and survival of committed progenitor cells in 
the myeloid lineage (Burgess and D 1980; Kinoshita, T et al. 1995).  It is also known 
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that GM-CSF can trigger immune responses, either directly or through up-regulation 
of interleukin-1, thereby activating the adaptive immune system (Khameneh, Isa et al. 
2011). In contrast to what its name originally suggested however, GM-CSF also has 
the potential to increase megakaryopoiesis, either directly (Briddell and JE Brandt 
1992) or in synergy with interleukin-3 (Robinson, McGrath et al. 1987; Hoffman, R et 
al. 1990). Furthermore, data based on bulk culture has shown a cell-cycle relevancy 
for GM-CSF, specifically increasing megakaryocyte production when added during 
early S-phase and increasing granulocyte production when added during G1-phase 
(Colvin, Dooner et al. 2007). In addition, leukemic cancer cell lines have been 
established that respond to this factor by differentiation into the megakaryocytic 
lineage. This makes it of particular interest in a clinical setting and for studies on the 
potential of directing lineage production from HSPCs by cytokines (Komatsu, H et al. 
1991). 
 
Erythropoietin 
The difficulties in obtaining erythroblasts in vitro have mainly been overcome 
by the addition of erythropoietin (EPO). With previous studies requiring adherent 
stromal layers for the production of mature erythrocytes, a stroma free culture 
technique was established using erythropoietin, allowing erythropoiesis without 
disturbing production of other blood lineages (Eliason, Testa et al. 1979; Estment and 
Ruscetti 1982). In 1996 it was shown with an EPO receptor double knock-out mouse 
that the EPO receptor, being expressed on different myeloid cell types, is essential for 
the development of full grown erythrocytes. Erythroid progenitors however could be 
produced but could not differentiate past the erythroblast state (Kotkow and Orkin 
1996). Through up-regulation of c-jun, EPO was found to be controlling cyclin D 
levels, necessary for hypophosphorylation of Rb and which points to a potential 
influence of G1-phase in erythroid lineage production (Lopez-Bergami, Huang et al. 
2007). EPO also affects cell-cycle progression through c-kit down-regulation, Erk1/2 
and STAT5 signaling (Fang, Menon et al. 2007; Wang, Akbarian et al. 2013). 
Together this indicates EPO can alter both cell-cycle phase progression and cell 
surface marker expression, but a direct influence on HSC level with respect to cell-
cycle phase and lineage production has not yet been elaborated.  
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Medium conditions that allow production of all myeloid lineages from 
multipotent progenitors (“permissive conditions”) 
To date it remains difficult to attain production of all myeloid lineage subsets 
from a single starting cell in vitro. Whilst purification may disrupt viability of 
primitive hematopoietic cells, the main problem is thought to be cytokine conditions 
that, when not mixed in optimal concentrations, do not allow production of all 
lineages. This major hurdle has been overcome with the establishment of optimized 
culture conditions by Takano et al., which revealed the highest yield of granulocytes 
(neutrophils), erythrocytes, macrophages and megakaryocytes (GemM) producing 
cells on a clonal basis (Takano, Ema et al. 2004). In addition to SCF and TPO, 
required for survival and proliferation of HSCs, these conditions comprise IL-3, EPO 
and fetal calf serum (FCS). Further media additions are 2-mercaptoethanol and L-
glutamine to ensure low oxidative stress (Das, Kar Mahapatra et al. 2007). 
 
Although the effect of many of these cytokines on lineage production does not 
necessarily require clonal culture, read-out of individual cell fates cannot be 
performed in bulk culture. If the effect on early cell fates is lost or unknown, clonal 
proliferation and apoptosis rates may mask the overall production of mature lineages 
and individual cell-cycle dependency cannot be assessed (Figure 1.6-1). Most of 
current published data regarding cell-cycle progression has been acquired with loss of 
single-cell clonal identity and therefore pose ambiguous outcome. To be able to 
conclusively identify the role of cell-cycle phase in cytokine induced lineage 
production, current data requires continuous observation rather than snapshot or 
endpoint analysis. 
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Figure 1.6-1: Cell fate detection requires continuous observation 
Cartoon representing cellular behavior including few of many possible cell fates. Depending on cell-
cycle different cell fates may occur leading to different lineage outcome and production. Black circles 
indicate nucleus, not on scale. 
 
1.7 Cell-cycle reporters 
 
In order to assess the influence of cell-cycle phase in lineage production upon 
cytokine addition, a non-invasive method needs to be applied to read-out both cell-
cycle state on a clonal level and allowing detection of lineage production without cell 
state interference. Furthermore, measurement of cell-cycle phase durations and cell 
cycle transit in order to read-out a potential effect of cytokines on cell fate and 
cellular behavior, requires continuous data on a singular level that is exclusively 
obtained in live time-lapse imaging. To date, live antibody staining does not provide 
such tools and other mechanisms to e.g. read-out DNA content through fluorescent 
labeling with Hoechst33342 could potentially interfere with intracellular signaling. 
For this reason, different knock-in mice have been generated that are based on a 
fluorescent reporter that is either directly bound or linked to cell-cycle specific 
expression of cell-cycle regulators. Unfortunately, only few cell-cycle reporter mice 
are available. Based on Cdt-1 (G1-phase accumulation) and Geminin (S/G2-phase 
accumulation), a double knock-in containing two different fluorescent proteins was 
!22!
made allowing visualization of the G1 to S-phase transition by flow cytometry and 
microscopy using fluorescence (Sakaue-Sawano, Kurokawa et al. 2007). The 
limitations however lie in the fact that for optimal quantification, two fluorescent 
wavelengths are required and time-consuming quantification needs to be done post-
acquisition. Furthermore, the transition does not reveal differences within G1-phase 
and since the reporter is not-ubiquitously expressed in blood (detectable in ~1% of 
HSCs), usage of this reporter mouse may not prove beneficial for HSC studies.  
 
Another reporter mouse allows distinction between interphase and metaphase, 
which is based on a fluorescent biosensor with a nuclear localization sequence during 
interphase and a plasma membrane targeting sequence that shows membrane 
localization upon nuclear envelope breakdown during metaphase. Hence, this cell-
cycle biosensor unfortunately provides no distinction between G1, S and G2-phase. 
Combined with its non-ubiquitous expression, it is not a good candidate to follow-up 
the influence of cell-cycle phase in differentiation (Burney, Lee et al. 2007; Hesse, 
Raulf et al. 2012). 
 
A very powerful tool, yet not available as a reporter mouse, is a proliferating 
cell nuclear antigen-based (PCNA) biosensor. PCNA tethers DNA polymerase delta 
to the DNA upon DNA synthesis in S-phase specific replication and the replication 
foci that are formed consist of trimers. This biosensor links each monomer to a 
fluorescent protein, thereby visualizing S-phase progression (Bravo, R et al. 1987; 
Leonhardt 2000). Its nuclear localization throughout all cell-cycle phases requires 
continuous high magnification fluorescent microscopy in HSCs to read-out both cell-
cycle state and cell-cycle phase durations and the absence of these foci during G1 and 
G2-phase furthermore requires a high temporal resolution to distinguish these phases 
due to the gradual, yet fast transition of replication foci and provides cell-cycle data 
retrospectively. For expression in primitive primary blood cells, this requires viral 
transduction with relatively high multiplicity of infection (MOI) to allow visualization 
at early time-points. For specific questions that can be answered with short-term 
imaging, rather than high-throughput imaging, testing and optimization, this may 
prove a very powerful tool. 
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To date, one of the best candidates to continuously detect cell-cycle state is 
based on the C-terminus of human DNA helicase-B, active and with nuclear 
localization during G1-phase to allow DNA repair. This phosphorylation-dependent 
subcellular localization domain (PSLD) consists of a nuclear localization signal and 
seven cyclin-dependent phosphorylation sites. Upon expression of cyclin E and cyclin 
A in the late G1-phase, PSLD is phosphorylated and pumped out of the nucleus by 
activation of a nuclear export signal. From early S-phase its localization is then purely 
cytoplasmic. This transition allows the observation of G1 to S-phase transition as well 
as metaphase when the nuclear membrane is degraded (Gu, Xia et al. 2004; Stubbs 
2005; Hahn, JT et al. 2009) (Figure 1.7-1). 
 
 
Figure 1.7-1: a PSLD-based cell-cycle fluorescent reporter 
PSLD subcellular localization during cell-cycle transition. Simplified cartoon does not indicate true 
scaling. PSLD (phosphorylation-dependent subcellular localization domain), FP (fluorescent protein).  
 
 Using PSLD allows continuous quantification of cell-cycle phase transitions 
and furthermore fulfills the requirements to non-invasively study the effect of 
cytokines on cell fate in different cell-cycle phases. In addition, this would also allow 
further quantification of cytokine directed signaling pathway activation through e.g. 
immunofluorescence or by use of biosensors in a cell-cycle dependent manner to 
elicit underlying molecular mechanisms that orchestrate cell fate. 
 
1.8 Signaling pathways involved in lineage production 
 
With so many factors influencing the cell fate, it is ultimately the signaling 
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pathways that mediate the effects of cytokines. Activated receptors, either by ligand 
binding or stimuli such as shear stress, cause intracellular and sometimes also 
extracellular modifications and attract adaptor molecules to activate kinases. They 
phosphorylate other proteins that can either dimerize and translocate or are directly 
transported to the nucleus, where they act on regulatory proteins to induce or repress 
transcription factor activation. 
Several cytokine-induced signaling pathways that are known to play a role in 
survival also have been shown to be important for HSC regulation. SCF mediated 
signaling through the c-kit receptor activates different signaling pathways, perhaps the 
best established being p42/44 (extracellular signal-regulated kinase, ERK1/2) and 
phosphatidylinositide-3 kinase (PI3K). Kit signaling has been shown to be crucial to 
maintain quiescence of HSCs (Thorén, Liuba et al. 2008) and defects in its 
downstream signal transducer and activator of transcription 5 (STAT5) have revealed 
major hematopoietic deficiencies (Bradley and Hawley 2002; Wang, Li et al. 2009). 
In addition to their importance in Kit signaling during quiescence, ERK1/2 and PI3K 
can directly affect survival and proliferation through up regulation of cyclin D1/2 
levels, facilitating transit into cell-cycle (Blomen and Boonstra 2007).  
PI3K, also activated through TPO/Mpl signaling (Kirito, Watanabe et al. 
2002), can also activate beta catenin and mediate different signaling cascades, 
including p300/CBP, Myc, Notch1 and cell-cycle regulators. Hence, it is not 
surprising that PI3K is not only important for HSC survival and proliferation but is 
also involved in the maturation of different committed progenitors towards the 
megakaryocytic lineage, possibly through the downstream target mTOR (mammalian 
target of rapamycin) (Raslova, Baccini et al. 2006). 
Mitogen activated protein kinases, including p38 and ERK1/2, can be 
activated by Mpl-signaling and are important for both proliferation and maturation of 
megakaryocytic progenitors (Melemed, JW et al. 1997; Whalen, SC et al. 1997; 
Fichelson and Freyssinier JM 1999). Furthermore, there is strong evidence that their 
activation is crucial for endomitosis in the megakaryocytic lineage, whereas Src 
kinases form negative factors for megakaryopoiesis (Rouyez, C et al. 1997; 
Rojnuckarin, JG et al. 1999; Kaminska, Klimczak-Jajor et al. 2008; Severin, Ghevaert 
et al. 2010). Although often found present throughout different phases of the cell-
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cycle, it has been hypothesized that their nuclear translocation is transient and cell-
cycle specific, creating a time window for MAPK to act and facilitate maturation of 
megakaryocytic progenitors (Blomen and Boonstra 2007; Kaushansky 2008). With 
the prospect of defining cytokine-induced differentiation, it should therefore be of 
extra interest to further investigate the role of cell-cycle phase and its dependency in 
signaling pathway activation. 
 
1.9 Clinical relevance for ex vivo HSC expansion 
 
Despite all the medical advances in the blood field, there is no fully reliable 
cure for leukemia. Patients that are confronted with severe blood disorders often have 
poor chances of survival and high chances of relapse. Furthermore, the burden they 
are facing every day when treated for blood malignancies strongly reduces quality of 
life. The underlying reason for blood disorders such as acute myeloid leukemia 
(AML) can often be traced to the existence of a single gene mutation or chromosomal 
aberration in a single cell, often termed leukemia initiating stem cell (LISC). The 
existence of such a cell, or pool of cells, is the main target in therapies targeting 
leukemia. Independent of their position in the hematopoietic hierarchy, these cells 
have three things in common, they: (1) proliferate fast due to an increased rate of self-
renewal divisions, (2) are stuck in differentiation and do not fully mature, and (3) 
often have a mechanism that protects them from standard drugs that target 
proliferating cells. In addition, these fast proliferating cells are often found to inhibit 
production of certain lineage subsets and drastically change the architecture of the 
bone marrow. 
 
Current therapies are mostly comprised of a combination of chemotherapy, 
radiation therapy, hormone treatment and daily medication. Ultimately, ablation of 
autologous bone marrow is performed. With the microenvironment staying relatively 
intact but drastically changed after bone marrow irradiation, depletion of all blood 
cells including HSCs requires the patient to undergo HSC transplantation. The 
problem that arises is that previously taken biopsies may again contain LISC and 
relapse may occur. Furthermore, these cells contain both HSCs and mature cells to 
sustain hemopoiesis at long-term and short-term, respectively, often in too low 
numbers to be effective. Consequently, non-autologous, or allogeneic HSC 
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transplants are often performed with the risk of inducing host-versus-graft-disease 
(HVGD), but mostly increasing the risk of graft-versus-host-disease (GVHD), in 
which the donor immune system induces an immune response and attacks recipient 
tissues (Ferrara, Levine et al. 2009; Blazar, Murphy et al. 2012).  
 
Some studies focus on the relief of the burden associated with GVHD and 
facilitating the efficacy of HSC transplants, by for example co-injection of 
mesenchymal stromal cells (Tolar, Le Blanc et al. 2010). Other studies focus on 
improving ways to induce stem cell expansion. Considering the fact that HSCs are 
hard to maintain ex vivo in short-term culture, it is obviously a challenge to induce 
self-renewal divisions without losing the potential to differentiate into all blood 
lineages life-long. With the discovery that umbilical cord blood cells are not only 
enriched for HSCs but simultaneously have a much lower immune response upon 
stimulation with mismatched human leukocyte antigen (HLA) cells (and therefore are 
less susceptible to the recipients foreign body reaction to trigger GVHD) these cells 
have become a topic of interest (Harris, Schumacher et al. 1992; Rocha, Cornish et al. 
2001). Their better reconstitution potential and the fact that they do not require 
biopsies would further make this procedure highly effective and lower the patient’s 
burden in clinical setting. However, their low abundance and the high number of 
HSCs necessary per effective treatment still require ex vivo expansion. 
 
1.10 Expansion methods and limitations 
 
A net ex vivo expansion of murine HSCs has first been achieved in 1997, 
where freshly isolated HSCs were kept under different culture conditions for different 
periods of time, after which they were transplanted. Using limiting dilution assays, 
they found a ~4 fold increase after 10 day when cultured with interleukin-11, SCF and 
Flt-3. Similarly and by using the same conditions, a ~4 fold increase in HSC number 
was found by transplanting cells that had already divided, as determined by reduced 
levels of CFSE in flow cytometry (Miller and Eaves 1997; Oostendorp, Audet et al. 
2000). Using SCF and thrombopoietin, Ema et al. pointed to the existence of potential 
self-renewal divisions in vitro, although overall absolute numbers resulted in a net 
loss (Ema, Takano et al. 2000). These studies showed that without stroma co-culture 
it was possible to not only maintain HSCs but potentially even increase their ex vivo 
! 27!
numbers. Since then media additions have become popular to induce ex vivo HSC 
expansion.  
 
Addition of retinoic acid receptor agonists retains to some extent the 
repopulation activity of hematopoietic stem and progenitor cells after two weeks of 
culture (Purton, Bernstein et al. 2000). However, LSK cells were cultured in bulk and 
transplanted as such and HSC numbers were not determined through limiting dilution 
assay. This forms a problem since this could potentially point to an effect caused by 
repressed differentiation of MPPs rather than HSC maintenance. Moreover, 
repopulation activity, which was measured by peripheral blood contribution over 
several weeks, showed a strong decline which is characteristic for MPPs and did not 
reach the same contribution levels compared to freshly isolated, e.g. non-cultured and 
transplanted LSK cells. A more recent study found that the G0S2 protein, that is 
solely up-regulated through retinoic acid in the hematopoietic system, enhanced the 
quiescence of LSK SLAM HSCs (Yamada, Park et al. 2012). The exact mechanism is 
however still not known. 
 
Well known for their capacity to maintain stemness of HSCs are the AFT and 
PA6 stromal cell lines. AFT cells are a clonally expanded cell line that has been 
shown to maintain HSC numbers up to 4 weeks of ex vivo culture by a mechanism 
still unresolved (Nolta, Thiemann et al. 2002). Originating from fetal liver, these cells 
were thought to have the potential to induce self-renewal divisions since primary fetal 
liver HSCs rapidly expand in this environment during development. Although not 
observed in vitro, it might well be that AFT cells could still possess this capability but 
their immortalization, media conditions and potential changes in karyotype or a 
combination thereof are the cause of the loss of their potency to expand HSCs. 
Alternatively, PA6 cells (pre-adipocytes from mouse calvaria) have been shown to be 
able to maintain HSC numbers and potentially increase their numbers in short-term 
culture (Kodama, Sudo et al. 1984; Shimizu, Noda et al. 2008). However, stromal co-
cultures seem only capable to a limited extent to maintain HSC potency rather than 
inducing HSC expansion.  
 
Through genetic manipulation, further efforts in HSC expansion have been 
successful. Deletion of a G1-phase inhibitor, p18, in an in vivo mouse model has been 
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shown to increase self-renewal divisions in HSCs and facilitate engraftment upon 
transplantation (Yuan, Shen et al. 2004). Despite the increased cell-cycle entry, no 
long-term exhaustion of the HSC pool has been observed after deletion of p18 even to 
an extent of quaternary transplants, in contrast with previous studies that showed 
increased HSC cell-cycle activity (Yu, Yuan et al. 2006).  
 
From in vivo expression levels, it is known that Notch signaling plays an 
important role in maintaining quiescence of HSCs. Its overexpression in LSK cells 
results in the immortalization of cells with an undifferentiated, blast-like phenotype. 
By culturing them with specific cytokines, these cells were capable of long-term 
donor contribution upon transplantation, but showed lineage-bias in vitro and in vivo 
(Varnum-Finney, Xu et al. 2000). Immortalization of LSK Thy-1.1low cells by 
overexpression of the bcl-2 gene, an anti-apoptotic gene, resulted in a minimal 
increase in vivo. In vitro plating efficiencies were higher and chimerism was stronger 
even in competitive repopulating units with wild-type HSCs (Domen, Cheshier et al. 
2000). Although not present in younger mice, adult and aging mice showed an 
increased prevalence of myeloid and lymphoid leukemia. Its in vitro potential has not 
been reported to date. 
 
The limited expansion that was achieved through various HSC manipulations 
did not lead to improvements in a clinical setting and requires genetic engineering and 
modification. This not only should provide a more robust method but also shows a 
direct effect from gene up-regulation rather than a heterogeneous effect of extrinsic 
factors. Simultaneously, genetic engineering could not only be directed to expansion 
of existing HSCs but also to induction of an HSC phenotype in multipotent 
progenitors that have a much higher in vivo prevalence. Furthermore, in order to 
understand the underlying mechanism of HSC function and expansion as well as how 
they relate to leukemic cells, HSC behavior will need to be studied and compared to 
correlate with gene function. From gene expression profiling many hematopoietic 
regulators have been identified and through overexpression of various genes that are 
highly and/or exclusively expressed in HSCs, the potential for HSC expansion has 
been further explored. The exclusive expression of several of the homeobox genes at 
the HSC level made them of key interest in genetic engineering to induce HSC 
expansion. However, differences in their behavior towards non-expanding or 
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differentiating HSCs still need to be elucidated in order to understand the underlying 
mechanism. 
 
1.11 Homeobox genes 
 
During development, proliferation and differentiation as well as induced 
apoptosis are tightly controlled in order to form highly specialized tissues. Master 
regulators of these processes are a set of genes called homeobox genes (HOX), from 
homeosis, a process in which one body part transforms into another, which occurred 
in drosophila melanogaster upon mutations in these genes. Highly preserved during 
evolution and amongst species, they are found clustered on 4 chromosomes and are 
abbreviated HOXA-D, having a total of 39 genes in both mouse and human. Each 
cluster contains between 9 and 11 genes that are not only linked within each cluster 
but also have synergistic functions between parallel HOX clusters forming a total of 
13 functional groups that show large homology (Lappin, DG et al. 2006). Not only do 
their temporal expression correlate with their chromosomal location (3` to 5`), their 
expression is also spatially defined, occuring from the anterior to posterior region, 
respectively (Figure 1.11-1, (Lappin, DG et al. 2006).  
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Figure 1.11-1: Conservation between the HOM-C and HOX gene clusters 
Classification and organization of 39 HOX genes in 13 parallel functional clusters. The 3`genes are 
expressed more anteriorly and in earlier developmental stages than the 5`genes. With copyright 
permission from author (TRJ Lappin). 
 
The main functional parts of HOX proteins are the homeodomain (HD) at the 
C-terminus, the nuclear localization sequence and the TALE (three amino acid loop 
extension) region, both found at the N-terminus. The homeodomain consists of 60 
amino acids that define its DNA binding specificity. The N-terminus facilitates the 
DNA binding through binding of co-factors at the TALE region, such as Meis-1 and 
Pbx (Lappin, DG et al. 2006; Ohta, Sekulovic et al. 2007) (Figure 1.11-2).  
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HOX Genes: Seductive Science, Mysterious Mechanisms 25
www.ums.ac.uk
Fig 2. Conservation between the HOM-C and HOX gene clusters.
 The four Hox gene clusters found in mammals are conserved from the Drosophila Hom-C complex in terms of nucleotide 
sequence and colinear expression.  During embryonic development, the genes are expressed in a pattern that correlates 
with the chromosomal positioning, depicted here for human and mouse.  The 3` genes are expressed both earlier and 
more anteriorly than the 5` genes.
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Figure 1.11-2: Conserved homeobox gene and protein structure 
Schematic overview of HOX gene and HOX protein structure with different domains (not on scale). 
TALE (three amino acid loop extension) binding domain and variable domain are located at the N-
terminus whereas the homeodomain (DNA binding) is found at the C-terminus. 
 
In HSCs, HOX genes A, B and C are highly expressed. Upon differentiation, 
their expression is down-regulated, as during development, from 3`to 5`, suggesting 
that 3` HOX genes play a role in retaining multipotency or self-renewal capacity. The 
high expression level of HOXB3 and HOXB4 in HSCs (Sauvageau, Thorsteinsdottir 
et al. 1995; Lawrence, Sauvageau et al. 1996) has proven the plausibility of this 
hypothesis, since overexpression studies revealed a significant increase in HSC 
numbers in ex vivo culture (~80 fold), more comparable to the normal in vivo 
proliferation capacity upon transplantation (~100 fold) (Pawliuk, Eaves et al. 1996; 
Antonchuck, Sauvageau et al. 2002; Buske, Feuring-Buske et al. 2002; Sauvageau, 
Iscove et al. 2004). Moreover, HOXB4 overexpression leads to a much better 
engraftment potential compared with freshly isolated HSCs (Antonchuk, Sauvageau 
et al. 2001). This striking effect not only lies in the potency of HOXB4 to expand 
HSCs under culture conditions normally pushing myeloid differentiation, but 
similarly in the fact that this is reversible upon transplantation and homing into the in 
vivo HSC niche. 
 
On the other hand, overexpression or deregulation of other HOX genes leads 
to many blood disorders and malignancies, ranging from a perturbed lymphoid 
differentiation potential to the onset of latent leukemia (Thorsteinsdottir, Sauvageau et 
al. 1997; Buske, M et al. 2001; Thorsteinsdottir, Kroon et al. 2001; Owens and 
Hawley 2002; Thorsteinsdottir, Mamo et al. 2002; Sitwala, Dandekar et al. 2008). 
HOXA9 overexpression was found to further increase HSC expansion but resulted in 
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a latent leukemia onset. The fast proliferation of these cells and their blast-like 
phenotype, residing in an undifferentiated state in vitro, made it of key interest to 
further investigate the potential of different HOX gene-based engineered constructs 
that could further enhance HSC expansion but with leukemia exclusion. 
 
1.12 NA10HD 
 
About 5% of all AML cases are related to chromosomal rearrangements or 
translocations affecting HOX genes. The translocation t[(7;11)(p15;p15)]-  HOXA9, 
with nucleoporin 98 (NUP98)- results in rapid onset of AML and rapid proliferation 
(Borrow, Shearman et al. 1996). This was confirmed by overexpression of a construct 
containing this fusion gene in healthy primary HSCs, which indeed led to rapid 
leukemia onset upon transplantation (Kroon, Thorsteinsdottir et al. 2001; Calvo, 
Sykes et al. 2002). Other HOX fusions with NUP98 were found to increase HSC 
expansion with sometimes a very latent leukemia onset. The underlying mechanism is 
most likely the binding of CREB binding protein (CBP) and p300, both having a high 
affinity for the FG repeats at the N-terminus of NUP98 and acting as adapter 
molecules and co-activators (Kasper, PK et al. 1999; Ghannam, Takeda et al. 2004) 
(Figure 1.12-1). The question then was whether upon overexpression, different HOX 
genes are intrinsically oncogenic or became oncogenic upon fusion with NUP98 
(Abramovich, N et al. 2005). To test this, constructs were engineered containing 
fusions of NUP98-HOXB4 and NUP98-HOXA10, which were then transduced into 
HSCs and transplanted after ex vivo cultivation. While overexpression of NUP98-
HOXB4 further increased the HSC expansion potential without developing leukemia, 
NUP98-HOXA10 overexpression also resulted in a strong fold expansion of HSCs, 
albeit with a latent leukemia onset (Pineault, Abramovich et al. 2004).  
 
 
Figure 1.12-1: NUP98-HOXA10 fusion protein with protein complex partners 
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The TALE domain can bind adapter molecules PBX and Meis1, which can coactivate other down-
stream targets, whereas the NUP98 is often co-localized with CBP/p300. In NA10hd the TALE domain 
is missing. 
 
Interestingly, the leukemic potential of NUP98-HOXA10 seemed to be 
dependent on binding of Meis-1and independent of its DNA binding capacity. Thus, 
upon binding of CBP through NUP98 interaction, the flanking domains of the HOX 
gene containing the TALE domain seemed sufficient to induce leukemia (Pineault, 
Abramovich et al. 2005). By deletion of this TALE domain (NA10hd), Ohta et al. 
postulated the potential of HSC expansion could be maximized while the risk of latent 
leukemia was lost. Using limiting dilution assays in competitive repopulating assay, 
they showed a 1000 fold net increase in HSCs after 10 days of in vitro cultivation 
(Ohta, Sekulovic et al. 2007), in the range of the maximum in vivo HSC proliferation 
(~8400 fold, (Sauvageau, Iscove et al. 2004). Moreover, no leukemia was detectable 
and no in vivo lineage bias was observed, contrary to lymphoid bias upon HOXB4 
overexpression (Haddad, Pflumio et al. 2008). 
 
Due to their promising clinical potential, most studies now focus on further 
improving HSC expansion, using NA10hd or HOXB4 overexpression as a standard 
base line. Initially providing good results and potential genes of interest (Deneault, 
Cellot et al. 2009), these studies have recently been interpreted with care since the 
observed effect may come from an altered phenotype in overexpressing feeder lines, 
inducing different secreted molecules (Deneault, Wilhelm et al. 2013). Until now, 
NA10hd overexpression is therefore the most effective HSC expansion method. With 
recent advances in primate models, clinical applications may be the next step to 
proceed (Watts, Zhang et al. 2011). 
 
Despite the strong contrast from control HSCs that rapidly lost their self-
renewal potential due to myeloid differentiation, a NA10hd specific mechanism has 
yet to be defined. At first sight, no direct differences in proliferation rates were found. 
Although initially tested in bulk cultures with poor HSC purities by 5-fluoroacil 
treatment, a drug that ablates cycling cells and mobilizes quiescent cells such as 
HSCs, a recent paper could show similar results using clonal culture and higher HSC 
purity (Sekulovic, Gasparetto et al. 2011). In addition they showed that further 
addition of thrombopoietin fully diminishes HSC expansion. With data suggesting the 
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acquisition of a fetal liver HSC phenotype due to its high proliferation capacity, until 
now nothing is known about the mechanism of NA10hd induced HSC expansion, 
although preliminary comparisons have revealed multiple down-stream targets such 
as FLT3, HLF and JAG2 (Palmqvist, Pineault et al. 2007). 
 
Together this shows that recent gene profiling studies and further categorization 
and modification of NA10hd-induced expansion were still insufficient to elicit an 
underlying mechanism. Both the influence of extrinsic factors as well as behavioral 
differences are poorly understood. Furthermore, little is known about the in vivo 
reversibility and control of both self-renewal and differentiation. Since the majority of 
these studies were performed in bulk culture, large heterogeneity would mask the 
existence of distinct classes and behavioral subsets would not be detected. In addition, 
inheritance of daughter cells with respect to both marker expression and proliferation 
rate cannot be assessed since genealogy is lost, which furthermore leaves the question 
unanswered whether true HSCs are expanded or HSC potential is induced. For these 
reasons, a clonal in vitro read-out using continuous time-lapse imaging would prove 
an outcome in defining NA10hd behavior. Long-term imaging for more than 7 days 
has been difficult to implement due to either accumulation of high numbers of cells or 
following low density seeding. While the former results in loss of clonal identity, the 
latter has the consequence that larger surface areas need to be covered with the 
consequence of impairing temporal resolution. Further optimization of both culture 
conditions as well as software and imaging techniques should allow such read-outs 
with preservation of genealogy. Not only would this provide deeper insight in 
NA10hd behavior, combined with quantification of surface marker expression 
through live fluorescent antibody labeling, co-culture with stroma cells or control 
cells this would furthermore elicit cellular subsets and the influence of extrinsic 
factors such as cell-cell contact, respectively. 
 
1.13 Stroma co-culture 
 
PA6 cells are known to have the capacity to maintain HCSs stemness over 
multiple days under co-culture conditions. Their expression of SCF, Sca-1 and CD34 
as well as interleukin-6 indicates their importance for survival and HSC maintenance 
and differentiation, respectively (Satoh, Mioh et al. 1997; Satoh, Mioh et al. 1997). 
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The expression of chemokine ligand 5 (CXCL5) further functions as a 
chemoattractant (Shimizu, Noda et al. 2008), similar to the production of the related 
CXCL12 in the in vivo niche. For HSC maintenance it has been shown that cell-cell 
interaction of the HSCs with the stromal cell layer is indispensable (Kodama, Amagai 
et al. 1982). Although PA6 cells do not permit B lymphoid development, addition of 
interleukin-7 can fully reestablish this potential (Sudo, Ito et al. 1989). 
 
Due to their high optical clarity and their contact inhibition of growth upon 
confluence, these stromal cells form an excellent substrate to study HSC behavior. 
Mimicking in vivo cell-cell interactions with their niche or mimicking physiological 
conditions, HSCs can be observed long-time. With use of time-lapse imaging, HSCs 
can be tracked and factors as adherence, motility, apoptosis, and cell lifetime can be 
quantified in progeny of late generations and inheritance can be assessed, which to 
date has not been shown due to technical difficulties in both imaging and cultivation 
and cannot be detected in bulk culture or by snapshot analysis. Moreover, with use of 
fluorescent imaging and live antibody staining, marker expression can be accurately 
attributed on a clonal basis (Eilken, Nishikawa et al. 2009). Taken together, this 
method provides new insight and allows defining a signatorial behavior of HSCs 
during in vitro expansion. 
 
1.14 Conclusion 
 
There is evidence that cell-cycle phase may play a direct role in cytokine 
induced lineage production but HSC heterogeneity and technical challenges so far 
didn’t allow to make the point. The lack of live cell-cycle quantification and the fact 
that most studies are performed on a population level furthermore hampered the 
assessment of cell-cycle dynamics and the existence of behavioral subsets. In 
addition, cytokines are known to direct blood lineage production but to date the 
question remains whether the effect on cell fate can be dependent on the cell-cycle 
phase at the time-point of administration. Such an effect on HSCs has not yet been 
shown. Finding such a correlation and unraveling the underlying molecular 
mechanism would potentially improve lineage specific production in a clinical setting 
in vitro and in vivo. For this reason, a clonal read-out that allows live cell-cycle 
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quantification while assessing lineage commitment would be of key interest to answer 
these long-standing questions. 
 
Instead of directing lineage production to derive specific mature subsets, another 
focus lies in ex vivo expansion of HSCs to treat patients that require transplantation. 
The engineered fusion protein NA10hd has been shown to induce over a 1000-fold 
expansion in vitro within 1 week of culture. However, its mechanism is still unknown. 
To further understand what drives this expansion and how these cells differ from non-
manipulated HSCs that differentiate in vitro, the behavior of these NA10hd cells, in 
terms of cell division rate, apoptosis, marker expression, adherence and migration 
needs to be followed up. The in vivo reversion of the differentiation block found in 
vitro as well as the reduced proliferation kinetics furthermore require in-depth 
assessment how niche or cell-cell interactions are involved in altering NA10hd 
behavior. 
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2 Aims of the thesis 
 
It has long been an outstanding question whether cells receiving the same 
cytokine in different cell-cycle phases will have diverging cell fates. Moreover, it still 
remains unclear whether at the level of the most primitive HSCs, cytokines can 
already direct lineage decision. The aim of this thesis is to verify whether both 
phenomena exist using time-lapse imaging at single-cell resolution. For this purpose, 
live cell-cycle quantification first needs to be established in primary HSCs. This not 
only allows assessing and scoring of cell-cycle phase upon cytokine addition but also 
allows observing how HSCs transit through cell-cycle over multiple generations.   
 
End-point lineage production and thus multipotency can be correlated with both 
the initial cell-cycle phase and cell-cycle durations and transitions in subsequent 
generations, identifying a lineage-specific behavior so far not possible due to either 
loss of ontogeny or initial cell-cycle state. Using time-lapse imaging, cytokines can be 
also added after the first in vitro cell-cycle division to test whether cell-cycle specific 
cell fates are equally applicable to daughter cells and test for HSC specificity. With 
such a technique, the effect of specific additional cytokines can be directly measured. 
 
Focusing specifically on cells with multilineage potency, in-depth analysis of in 
vitro NA10hd HSC behavior will be completed by comparison of cell lifetimes of 
progeny and ancestry, which to date remained elusive. Finally, the effect of stromal 
co-culture will shed light on the effect of cell-cell contacts on NA10hd HSC behavior, 
mimicking the reduced proliferation found in the in vivo niche.  
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3 Materials, methods and experimental procedures 
 
 
3.1 Purification 
3.1.1 HSC isolation 
 Femurs, tibiae and pelvic bones were dissected from male 12 weeks old 
C57Bl/6 mice and excessive tissue was removed. Bones were crushed using a mortar 
and pestle, re-suspended in 2% fetal calf serum (FCS) (cat. no. A15-101, PAA) in 
Dulbecco’s phosphate buffered saline (PBS) (cat. no. 14190-094, Gibco, Life 
Technologies, Paisley, UK) and passed through a 100 µM cell strainer (cat. no. 
352360, BD Falcon, Schubert & Weiss Ombilab GmbH, Munich, Germany) into a 50 
mL polypropylene (PP) tube (cat. no. 352070, BD Falcon, Schubert & Weiss Ombilab 
GmbH, Munich, Germany). After centrifugation (all centrifugation steps performed at 
240 RCF, 5 min 4°C, (cat. no. 5805, Rotanta 460R, Hettich Zentrifugen, Tuttlingen, 
Germany)), erythrocyte lysis was performed using ACK lysing buffer (cat. no. 10-
548E, Lonza, Walkersville, USA) for 2 min on ice at 2.5 µL/106 cells.  Cells were 
washed and resuspended in FACS buffer containing 5% FCS in PBS with 1 mM 
EDTA (cat. no. ED4SS-100G, Sigma-Aldrich, Steinheim, Germany) at 108 cells/mL 
and lineage depletion was performed using the following antibodies: 
 
Table 3.1-1: Lineage depletion for HSC purification 
Antibody Clone Cat. No. 
B220-biotin RA3-6B2 13-0452-86 
CD3-biotin 145-2C11 13-0033 
CD19-biotin 1D3 13-0193-85 
CD11b-biotin M1/70 13-0112-85 
Gr-1-biotin RB6-8C5 13-5931-85 
Ter119-biotin TER-119 13-5921-85 
Cells were stained at 50 ng/106 cells. All antibodies were obtained from eBioscience, San Diego, USA. 
 
After 20 min incubation on ice, cells were re-suspended in buffer and Roti-
MagBeads Streptavidin (cat. no. HP57.1, Carl Roth, Karlsruhe, Germany) was added 
at 0.4 µL/106 cells. After 10 min at room temperature (RT), cells were transferred into 
14 mL polypropylene tubes (cat. no. 352059, BD Falcon, Schubert & Weiss Ombilab 
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GmbH, Munich, Germany) and lineage depletion was performed for 7 min at RT 
using an Easy Sep magnetic assisted cell sorter (cat. no. 18001, Stem Cell 
Technologies, UK).  
Lineage negative (Lin-) cells were stained with fluorescent protein conjugated 
antibodies for further purification in 100 µL buffer: 
 
Table 3.1-2: HSC and MPP purification using fluorescence in flow cytometry 
Antibody Concentration Clone Company Cat. No. 
CD48 FITC 40 ng/106 cells HM48-1 Biolegend 103404 
CD150 PE 40 ng/106 cells TC15-12F12.2 Biolegend 115904 
CD135 PE Cy5 40 ng/106 cells A2-F10 eBioscience 15-1351-81 
CD117 PE Cy7 60 ng/106 cells 2B8 eBioscience 25-1171 
CD34 E660 100 ng/106 cells RAM34 eBioscience 50-0341-82 
SA APC E780 40 ng/106 cells  eBioscience 47-4317-82 
Ly6A/E PB 40 ng/106 cells D7 Biolegend 108120 
Fluorescence-conjugated antibodies were used for HSC enrichment. Used abbreviations: Fluorescein 
isothiocynate (FITC), phycoerythrin (PE), phycoerythrin cyanine 5 (PE Cy5), phycoerythrin cyanine 7 
(PE Cy7), eFluor660 (E660), streptavidin allophycocyanin eFluor 780 (SA APC E780), Pacific Blue 
(PB). 
 
Compensation tubes were prepared with Lin+ cells at 0.2 µg/50µL cell 
suspension with the above antibodies. Cells were incubated for 60-90 min at 4°C. 
Before cell sort, cells were strained through a 35 µM filter (cat. no. FALC352235, BD 
Falcon, Schubert & Weiss Ombilab GmbH, Munich, Germany) into a 5 mL PP tube. 
 
3.1.2 Flow cytometry 
All cell purifications and analyses were performed on a FACSAria III machine 
(Becton Dickinson, San Jose, USA) with FACSDiva software. Equipped with 4 
lasers, following filters were used for different fluorochromes and fluorescent 
proteins: 
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Table 3.1-3: Fluorescence activated cell sort 
Laser Filter Fluorochrome / 
fluorescent protein 
405 nm 450/40 PB 
488 nm 530/30 FITC, VENUS 
 695/40 PerCP E710 
561 nm 586/12 PE 
 610/20 PI, mCHERRY 
 670 PE Cy5 
 780/60 I PE Cy7 
633 nm 660/20 E660 
 730/45 Alexa700 
 780/60 II APC E780 
Multicolor flow cytometry allows usage and detection of up to 10 antibodies simultaneously and 
facilitates high purification of HSCs. Laser, excitation and emission settings for flow cytometry. 
 
Compensation was performed using biexponatial settings and single stain 
compensations. Gates were set using unstained control and contour plots. Before 
sorting, drop delay was performed using auto settings and accudrop fluorescent beads 
(cat. no. 345249, BD) and a test sort was performed. Purification was then performed 
using a 70 µM nozzle and a frequency of 87 kHz at an average of ~104 events/second 
into 5 mL PP tubes containing 2 mL of serum free essential medium (StemSpan 
SFEM, StemCell Technologies Inc.). Stream instabilities were prevented by cleaning 
the nozzle using a ultrasonic cleaner (cat. no. USC100T, VWR, Leuven, Belgium). 
3.2 Vector cloning 
3.2.1 Plasmids 
Plasmids were cloned according to standard digestion and ligation protocols 
(Fermentas). DNA was generated by reverse transcriptase polymerase chain reaction 
(RT-PCR, cat. no. 28104, Qiagen) when necessary and purified using gel 
electroporation and extraction kits (cat. no. 20021, Qiagen). Following vectors were 
used in the course of both projects: 
 
Table 3.2-1: Plasmids 
In-house # Domains 
442 pRRL.RRE.PPT.SFFV.IRES-VENUSnucmem.PRE.SIN 
638 pRRL.RRE.PPT.SFFV.FNA10HD.IRES-VENUSnucmem.PRE.SIN 
663 pRRL.RRE.PPT.SFFV.IRES-VENUSPSLD.PRE.SIN 
679 pRRL.RRE.PPT.SFFV.mCHERRYPSLD.PRE.SIN 
860 pRRL.RRE.PPT.SFFV.FNA10HD.IRES-mCHERRYPSLD.PRE.SIN 
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 The pRRL vector contains the promoter of the Rouse sarcoma virus (RSV), 
the 5´unique region (RU5), the primer binding site (PBS) for viral reverse 
transcriptase and the gag domain that provides core structural proteins. The rev 
(nuclear localization signal and for synthesis) responsive element (RRE) allows 
translation. The polypurine tract (PPT) facilitates initiation of the DNA plus strand, 
the post-transcriptional regulatory element (PRE) enhances levels of transcripts and 
the self-inactivating (SIN) domain provides further safety by leaving a defective 
promoter. All vectors contain ampicillin resistance. 
 
Expression of all proteins of interest (bold) is driven by the spleen focus-
forming virus (SFFV). Fluorescent proteins (VENUS or mCHERRY) were chosen for 
their strong emission, their low phototoxicity and their ease of combination with 
many live fluorescent antibodies. In co-expressing vectors, expression of fluorescent 
reporters was driven by an internal ribosome entry site (IRES). The nucmem domain 
stands for nuclear membrane localization and contains the human importin alpha 1 
domain. The PSLD domain is described in 1.7. The Nup98-HOXA10homeodomain 
(NA10hd) contains a Flag-tag (F) at the N-terminal end combined with a linker 
protein, thereby not hampering its functional domains. 
3.2.2 DNA preparation 
DNA was extracted using a QIAGEN Plasmid Kit (cat. no. 12125, Qiagen 
Sciences, Hilden, Germany). Briefly, DNA from ligation products was transformed 
into DH5 competent bacteria using heat-shock and incubated overnight on agar plates 
containing ampicillin.  
Single colonies were picked and inoculated overnight on a 37°C shaker in 4 
mL of ampicillin containing LB medium. DNA extraction was then performed 
according to protocol using a microcentrifuge (Mikro 200, cat. no. 2400, Hettich 
Zentrifugen, Tuttlingen, Germany) and DNA was eluted in 30 µL milli-Q water. Test 
digests were performed and DNA quantity was measured. DNA was stored at -20°C. 
3.2.3 Transfection 
Polyethylenimine (PEI) solution was prepared by dissolving 100 mg PEI (cat. 
no. 23966, Polysciences Inc., Warrington, USA) in 900 mL 150 mM NaCl (cat. no. 
32038-1EA, Sigma-Aldrich, Steinheim, Germany) at 80°C overnight. Solution was 
cooled and pH was adjusted to 7.8 using HCl. Volume was adjusted to 1 L using 150 
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mM NaCl and solution was filtered and stored at 4°C. 500 ng of plasmid DNA was 
then added to 66 µL polyetylenimine solution, vortexed for 10 s and incubated for 10 
min at RT. Solution was then carefully added to each well containing 500 µL medium 
on HEK 293 cells and gently mixed by shaking. Expression and localisation were 
assed after 24 to 48 hours by epifluorescent microscopy. 
3.3 Lentiviral production and transduction 
3.3.1 DNA preparation 
High quantities and concentrations of DNA were obtained using a QIAGEN 
Plasmid Kit (cat. no. 12165, Qiagen Sciences, Hilden, Germany). Briefly, 500 µL of 4 
mL DNA containing bacterial culture was pipetted or DNA containing bacteria from 
glycerol stocks was inoculated into 100 mL ampicillin containing LB and incubated 
overnight on a 37°C shaker. DNA was then extracted and purified according to 
protocol and eluted in 100 µL milli-Q water. DNA was stored at -20°C.  
3.3.2 HEK 293 culture 
Immortalised human embryonic kidney cells from the 293rd experiment 
(Lenti-X HEK 293 T, (cat. no. 632180, Clontech)) were kept in 24-well plates (cat. 
no. 353047, BD Falcon, Schubert & Weiss Omnilab, Munich, Germany) for 
maintenance and were seeded at ~105 cells per well in Dulbecco’s modified eagle 
medium (DMEM, cat. no. 31053-028, Invitrogen) containing 10% FCS. Cells were 
passaged every second day at a 1:8 to 1:10 ratio, using 0.05% trypsin (cat. no. 25300-
054, Gibco) and re-suspended in media without centrifugation. For up scaling for 
lentiviral production, 9-cm dishes were used (cat. no. 150350, Thermo Scientific, 
Roskilde, Denmark). HEK 293 cells were kept until passage number 40. 
3.3.3 Lentiviral production 
4 plates of HEK 293 cells were plated at 5x106 cells/60cm2 in DMEM 
containing 10% FCS. After 24 hours, media was aspirated and 10 mL of transfection 
media was added per plate (DMEM containing 2mM L-glutamine (cat. no. 25030-
081, Gibco) and 0.1 mM sodium pyruvate (cat. no. 41966-029, Invitrogen), 10% FCS 
1% penicillin/streptomycin, 100 U/mL and 0.1 mg/mL respectively (P/S, cat. no. 
15070063, Gibco, Life Technologies, Paisley, UK) 20 mM HEPES (cat. no. 15630-
056, Invitrogen). Then viral envelope vectors were added, diluted in 500 µL 0.25 M 
CaCl2 in H2O and mixed with 500 µL 2x HEPES buffered saline (50 mM HEPES, 
! 43!
280 mM NaCl, 1,5 mM Na2HPO4 (cat. no. P030.3, Carl Roth, Karlsruhe, Germany) in 
H2O (pH 7.1)) with added CaPO4 (cat. no. CAPHOS-1KT, Sigma-Aldrich, Steinheim, 
Germany) to 1M: 
 
Table 3.3-1: Viral envelope DNA used for transduction 
Plasmid 
Function Quantity 
pUC19.RSV.REV (392) 
Packaging 2 µg 
CMV.betaglobin.gag.pol.RRE.PolyA.pUC19 (393)   Packaging 5 µg 
pMD2-VSVG.IRES-Puromycin (495) 
Envelope 5 µg 
pAdVAntage (cat. no. E1711, Promega) 
Translation 6 µg 
Gene containing plasmid 
Expression 5-8 µg 
Abbreviations: Cytomegalo virus promotor (CMV), vesicular stromatitis Indiana virus 
(VSVG). For others see 3.2.1. 
 
Cells were incubated overnight. At 48 hours, media was aspirated, 4.5 mL of 
transfection media was added containing 50 mM sodium butyrate (cat. no. B5887, 
Sigma-Aldrich, Steinheim, Germany). 
At 72 hours, supernatant was collected and stored at 4°C. 4.5 mL of 
transfection media was added to all plates. At 96 hours, supernatant was again 
collected and pooled before centrifugation (200 RCF, 5 min at 4°C) in ultracentrifuge 
tubes (cat. no. 326823, Beckmann). Supernatant was filtered through a 0.22 µM filter 
into a new ultracentrifuge tube and centrifuged at 50000G for 1 hour at 4°C after 
calibration. Supernatant was removed and pellet was vortexed with 200 µL SFEM 
after 15 min incubation on ice. Virus was then aliquotted and stored at -80°C. 
Titer was calculated using dilution series and calculating the percentage of 
positive cells per cell number by FACS analysis on NIH 3T3 cells at day 2 after virus 
addition in DMEM 10% FCS. 
3.3.4 Lentiviral transduction 
Cells were washed and counted by spinning down (240 RCF, 1 min at 4°C) 5 
µL cell suspension into a well of a Nunc minitray (cat. no. 163118, Thermo Fisher 
Scientific, Roskilde, Denmark). The volume and amount of viral particles was 
calculated by dividing the cell number with the titer multiplied with the desired 
multiplicity of infection (MOI). For cell lines, a MOI between 1 and 10 was found 
sufficient, higher numbers were toxic in some cases. For primary cells, an optimum 
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was found at MOI 600, providing highest transduction efficiency (~80%) and no 
detectable increase in toxicity. Cells were transduced in 100 µL media in a 96-well 
Nunclon microwell plate (cat. no. 167008, Thermo Fisher Scientific, Roskilde, 
Denmark) and incubated for 24 to 48 hours before use. 
3.4 Cell-cycle reporter validation 
3.4.1 Propidium Iodide staining  
Cells were washed and resuspended in 1 mL PBS. 2.5 mL of absolute ethanol 
(cat. no. 1009831000, Merck) was added drop wise and cells were fixed on ice for 5 
min with repeated vortexing. Cells were centrifuged at 300 RCF for 5 min at 4°C and 
resuspended in 300 µL of 50 µg/mL propidium iodide (PI) (cat. no. P4170-25MG, 
Sigma-Aldrich, Steinheim, Germany) with 100ng/mL RNase A (Qiagen Sciences, 
Hilden, Germany) in PBS. After 1 hour of incubation at 37°C 5% CO2, cells were 
centrifuged and 200 µL of supernatant was pipetted off before analysis. 
Analysis was performed with FACSAria III using a 488 nm laser and 610 nm 
BP filter (see 3.1.2). Data was then processed with Flowjo software (Flowjo version 
X, Tree Star, Inc., OR, USA), using a Watson-Pragmatic or Dean-Jett-Fox model for 
distribution to set gates for different cell-cycle phases. 
Alternatively, PI signals were quantified in a 384-well plate (cat. no. 88401, 
IBIDI, Martinsried, Germany) using Lumencor 590 nm (Laser2000) and suiting 
mCHERRY filter (cat. no. F36-508, AHF, Germany). Images were quantified using 
AMTsingle software (unpublished). 
3.4.2 PSLD quantification  
To verify the validity of PSLD in determining cell-cycle phase, cells stained 
with PI were directly compared with cells that had been transduced with a 
mCHERRYPSLD expressing lentiviral vector (see 3.2 and 3.3). Cells were 
categorized using published descriptions and cell numbers were assessed using FIJI 
software (ImageJ 1.47k, NIH, USA). Comparison was then performed using MS 
Excel plotting and Graphpad Prism 5 (GraphPad Software, Inc., CA, USA).  
 
 
! 45!
3.5 Erythrocyte detection using fluorescent antibodies 
Granulocyte-macrophage progenitors (GMPs) and megakaryocyte-erythrocyte 
progenitors (MEP) were sorted by flow cytometry (Lin- Ly6A/E- CD117+ CD34+ 
CD16/CD32+ and Lin- Ly6A/E- CD117+ CD34- CD16/CD32-, respectively). GMPs 
were cultured for 5 days in SFEM with 10 ng/mL M-CSF, with live antibody staining 
using anti-F4/80-conjugated APC and CD71-conjugated FITC (See 5.7). MEPs were 
cultured in SFEM 100 ng/mL SCF 100 ng/mL TPO 10 ng/mL IL-3 2 U/mL 
erythropoietin (cat. no. C-60022, Promokine) 10% FCS 50 µM 2-mercaptoethanol 
(cat. no. M3148-25ML, Sigma-Aldrich, Steinheim, Germany) and 1% L-glutamine 
with anti-CD105-conjugated Alexa 555 and anti-CD71-conjugated FITC (see 3.7). 
Cultures were analyzed after 5 and 7 days and CD71 signals were quantified.  
As a comparison, freshly stained lineage subsets from whole bone marrow were 
compared for CD71 expression using flow cytometry.  
 
3.6 Cell culture 
Cells were incubated at 37°C, 5% CO2 and 99% humidity in a controlled 
incubator (CD210, Binder, Tuttlingen-Möhringen, Germany). Tips were obtained 
from Greiner Bio-one (cat. no. 710190 (2 mL), 606180 (5 mL), 607180 (10 mL) and 
760180 (25 mL), Frickenhausen, Germany) and Omnitip (cat. no. 81710 (10 µL), 
83710 (200 µL) and 85710 (1200 µL), Warsaw, Poland). 
3.6.1 Cell line maintenance 
Alpha minimal essential medium (aMEM, cat. no. 11900-016, Invitrogen, 
Germany) containing 10% FCS and 1% P/S was prepared and pre-heated at 37°C. 
Cells were taken out of liquid nitrogen tank and cryotube was put on ice to avoid 
thawing to complete. Cells were then transferred into a 37°C water bath (cat. no. 
1002, GFL, Burgwedel, Germany) to thaw.  Upon dissolving of last crystals, cell 
suspension was gently transferred into a 15 mL PP tube (cat. no. 352095, BD Falcon, 
Schubert & Weiss Omnilab GmbH, Munich, Germany) and 10 mL of pre-heated 
media was added drop wise while rolling the tube on an inclined angle to mix gently. 
Cells were centrifuged at 200 RCF for 5 min at 4°C. Supernatant was removed and 
cells were gently re-suspended in 3 mL media and transferred into a 6-well plate (cat. 
no. 140685, Thermo Fisher Scientific, Roskilde, Denmark). Media was refreshed after 
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24 hours. Cells were grown as desired and re-frozen to maintain cell lines and to 
avoid batch depletion. Confluent cells were trypsinised with 1 mL 0.05% trypsin for 2 
min at 37°C 5% CO2. Trypsin was inactivated by adding 9 mL of media and cells 
were centrifuged at 200 RCF for 5 min at 4°C. Cells were re-suspended in 3 mL FCS 
10% dimethylsulfoxide (DMSO, cat. no. D2650, Sigma-Aldrich, Steinheim, 
Germany) and 1 mL of cell suspension was gently pipetted into each cryovial (cat. no. 
290174707, Neolab). Cryovials were stored at -80°C for 24 hours and then transferred 
to liquid nitrogen tanks. 
 
3.6.2 PA6 culture 
MC3T3-G2/PA6 cells were cultured in alpha minimal essential medium 
(aMEM, cat. no. 11900-016, Invitrogen, Germany) with 10% FCS and 1% 
penicillin/streptomycin, 100 U/mL and 0.1 mg/mL respectively (P/S, cat. no. 
15070063, Gibco, Life Technologies, Paisley, UK) in a 37°C incubator. Cells were 
passaged every 3 to 4 days, when reaching approximately 95% confluence, by 
trypsinisation for 2 min at 37°C and re-suspension in medium at a 1:4 ratio. For 
experiments, passage numbers from 3 to 15 were used. 
3.6.3 NA10HD culture 
NA10HD cells for time-lapse experiments and cells that were kept for long-
term culture, were incubated in a 37°C incubator. Media consisted of 100 ng/mL SCF 
(cat. no. 250-03), 3 ng/mL IL-3 (cat. no. 213-13), 10 ng/mL IL-6 (cat. no. 216-16), all 
obtained from Peprotech, 10% FCS and 1% PS in DMEM. Media was refreshed every 
third day and cells were serially diluted when reaching confluence (~106 cells/mL).  
3.6.4 Co-culture 
MC3T3-G2/PA6 cells were inoculated in 100 µL cell suspension at 5000 
cells/cm2 into a silicone culture insert (cat. no. 80209, IBIDI, Martinsried, Germany) 
and cultured for 2 days in aMEM 10% FCS 1% P/S. After reaching confluency at day 
2 of culture, media was aspirated and HSCs were inoculated in Iscove’s modified 
Dulbecco’s medium (IMDM, cat. no. P04-20451, PAN) containing 100 ng/mL SCF, 
10% FCS, 20% horse serum (cat. no. 16050-122, Invitrogen), 10-7 M hydrocortisone 
(cat. no. H0888-1G, Sigma Aldrich, Steinheim, Germany) and 1% P/S. Experiments 
were performed in either 25 mL tissue culture flasks (cat. no. 353018, BD Falcon, 
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Schubert & Weiss Ombilab GmbH, Munich, Germany) or 24-well Nunclon plates 
(cat. no. 167008, Thermo Fisher Scientific, Roskilde, Denmark). In both cases, pre-
incubated media was added (15 mL and 1.5 mL, respectively) after cells had set at the 
bottom (approximately 1 hour)). After additional 2 hours of CO2 saturation, flasks 
were screwed tight and multi-well plates were sealed using 15 mm Tesa film tape 
(cat. no. 57370-00002, Tesa SE, Hamburg, Germany) before conducting the 
experiment. 
3.6.5 Clonal analysis and media optimization 
Freshly isolated HSCs were virally transduced with a lentiviral vector 
expressing mCHERRYPSLD (see 3.1-2 and 3.3.4) in SFEM 100 ng/mL SCF and 100 
ng/mL TPO (MOI 600) for 24-44 hours. 
 
For media testing, limiting dilution was applied to obtain an average of 1 cell 
per 3 wells. Cells in media suspension were then pipetted into a 1536-well plate (cat. 
no. 783892, Greiner Bio-One, Frickenhausen, Germany) using a multi-pipette (Rainin 
Pipet-Lite (cat. no. L12-20, Mettler Toledo, Oakland, USA)) set at 10 µL and special 
Rainin tips (cat. no. RT-L10, Mettler Toledo, USA) and a 50 mL reagent reservoir 
(cat. no. 4870, Corning Incorporated, NY, USA). 
 
In experiments for media optimization, phenol red free SFEM was used with 
SCF and a combination of TPO, IL-3, erythropoietin (cat. no. C-60022, Promokine), 
GM-CSF (cat. no. 167315-03-B), G-CSF (cat. no. 167250-05-B, both Peprotech), 
FCS, 2-mercaptoethanol (cat. no. M3148-25ML, Sigma-Aldrich, Steinheim, 
Germany) and L-glutamine. Media was filtered using a 0.2 µM Minisart filter (cat. 
no. 16532, Sartorius, Goettingen, Germany) and a 20 mL injekt syringe (cat. no. 
4606205V, B.Braun, Carl Roth, Karlsruhe, Germany). 
 
For clonal analysis at 24 or 44 hours, cells were washed in 15 mL PP tubes and 
re-suspended in FACS buffer and single mCHERRYPSLD expressing cells were 
sorted into a 384-well plate (cat. no. 88401, IBIDI, Martinsried, Germany) using a 
single-cell sorting mode and gates set according to a non-transduced control. Wells 
were filled with 100 µL media, pipetted with a multi-pipette (Transferpipette-12 (cat. 
no. 0533267, Eppendorf)) and using a reagent reservoir. Wells were sealed using a 
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gas permeable membrane to prevent evaporation (Breathe Easy, cat. no. BEM-1, 
Diversified Biotech, USA).  
 
Small holes were drilled with needles in 2 opposite corners of each lid and bent 
needles (26G x 1”, cat. no. 4657863 and 23G x 1.25”, cat. 4657640, B.Braun, Carl 
Roth, Karlsruhe, Germany) were fixed with silicone for fixation (Aquasil, cat. no. 
6139100V00, JBL GmbH, Neuhofen, Germany) to allow gas perfusion. After cell 
seeding, plates were sealed using Tesa film to ensure optimal gas flow. 
 
3.7 Protein detection on living cells 
Cells were characterized according to marker expression, detected by 
fluorochrome conjugated antibody addition to culture medium. For both 
quantification using epifluorescent microscope imaging and for FACS analysis, 
different combinations of the following antibodies were used, depending on 
experiment: 
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Table 3.7-1: Live in culture antibody quantification 
Antibody Clone Fluorochrome Company Cat. No. 
CD11b 
 
       
CD16/CD32 
 
 
CD41        
CD43        
M1/70  
 
               
2.4G2 
93 
93 
MWReg30 
S7 
FITC 
A488 
PE             
A647 
A700 
PerCP Cy5 
PE 
FITC 
3.8 eBioscienc
e 
eBioscienc
e 
eBioscienc
e    BD 
Pharminge
n 
eBioscienc
e 
Biolegend 
BD Pharmingen 
BD Pharmingen 
11-0112-82 
53-0112-82 
12-0112-83 
553142 
56-0161-82 
45-0161-82 
558040 
561856 
CD48 
CD71 
CD105 
CD117 
HM48-1 
R17217 
MJ7/18 
2B8 
A647 
FITC 
A647 
PE Cy7 
Biolegend 
eBioscience 
eBioscience 
eBioscience 
103404 
111-0711-82 
14-1052-82 
25-1171 
CD150 TC15-12F12.2 PE Biolegend 115904 
CD135 A2-F10 PE eBioscience 12-1351-83 
CD34 
F4/80 
RAM34 
BM8 
E660 
A647 
eBioscience 
eBioscience 
50-0341-82 
16-4801-85 
Gr-1 RB6-8C5 PE eBioscience 12-5931-82 
Ly6A/E  
Ly6G 
Ter119 
D7 
1A8 
TER-119 
A647 
A555 
FITC 
Biolegend 
eBioscience 
eBioscience 
108120 
14-5981-82 
11-5921-81 
Fluorescent antibodies used for live detection of surface marker expression. Abbreviations: 
Fluorescein isothiocynate (FITC), phycoerythrin (PE), peridinin-chlorophyll cyanine 5 
(PerCP Cy5), phycoerythrin cyanine 7 (PE Cy7), eFluor660 (E660), Alexa dye (A). Used at 
final concentration of 25 ng/mL. 
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3.8.1 Antibody labeling  
Antibodies were conjugated according to manufacturer’s protocol. Briefly, 1 
mg of primary antibody was mixed with a succinimidyl ester conjugated fluorescent 
protein, which created a covalent bond at the primary amine group without interfering 
with the functional domains. Antibodies were filtered and aliquoted and stored at 4°C 
at a concentration of 0.2 µg/µL. Labeling kits were obtained from Invitrogen (Alexa 
488, cat. no. A10468, Alexa 555, cat. no. A20187, Alexa 647, cat. no. A20186). 
3.9 Differentiation and proliferation assay 
HSCs were virally transduced at 600 MOI (see 3.3.4) for 48 hours with a 
lentiviral vector containing NA10HD with an IRES-driven nuclear membrane-bound 
VENUS reporter, or a mock-infect control without NA10HD in DMEM containing 
10% FCS, 100 ng/mL SCF, 10 ng/mL IL-6, 6 ng/mL IL-3 and 1% P/S. Cells were 
washed and re-suspended in media and triplicate wells were seeded with each well 
containing 100 cells. Cell numbers were assessed by imaging and cell counts using 
Fiji software for day 1 to 3, and 5 µL aliquots were used for counting in minitrays at 
later days. Cells were maintained as described (see 3.6.3). Expression of CD48 was 
quantified using live antibody staining (see 3.7) and both cell numbers and CD48 
expression were quantified for NA10HD cells, non-transduced cells (~40 percent) in 
NA10HD wells and mock-infected cells. Proliferation and differentiation curves were 
created using MS Excel. 
3.10 Immunohistochemistry 
3.10.1 NA10HD expression 
HSCs were virally transduced in DMEM containing 10% FCS, 100 ng/mL 
SCF, 10 ng/mL IL-6, 6 ng/mL IL-3 and 1% P/S with a lentiviral vector containing 
NA10HD with an IRES-driven nuclear membrane-bound VENUS reporter or a mock-
infect control without NA10HD at MOI 600 (see 3.1-2 and 3.3.4). Cells were washed 
and re-suspended in media. 30 µL of cell suspension was pipetted on a 18-well poly-l-
lysine coated IBIDI microslide (cat. no. 81806, IBIDI, Martinsried, Germany). Cells 
were allowed to set for 30 min in incubator after which media was gently aspirated.  
Cells were fixed with fresh 4% paraformaldehyde for 10 min at RT. Cells 
were carefully washed once with PBS and permeabilised with 0.1% Triton X 100 in 
PBS (cat. no. 3051.3, Carl Roth, Karlsruhe, Germany) for 5 min at RT. After washing 
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3 times with PBS, cells were blocked with 1% bovine serum albumin (BSA, cat. no. 
B4287-5G, Sigma-Aldrich, Steinheim, Germany) in PBS for 1 hour at 37°C. 
Rabbit@FLAG primary antibody (polyclonal, cat. no. F7425, Sigma-Aldrich, 
Steinheim, Germany) was then added at 2 µg/mL, 1% BSA in PBS and incubated 1 
hour at RT. After washing 3 times with PBS, A647@rabbit at 1 µg/mL in 1% BSA in 
PBS was added for 30 min at RT. 2 mg/mL Hoechst33342 in PBS was added for 20 
min at RT and specimen was washed 3 times with PBS before adding mounting 
solution (Aqua-Poly/Mount mounting solution, cat. no. 18606-20, Polysciences, 
USA) and mounting microscope slides (cat. no. J1800AMNZ, Thermo Fisher 
Scientific, Gerhard Menzel, Braunschweig, Germany). Images were obtained using 
confocal microscopy (see 3.9.3) and a 63x objective. 
3.10.2 Pathway activity 
Freshly isolated HSCs were virally transduced overnight with an 
mCHERRYPSLD overexpressing lentiviral vector (see 3.1 and 3.3.4) in media, 
SFEM containing 100 ng/mL SCF, 100 ng/mL TPO and 1% P/S at MOI 600. Cells 
were washed, re-suspended in media and 15 µL cell suspension was inoculated onto a 
cover slip containing silicone micro-wells (cat. no. 9850003, Interchim, France). Cells 
were allowed to set for 2 hours in incubator, after which media was carefully pipetted 
off and cells were fixed using 20 µL 10% formalin solution (cat. no. HT5014-120ML, 
Sigma-Aldrich, Steinheim, Germany) for 10 min at RT. After washing twice with 
PBS, 10 µL PBS was pipetted on each micro-well and cells were imaged using a 10x 
Fluar objective and 1.0x Tv adapter for brightfield and fluorescence using a mcherry 
filter.  
Cells were then permeabilised in 20 µL blocking buffer containing PBS, 1% 
BSA, 0.1% Triton X 100 and 10% donkey serum (cat. no. 017-000-121, Jackson 
ImmunoResearch Laboratories, Inc., USA) for 60 min at RT. Buffer was then 
carefully aspirated and 20 µL of primary antibodies (either rabbit@p-p38(Tyr182) 
(clone D3F9, cat. no. cat. no. 4511S, Cell Signaling) and mouse@p-Src(Tyr416) 
(clone 9A6, cat. no. 05-677, Upstate (Millipore)), or rabbit@p-p44/42 (clone 
D13.14.4E, cat. no. 4370, Cell Signaling) and mouse@p-Akt(Ser473) (clone D9E, 
cat. no. 4060, Cell Signaling)  (4 µg/mL in blocking buffer) were added and incubated 
overnight at 4°C. Cells were washed 3 times for 5 min in PBS 0.1% Triton X 100 
after which 20 µL 1 µg/mL biotin@mouse (cat. no. 200-002-211, Jackson 
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ImmunoResearch, USA) in blocking buffer was added for 1 hour at RT. Cells were 
washed again 3 times for 5 min in PBS 0.1% Triton X 100 and 20 µL 1 µg/mL 
Streptavidin-Alexa700 (cat. no. S-21383, Invitrogen) in blocking buffer was added 
and incubated for 1 hour at RT. After washing 3 times for 5 min, 1 drop (~20 µL) of 
Vectashield hard set mounting medium with DAPI was added and microscope slides 
were added. 
Cells were imaged with a 10x Fluar objective and 1.0x Tv adapter using 
epifluorescent microscopy. Lumencor excitation was used to obtain fluorescent 
images (450nm with DAPI filter for DAPI, 485nm with eGFP filter for p-p38 and p-
p44/42-Alexa488, 585nm with mCHERRYfilter for mCHERRYPSLD, 688nm with 
iRFP filter for p-AKT and p-Src-biotin-Alexa700). Images were processed and 
analysed using Fiji software. 
3.10.3 Confocal imaging 
Confocal microscopy was performed on a Leica SP5 spectral scanning confocal 
microscope with a five photomultiplier tube (PMT) detector array configuration and 
equipped with the following laser lines: 405 blue diode (405nm), Argon (458nm, 
476nm, 488nm, 496nm and 514nm), DPSS 561 (561nm) Helium Neon 1 (HeNe1, 
594nm) and HeNe2 (633nm). Images were acquired at 400Hz in the bidirectional 
mode with phase correction, 512x512 resolution, a pinhole size of 1 Airy unit, using a 
63x glycerol immersion lens giving a 0.863mm optical section thickness) in the xyz 
mode. 
3.11 G1 phase enrichment 
3.11.1 Cell-cycle prevalence optima 
Using pre-incubated HSCs that were virally transduced for 24 hours with a 
mCHERRYPSLD expressing lentiviral vector in SFEM with 100 ng/mL SCF 100 
ng/mL TPO 1% P/S, cell-cycle phases were quantified for multiple generations (see 
3.6.5 and 3.11) and distributions were plotted. The maximum percentage of G1-phase 
cells for generation 1 cells was calculated and used for experiments studying the 
influence of cytokine addition in G1-phase in subsequent generations. 
3.11.2 Cell-cycle inhibitors 
For cell-cycle phase synchronization, different chemical inhibitors were used 
for testing. Multipotent progenitors (LSK CD150- CD34+ CD48+) were sorted and 
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transduced as described in 3.1-2, 3.3.4 and 3.10.1.  During transduction, chemicals 
were added at different concentrations and for different incubation times. For G1-
phase enrichment, hydroxyurea (cat. no. H8627-1G) and L-Mimosine (cat. no. 
M0253-100MG) were used. Nocodazole (cat. no. M1404-2MG), a G2/M-phase 
inhibitor was used as a control together with a control without inhibitors. All 
inhibitors were obtained from Sigma-Aldrich, Steinheim, Germany. Cells were 
washed and plated in fresh medium and imaged (see 3.6.5 and 3.11) to assess cell-
cycle phase, cell-cycle transition and toxicity. As a control, PI staining was used and 
cell-cycle distribution was assessed as described in 3.4.1. 
3.11.3 Hypothermic culture 
Multipotent progenitor cells were sorted and transduced as described in 3.10.2. 
Cells were washed and plated in CO2 saturated fresh medium and plated into a 384-
well plate. Cells were imaged (see 3.6.5 and 3.11) whilst being kept in incubators at 
33°C or 37°C and cell-cycle distribution and transition were compared. 
3.12 Time-lapse imaging 
Imaging was performed on a Zeiss Axio Observer Z1 microscope (Zeiss, 
Munich, Germany) using a 10x FLUAR objective (440135-0000, Zeiss, Germany), 
0.5, 0.63 or 1.0x adapter and an AxioCamHRm camera (1388 x 1040 pixels, Zeiss, 
Germany). X-Y positioning was enabled using a motorized stage (cat. no. 0431478, 
Märzhäuser, Wetzlar-Steindorf, Germany) and a PECON heating system combined 
with a XL incubator (Erbach, Germany) were used to maintain 37°C incubation. CO2 
levels were maintained by either sealing of multi-well plates or culture flasks, both 
containing cells in pre-CO2-saturated medium, or by gas perfusion with 5% CO2 5% 
O2 using self-made incubation lids. Image acquisition was done with Axiovision 4.5 
using acquisition macros developed by the lab. All pictures were stored as PNG files 
with 50% compression. Brightfield images were taken with a focus shift to enhance 
contrast whilst retaining cellular morphology. Fluorescent images were taken using a 
HXP 120 (Zeiss, Germany) light source and a combination of following filter sets: 
 
Table 3.12-1: Detection of fluorescence in time-lapse microscopy 
Protein / 
fluorochrome 
Excitation Band pass Emission Company Cat. no. 
DAPI 387/11 409 447/60 AHF F36-513 
Hoechst33342 436/25 455 480/40 Zeiss 489047-9901-000 
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FITC 470/40 495 525/50 AHF F46-002 
VENUS 500/25 515 535/30 Zeiss 489046-9901-000 
Alexa 555 / PE 550/25 570 605/70 Zeiss 489043-9901-000  
mCHERRY 562/40 593 641/75 AHF F36-508 
APC 620/60 660 700/75 AHF F46-006 
Alexa 647 670/30 700 794/160 AHF F47-670 
 
Data was analyzed using TTT software (Eilken, Nishikawa et al. 2009; Rieger, 
Hoppe et al. 2009) developed by the lab on Fujitsu Celsius workstations with 48 GB 
of RAM, dual-core CPU and Windows 64-bit operating systems. Behavior, cell fate 
and fluorescence of single-cells was manually tracked using contrast enhancement 
and displayed and stored in pedigree format. The first picture taken in the time-lapse 
sequence indicated the time of movie start. Each starting cell at this point was 
considered generation 0 or mother cell and subsequent progeny were considered 
generation 1 (daughter cells), generation 2 (granddaughter cells) and so on. Cell 
lifetime was calculated from the first time point at movie start for generation 0 or 
from the first time point after division until occurrence of cell fate, either apoptosis or 
cell division. 
3.13 Quantification of fluorescent signal 
Fluorescence signals were measured using background correction using 
software developed by the lab, AMTsingle for static snapshots and QTFy for time-
lapse quantification.  
3.14 Statistics  
3.14.1 Data analysis  
Data and features obtained by creation of pedigrees or obtained from 
quantified images was processed with statistics software developed in the lab. Data 
was exported using CSV format and further processed in either Microsoft Excel for 
Mac 2011 (version 14.1.0, Microsoft Corporation) or Graphpad Prism 5. 
3.14.2 Graphical output  
Graphical representation and plots were created using either Graphpad prism 
or Microsoft Excel for Mac 2011. Mathlab was used to display cell-cycle transition 
for multiple trees and data sets. Flowjo was used to display FCS files and data 
obtained by flow cytometry. 
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3.14.3 Statistical tests  
Statistics were performed using Graphpad Prism 5. For data with normal 
distribution student’s t-test or Welsh’ test were applied, depending on sample size and 
using one-tailed hypotheses. For not normally distributed data non-parametric one-
tailed Mann-Whitney-U tests were applied, assuming unequal sample size. 
4 Results 
4.1 PSLD as a live cell-cycle reporter to quantify G1 to S-phase 
transition. 
 
It has long been hypothesized how cells transit through cell-cycle and whether 
cytokines can affect both cell fate and the cell-cycle state or cell-cycle phase durations 
in dividing cells. The current limitations mainly lie within the inability to obtain live 
cell-cycle quantification without losing clonal identity. To this extent, PSLD was 
validated as a live cell-cycle reporter (Figure 4.1-1 and (Hahn, JT et al. 2009). To 
verify whether PSLD allows detection of different cell-cycle phases, the construct 
was virally transduced in NIH-3T3 cells and imaged using continuous time-lapse 
microscopy. In Figure 4.1-1A, the G1-phase specific nuclear localization can be 
clearly visualized (i, vii-viii, xii) and the cyclin-dependent nuclear export into the 
cytoplasm can also be observed (ii-v, iv-x). During M-phase, upon nuclear membrane 
degradation, the PSLD signal also diffuses into this previous enclosure where it can 
be detected until cytokinesis (vi, xi). From these pictures, it can be said that the PSLD 
signal can be detected in distinct subcellular compartments over multiple generations 
in a cell-cycle dependent manner.  
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Figure 4.1-1: PSLD can be used to detect cell-cycle phase transitions 
PSLD allows quantification of cell-cycle phase durations. Example pedigree of a NIH-3T3 cell 
transduced with mCHERRYPSLD. Arabic numbers indicate cell hierarchy, Roman numbers indicate 
stages within cell-cycle. Time-scale in d:hh:mm. Scale bar 20 µm. 
Furthermore, it can be observed that cell lifetime of daughter cells can differ 
due to distinct cell-cycle phase durations (Figure 4.1-1 vii cell 2 and 3). Time-lapse 
example movies are provided in Supplemental Movie 1 and 2.  
Next, characterization was performed to test whether the observed PSLD localization 
correlates with the postulated cell-cycle phase in order to define the cell-cycle 
resolution (Figure 4.1-2A).  
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Figure 4.1-2: PSLD quantification provides a valid tool to detect G1- to S-phase 
transition 
A. Live PSLD scoring correlates with established invasive methods to quantify cell-cycle state. PI 
stained MPPs were gated for single-cells and analyzed for cell-cycle using Watson distribution (10.000 
events). A comparison was drawn with imaging (PI stained or PSLD transduced, 300 cells each) (from 
3 independent experiments). Green lines show G1-phase gate according to histogram distribution. B. 
Cell-cycle phase heterogeneity exists in common used cell lines. Cell-cycle distributions for NIH-3T3 
cells (generation 1,2 and 3) (n=120 cells). Scale bar 15 µm. 
 
For this, a classic method using propidium iodide (PI) labeling and detection 
by flow cytometry was compared with manually scored PSLD signal in multipotent 
blood progenitors (LSK CD150- CD34+ CD48+). To support the strength and 
resolution of microscopy PI labeled cells were also imaged, and quantified signals 
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were compared with signals obtained by flow cytometry. The lack of significant 
differences between all methods demonstrates the correlation between PSLD 
localization and the respective cell-cycle state. Using time-lapse imaging, cell-cycle 
phase durations were quantified over multiple generations (Figure 4.1-2B). Overall, 
NIH-3T3 cell-cycle transitions and durations in in vitro culture are homogeneous, 
although it becomes apparent that some heterogeneity exists, especially for G1-phase 
duration, showing even heterogeneity in common used cell lines.  
 
4.2 Hematopoietic stem and progenitor cells are sorted with high purities 
using established sorting schemes 
 
HSCs were enriched as shown in Figure 4.2-1. Since CD34 has been proposed 
to also be expressed on cycling HSCs, we use CD34lo to increase the prevalence of 
quiescent cells (Becker, Nilsson et al. 1999; Glimm, Oh et al. 2000; Orschell-
Traycoff, Hiatt et al. 2000; Nygren, D et al. 2006; Dooner, Colvin et al. 2008).  
Cells were cultured for 48 hours in SFEM 100 ng/mL SCF 100 ng/mL TPO 
after which they were re-stained to quantify marker expression (Figure 4.2-1B). 
Following FACS analysis, >95% of the cells did not down-regulate Ly6A/E or 
CD117 expression and did not up-regulate progenitor markers CD34 and 
CD16/CD32. According to this data, most cells still reside within a primitive state 
which confirms previous data that show HSCs can be retained after multiple days of 
culture using these culture conditions (Ema, Takano et al. 2000). Following these 
data, this likely allows a pre-incubation necessary for viral transduction without the 
loss of full multi-lineage potential. 
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Figure 4.2-1: Pre-incubation does not affect surface marker expression. 
A. HSPCs are sorted using 8 fluorescent antibodies. Example of sorting regime used to isolate HSCs 
(106 events from forward-/side scatter gate (top left) shown). Gates were drawn according to unstained 
controls (not shown). B. Short-term (48h) pre-incubation does not alter surface marker expression. Re-
analysis of re-stained sorted HSCs cultured in SFEM 100 ng/mL SCF and TPO for 48h (1000 events 
shown). 
 
4.3 HSCs go through cell-cycle in a non-synchronous fashion. 
 
To date, most data concerning cell-cycle transitions in primary cells is 
population-based or is obtained with methods that do not allow quantification in 
living cells and hence do not provide continuous data and cannot provide information 
about cell-cycle phase durations. Especially in the blood field, little is known about 
how HSCs go through cell-cycle over time since these cells are rare and with current 
methods clonal identity is lost. The PSLD reporter used in this work allows following 
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HSC cell-cycle over multiple generations, continuously and with single-cell 
resolution (Figure 4.3-1).  
 
First, HSCs (LSK CD34- CD150+ CD48-) and MPPs (LSK CD34+ CD150- 
CD48-) were isolated and time-lapse imaging was initiated directly after plating, 
approximately 2 hours after sorting. Previous studies have shown that these cells had 
not yet entered cell-cycle and can be considered quiescent (Nygren, D et al. 2006; 
Colvin, Dooner et al. 2007). The in vitro division rates were obtained after tracking 
the first two cell divisions (Figure 4.3-1A) (n=3, 100-120 cells). This data shows that 
HSCs have a late cell-cycle entry and have a longer initial cell-cycle compared with 
multipotent progenitors as described previously (Dykstra, Ramunas et al. 2006; 
Nygren, D et al. 2006; Benveniste, Frelin et al. 2010). At 24 hours, the majority of 
HSCs are still within their first in vitro cell-cycle, since only <5% of HSCs have 
divided. For the next generation, the same effect can be observed. This not only 
shows that HSCs can be distinguished from MPPs by cell division time, but 
furthermore underlines the purity of freshly isolated HSCs, since previous work has 
shown a strong correlation between HSC in vitro cell-cycle and long-term 
repopulation potential in vivo (Benveniste, Frelin et al. 2010).  
 
To further investigate HSC cell-cycle dynamics, HSCs were isolated and 
virally transduced with a mCHERRYPSLD-expressing vector (Figure 4.3-1B). While 
lentiviral transduction can occur instantly, in order to detect the signal in the majority 
of transduced cells in epifluorescent imaging, a minimum pre-incubation time of 24 
hours was required (not shown) in which >95% of the HSCs still reside within their 
first in vitro cell-cycle. Quantification of cell-cycle phase durations showed that 
indeed the majority of the cells were in S/G2 phase at the start of time-lapse imaging 
(Figure 4.3-1C) and cell-cycle transit did not occur in a synchronous fashion (n=3, 75 
cells). The peaks of G1 phase prevalence were found at 24 hours and 44-48 hours, in 
which the latter provided >95% cells that were no longer within their first in vitro 
cell-cycle.  
! 61!
 
Figure 4.3-1: HSCs transit through cell-cycle in a heterogeneous fashion 
A. HSCs show distinct in vitro division rates when compared with multipotent progenitors. Cell-cycle 
division rates (n=3, 100-120 cells). B. Experimental set-up for cell-cycle phase quantification in HSCs. 
C. HSPCs transit through cell-cycle asynchronously. Majority of HSPCs are in S/G2-phase at time of 
movie start, but progeny shows distinct cell-cycle phase durations. Continuous quantification and 
genealogy allows calculation of cell-cycle phase prevalence for different generations (n=3, 75 cells). 
Cells with lost identity were excluded. 
 
 
4.4 Optimized media conditions allow live detection of all myeloid 
lineages. 
 
To test which cytokine conditions allow lineage production without increasing 
apoptotic events, HSCs were freshly isolated, transduced with mCHERRYPSLD for 
24 hours and kept in culture under different cytokine conditions for a total of 14 days 
(Figure 4.4-1). Live antibody staining with anti-FcyR (CD16/CD32) enabled the 
detection of granulocytes and macrophages (Akashi, Traver et al. 2000) and 
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megakaryocytes were detected by morphology, multiple nuclei and the lack of FcyR 
expression (Figure 4.4-1 top and bottom, respectively).  
 
 
Figure 4.4-1: Lineage commitment can be live detected in culture 
A combination of antibody staining and morphological features detects myeloid progenitors. White 
arrowheads indicate macrophages (top, FcyR positive) and megakaryocytes (bottom, FcyR negative 
and polynucleated) after 14 days of in vitro culture. Scale bar 10 µm. 
 
In order to quantify clonal lineage production, HSCs were isolated and plated 
using limiting dilution with a Poisson statistic of 1:3 wells containing a single cell. 
This was confirmed by time-lapse microscopy during the first 24 hours (Figure 4.4-
2A). Lineage production was then assessed after 14 days by time-lapse imaging and 
quantification of PSLD signals and expression of CD16/CD32. Colonies without 
megakaryocytes and CD16/CD32 expression and wells with no or only apoptotic cells 
present, were counted as “none” and “apoptotic”, respectively. From 6 different 
media conditions, “permissive” conditions (Takano, Ema et al. 2004) (Figure 4.4-2B, 
far right) were least selective since multilineage production was observed and 
apoptotic events were low, the latter probably due to the addition of serum (n=4, 1340 
cells). Furthermore, the prevalence of colonies with no mature lineages was equally 
low, indicating a faster cytokine-induced lineage production. 
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Figure 4.4-2: Optimized media conditions allow live detection of all myeloid lineages 
A. Single-cell plating reliability using limiting dilutions (n=4, 1340 cells). B. Permissive conditions 
provide highest non-restricted lineage production and survival. HSC lineage production after 14 days 
culture (n=4, 1340 cells). Permissive conditions are marked with an asterisk. 
 
 
4.5 Live CD71 antibody staining can be used to detect erythroid 
production. 
 
Detection of myeloid lineages in situ in liquid cultures through automated 
high-throughput imaging greatly facilitates end-point analysis and eliminates the 
necessity of cumbersome techniques as semi-solid media-based colony assays or 
analysis using flow cytometry. The challenge however lies in finding appropriate 
markers that can simultaneously be detected using fluorescence imaging. For the 
purpose of this work, different fluorescent antibodies were combined with 
morphological characteristics and polynucleated structures. As described in Figure 
4.4-1, megakaryocytes and macrophages can be identified using an antibody against 
CD16/CD32 and features such as multiple nuclei and adherence. To further detect the 
existence of erythrocytes and erythroid progenitors, anti-CD71, a transferrin receptor 
highly expressed on erythroid cells, as previously reported (Fang, Menon et al. 2007; 
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Pronk, Rossi et al. 2007; Eilken, Nishikawa et al. 2009), was tested (Figure 4.5-1A). 
 
 
Figure 4.5-1: Live CD71 antibody staining specifically detects erythroid lineages 
A. CD71 expression only detects erythroid lineages and co-stain with CD105. Lin- CD117+ Ly6A/E- 
CD16/CD32+ CD34+ (GMP, top) and Lin- CD117+ Ly6A/E- CD16/CD32- CD34- (MEP, bottom) were 
freshly isolated and cultured for 7 days in SFEM containing 10 ng/mL M-CSF (top) or SFEM 
permissive medium including 2 U/mL EPO (bottom). B. CD71 quantification shows exclusive 
expression on erythroid cells. Data from day 7 imaging (n=3, 150 cells). *** p-value<0.001. Scale bar 
15 µm. 
 
To validate CD71 staining, granulocyte-macrophage progenitors (GMP) and 
megakaryocyte-erythrocyte progenitors (MEP) were sorted and cultured under 
instructive conditions for macrophages (SFEM + 10 ng/mL M-CSF) and permissive 
conditions (+ 2 U/mL EPO), respectively. As live antibodies, F4/80 (Alexa-555 
conjugated) was used to confirm a macrophage phenotype and CD105 (endoglin, PE 
conjugated) was used to detect early erythroid progenitors, as previously described 
(Buhring, Muller et al. 1991). In both cultures CD71 (FITC) was added for validation. 
All macrophages were adherent and expressed F4/80, whereas erythroid progenitors 
were non-adherent and expressed CD105 (Figure 4.5-1A). Furthermore, only 
erythroid progenitors expressed detectable levels of CD71 (Figure 4.5-1A and B), 
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thereby validating the use of CD71 antibody to detect erythroid lineages, as 
previously described (Zhang, Socolovsky et al. 2003; Pronk, Rossi et al. 2007). 
Combining these antibodies with morphological and polynuclear features, all myeloid 
lineages can be detected to further measure clonal full myeloid lineage production. 
 
 
4.6 Cytokines induce cell-cycle specific lineage production. 
 
Much of previous work concerning the influence of cell-cycle in cytokine-
induced lineage production has been done either on a population level or based on 
cell-cycle distributions, losing clonal identity. To identify whether some of these 
hypotheses and correlations also exist on a single-cell level, single-cells expressing a 
cell-cycle reporter were imaged and followed using continuous time-lapse imaging 
(Figure 4.6.1). Single HSCs were re-sorted after 24 hour -lentiviral transduction to 
allow cell-cycle reporter expression in cytokine supplemented medium and time-lapse 
imaging was initiated immediately (Figure 4.6-1A, left). End-point analysis after 14 
days using live antibody staining revealed the clonal lineage production and was then 
correlated with the initial cell-cycle phase at the time of cytokine addition and movie 
start (Figure 4.6-1A, right).  
 
Control cells not receiving cytokine supplements (SCF, TPO only) did not 
survive over the course of the experiment (not shown). However, since these cells 
retained viability until at least 7 days of culture, cytokine addition to these cells was 
performed at day 7 in order to identify lineage potential and production. At this time-
point, it was assumed that the majority of these cells were no longer primitive HSCs 
and lineage priming or maturation had already occurred. From this data, it can be 
observed that none of the control cells produced all myeloid lineages, i.e. 
granulocytes (G), erythrocytes (e), macrophages (m) and megakaryocytes (M) 
(GemM) (Figure 4.6-1A, right, n=3). In contrast, HSCs that were cultured under 
permissive conditions (Permissive) did produce GemM lineage. Although the 
production of specific lineages was not exclusive for either initial cell-cycle phase, 
G1-phase cells produced significantly more GemM lineage than S/G2-phase cells 
(n=6).  
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Figure 4.6-1: Clonal GemM production is enhanced in G1-phase cells 
A. Experimental set-up and clonal lineage production showing an increased production of all myeloid 
lineages during G1-phase and exclusively under permissive conditions. Phases indicate initial starting 
phase in generation 0. AB. G=granulocytes, m=macrophages, M=megakaryocytes, e=erythrocytes. 
SCF TPO (n=3), Permissive (n=6). B. Correction for initial cell-cycle prevalence shows distinct 
lineage production that is cell-cycle dependent. ABC. * p-value<0.05, ** p-value<0.01, *** p-
value<0.001). Blue bars and asterisks indicate total levels, black and white asterisks show cell-cycle 
specific significance. C. Permissive cytokine conditions induce survival in generation 1 cells that is 
independent of initial cell-cycle phase upon cytokine administration (generation 0). 
 
To correct for the higher starting cell number being in S/G2-phase at the time 
of cytokine addition (see also Figure 4.3-1C), initial cell-cycle phase prevalence was 
compared per lineage (Figure 4.6-1B). This correction then revealed that single-cells 
producing lineages restricted to one cell type, i.e. granulocytes (G) or megakaryocytes 
(M), were more prevalent in starting cells that were in S/G2 phase at the moment of 
cytokine addition (n=6). This is in line with previous work claiming megakaryocytes 
are more likely to arise from early S-phase cells upon cytokine change (Colvin, 
Dooner et al. 2007). My results however demonstrate this occurs at a single-cell 
resolution rather than on a population level.  
 
To investigate whether a negative selection might occur, i.e. cells that would 
have produced other lineages would not survive, apoptosis rates during pre-incubation 
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or within early generations were assessed and correlated with initial cell-cycle phase 
upon cytokine addition and start of time-lapse imaging (Figure 4.6-1C). For both 
control cells and cells in permissive conditions, initial apoptosis rates were low (2-
5%) and can be explained by the potential toxicity of viral transduction and the stress 
of double-sorting within 24 hours. G1-phase cells under permissive conditions showed 
more sensitivity to medium change and had an increase in apoptosis levels, albeit with 
very low total levels. For generation 1 cells however, controls had a significantly 
higher apoptosis rate than cells cultured in permissive conditions. Thus, addition of 
permissive cytokines and serum rescues cells that would have otherwise undergone 
apoptosis. However, no effect could be observed with respect to initial cell-cycle 
phase. The very low apoptosis rate in subsequent generations under permissive 
conditions therefore does not affect selectivity with respect to lineage production, i.e. 
the higher prevalence of GemM lineage production from G1-phase starting cells is not 
caused by selective apoptosis. 
 
 
4.7 Increased multilineage production from G1 phase cells is reversible. 
 
The observed effect of increased GemM production from G1-phase cells poses 
the question whether subsequent generations are also more susceptible to produce 
GemM lineage when receiving permissive cytokines during G1-phase. To test this, 
HSCs were pre-incubated for 44 hours, a time-point at which >95% of cells are no 
longer in generation 0 but, instead, in generation 1. Furthermore, at this time-point a 
maximum was found for G1-phase prevalence, reaching ~50% of generation 1 cells 
(see Figure 4.3-1C). Following the same experimental set-up (Figure 4.6-1A), lineage 
production was again correlated with the cell-cycle phase upon cytokine addition and 
start of time-lapse imaging (Figure 4.7-1A, left). The data shows again that G1-phase 
cells are producing more GemM lineage compared with S/G2-phase cells. In addition, 
the amount of Gm lineage producing cells is increased for both cell-cycle phases 
when compared with permissive cytokine addition at 24 hours. This is consistent with 
the fact that control cells that receive permissive cytokine addition after 7 days 
produce higher numbers of clonal Gm lineage production, suggesting lineage-bias to 
occur early (generation 1). 
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Having lost the ontogeny and behavior of these cells during the prolonged 
incubation time, another approach was performed to ensure the observed effect can be 
attributed to generation 1 cells in culture. For this purpose, HSCs were again pre-
incubated in SFEM 100 ng/mL SCF 100 ng/mL TPO for 24 hours and re-suspended 
in fresh control medium without permissive cytokines. Single-cells were cultured and 
imaged during the next 20 hours after which permissive cytokines were added. By 
doing so, the effect of generation 0 and generation 2 cells on lineage production could 
be fully excluded (Figure 4.1.7A, right). This data again shows a higher prevalence in 
G1-phase cells to produce GemM lineage. Although not significantly different to 
either permissive cytokine addition at 24 or 44 hours, the lower tendency could be 
explained by repeated washing steps that could interrupt SCF and TPO signaling. 
However, equally apparent is the loss of restricted megakaryocyte production, again 
more pronounced in S/G2-phase cells.  
 
 
Figure 4.7-1: G1-phase susceptibility to produce GemM is reversible in later generations 
A. Enhanced clonal GemM production from G1-phase cells re-occurs in daughter cells. At 44h 
preincubation (left, n=4) >95% of cells have divided. Addition to 100% generation 1 cells through 
imaging during preincubation (right, n=3) shows reproducibility. AC. G=granulocytes, 
m=macrophages, M=megakaryocytes, e=erythrocytes. B. Prolonged preincubation increases apoptosis 
rates in generation 1 cells but is not dependent on initial cell-cycle state. Phases indicate initial starting 
phase in generation 0. * p-value<0.05, ** p-value<0.01, *** p-value<0.001). Blue bars and asterisks 
indicate total levels, black and white asterisks show cell-cycle specific significance. C. Correction for 
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initial cell-cycle prevalence shows higher prevalence of GemM producing cells in G1-phase to be 
consistent in daughter cells (44h preincubation). 
 
In accordance with cytokine addition at 24 hours, G1-phase cells are more prone 
for apoptosis when receiving permissive cytokines in generation 0 (Figure 4.7-1B). 
Total apoptosis rate, however, does not differ between incubation times. Yet, with 
increasing incubation time in control medium, generation 1 cells die significantly 
more even when receiving permissive cytokines. This increased apoptosis does not 
point towards a cell-cycle selective effect since when comparing starting cell-cycle 
states, no difference in prevalence is detectable (~50%). The observed rescue effect in 
generation 1 after 24 hours of pre-incubation is therefore not equally applicable for 
prolonged pre-incubation, although total apoptosis rates in generation 1 are still 
significantly less when compared with control conditions (Figure 4.6-1C). 
 
The higher number of S/G2-phase cells makes it difficult to compare absolute 
numbers of lineage producing cells for different cell-cycle phases. When correcting 
for this by looking at cell-cycle phase distribution per lineage, the increased 
production of GemM lineage from G1-phase cells becomes highly significant (Figure 
4.7-1C). In contrast, the increased susceptibility of S/G2-phase cells to produce either 
granulocytes or megakaryocytes is no longer present. Although the same tendency 
can be observed, the loss of significance is mainly caused by the high variation. GmM 
lineage production however is mainly derived from S/G2-phase cells, which could not 
be detected at 24 hours and is in strong contrast to GemM producing cells that in 
addition produce erythrocytes. These data are conflicting with previous findings that 
imply a continuous model for HSC susceptibility to induce lineage maturation by 
indicating that HSCs in culture may have a rather altered or restricted potency with 
increasing incubation time. 
 
4.8 Live cell-cycle quantification reveals lineage-specific cell-cycle 
behavior 
 
The strength of time-lapse microscopy lies in the fact that cell-cycle phases can 
not only be scored but also quantified continuously over time. With initial data 
suggesting differences in lineage production depending on during which initial cell-
cycle phase permissive cytokines were added, the next question was whether a direct 
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effect on cell-cycle progression could be observed (Figure 4.8-1). For this purpose, 
cell-cycle phase durations of generation 1 cells were quantified and correlated with 
their ultimate lineage production, assessed by end-point analysis (see also 4.6-1A, 
left). Generation 0 cells were excluded at first, since they were not synchronized at 
the time of movie start. It followed that generation 1 cells ultimately producing 
GemM lineage had a significantly longer G1-phase (Figure 4.8-1A, left). The lack of a 
significant difference between granulocyte colonies is due to the very low n-number 
for this population (see also Figure 4.6-1A, right). Not shown here is the fact that 
megakaryocyte restricted producing cells have a significantly shorter G1-phase (p-
value<0.01). Now when adding up total G1-phase durations of mother (generation 0) 
and daughter (generation 1) cells, it becomes apparent that the total time-window in 
which cytokines can act during G1-phase is more than 2 fold higher (Figure 4.8-1A, 
right) (data from three independent experiments). Since none of the control cells in 
SCF TPO produce GemM lineage after 14 days of culture, a direct comparison cannot 
be made. However, when comparing G1-phase durations from dividing GemM 
producing cells with all dividing SCF TPO cells, none of the control cells reach the 
median G1-phase duration of GemM producing cells, pointing to an induced effect. 
 
Testing whether the same observation could be made using longer pre-
incubation times, the same analysis was performed on dividing cells that had been 
pre-incubated for 44 hours (Figure 4.8-1B). For these cells, the GemM specific longer 
G1-phase during generation 1 was no longer apparent, except when comparing with 
granulocytes and/or macrophages (Figure 4.8-1B, left). When comparing medians for 
all lineages, an overall shorter G1-phase duration can be observed when compared 
with 24 hour pre-incubation, in line with the general observation that HSCs in in vitro 
culture gradually attain a shorter cell-cycle. For this reason, it is likely that G1-phase 
durations decrease in subsequent generations and indeed, that differences in later 
generations are no longer detectable. In contrast, when looking at the total time-
window in which cytokines act during G1-phase, i.e. when combining mother 
(generation 0) and daughter (generation 1) G1-phase durations, a significant longer 
G1-phase is again apparent for GemM lineage producing cells (Figure 4.8-1B, right). 
This indicates the higher prevalence of cells with longer G1-phases in generation 0. 
Taken together, these data show that the observed longer G1-phase durations for 
GemM lineage producing cells reoccurs and is reversible in subsequent generations. 
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When looking at S/G2-phase durations (Figure 4.8-1C), no differences can be 
observed for either pre-incubation time although granulocyte restricted lineages have 
a much shorter S/G2 phase (p-value<0.001). Considering S-phase to be relatively 
constant, this would imply G2-phases for all lineages to be similarly long except for 
granulocytes, which would have a shorter G2-phase duration. This shows G1-phase is 
contributing to a general longer cell-cycle division time for GemM producing cells. 
 
 
Figure 4.8-1: Clonal GemM production correlates with long G1-phase durations 
A-D. G=granulocytes, m=macrophages, M=megakaryocytes, e=erythrocytes, control (SCF TPO only). 
A. GemM producing cells have a longer G1-phase duration than cells with restricted lineage 
production. 24 hour pre-incubation (n=3) outcome of dividing generation 1 cells (left) and cumulative 
dividing generations (0+1, right). B. This is reproducible in daughter cells, although to a lower extent. 
44 hour pre-incubation (n=4) outcome of dividing generation 1 cells (left) and cumulative dividing 
generations (0+1, right). C. S/G2-phase durations for dividing generation 1 cells are not different. 24h 
(top) or 44h (bottom) pre-incubation. D. Kinship comparison of generation total cell lifetime shows 
increased synchronicity for megakaryocytes and asymmetry in granulocyte producing cells. Ratio cell 
lifetime daughter 1 (longer):daughter 2 (shorter) with 24 hour pre-incubation (n=6). * p-value<0.05, ** 
p-value<0.01, *** p-value<0.001). Blue bars indicate median value. 
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The use of time-lapse imaging not only allows one to track behavior and 
ontogeny but also allows a direct comparison of sister cells. To this purpose, cell 
lifetimes were directly compared between sister cells and the ratio was calculated 
(Figure 4.8-1D, data from 6 independent experiments). Although no clear pattern 
could be observed for cells producing GemM lineage, granulocyte producing cells 
have more asymmetry when compared with other lineages (p-value<0.01). In contrast, 
cells that are restricted towards the megakaryocyte lineage have an increased 
symmetry, i.e. dividing daughter cells have a similar cell lifetime. The reason for this 
is not yet clear and may require in-depth analysis of later generations, including live 
quantification of marker onset. 
 
4.9 GM-CSF alters cell fate in a cell-cycle dependent manner. 
 
Previous publications using population-based data have shown the capability 
of GM-CSF to induce megakaryocyte maturation within the first in vitro cell-cycle of 
HSCs (Robinson, McGrath et al. 1987; Colvin, Dooner et al. 2007). While in these 
studies total numbers in end-point analysis were indeed increased and correlated with 
pre-incubation time, it cannot be ruled out that G1-phase cells, also present at the time 
of cytokine change, were equally susceptible. Furthermore, a selective effect may 
have occurred, inducing apoptosis or reducing proliferation of other lineages. To 
address this question in more detail, the same experimental set-up was chosen as 
above (see Figure 4.6-1A, left) allowing direct cell-cycle assessment and correlation 
with end-point lineage production (Figure 4.9-1). Cells were either cultured using 
permissive culture media or with further addition of GM-CSF. This method was 
thought to be least selective, since overall apoptosis rates were low under permissive 
conditions and all lineages could be produced.  
 
After 24 hours of pre-incubation (data from 4 independent experiments), GM-
CSF induced higher apoptosis that was specific for G1-phase cells (Figure 4.9-1A, 
left). Although a similar trend could be observed for generation 1 cells, there was no 
significant difference between starting cell-cycle phases. After 44 hours of pre-
incubation (data from 3 independent experiments), no difference between control 
conditions and GM-CSF addition could be detected indicating that HSCs in early 
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generations are most sensitive to GM-CSF induced apoptosis during G1-phase (Figure 
4.9-1A, right). 
 
When looking at clonal lineage production, no cell-cycle specific effect of 
GM-CSF after 24 hours pre-incubation could be observed (Figure 4.9-1B, left), 
although total GemM lineage production was reduced. After 44 hours of pre-
incubation however, GemM lineage production was almost exclusively observed from 
G1-phase cells (Figure 4.9-1B, right). Furthermore, megakaryocyte production was 
significantly increased for S/G2-phase cells (p-value<0.05), which follows previously 
published data (Colvin, Dooner et al. 2007) and is also observed after 24 hours of pre-
incubation under control permissive conditions (Figure 4.6-1B). Although a direct 
comparison with published data cannot be drawn due to the presence of different 
cytokines that could bind competitively or could have either a synergistic or 
antagonistic effect, these data for the first time show the effect of GM-CSF on 
different cell-cycle phases on a single-cell resolution. 
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Figure 4.9-1: GM-CSF addition reduces GemM production and increases apoptosis 
A. GM-CSF addition increases apoptosis in generation 0 G1-phase cells. Cell-cycle phases indicate 
cell-cycle state in starting cells (generation 0) at the time of movie start and medium addition (24h n=4, 
44h n=3). B. GM-CSF reduces GemM production not cell-cycle specifically. G=granulocytes, 
m=macrophages, M=megakaryocytes, e=erythrocytes. C. Switching to GM-CSF increases apoptosis 
S/G2-phase specifically. Correlation of apoptosis in generation 1 cells with cell-cycle phase of 
generation 0 at time of cytokine addition. * p-value<0.05. Blue bars and asterisks indicate total levels, 
black asterisks show cell-cycle specific significance. 
 
To further verify whether a selective or apoptosis-inducing effect may exist 
upon GM-CSF addition, published methods (Colvin, Dooner et al. 2007; 
Quesenberry, Dooner et al. 2010) were adopted to the current single-cell resolution 
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time-lapse set-up (Figure 4.9-1C, left). Following 24 hours of pre-incubation in a 
basal control permissive medium containing both Flt-3 and thrombopoietin, cells were 
washed and re-suspended in medium with G-CSF and GM-CSF or in control 
permissive medium. Following time-lapse imaging (data from 3 independent 
experiments), a 3-4 fold increase in apoptosis could be observed in generation 1 cells 
when changing conditions to G-/GM-CSF, the majority having been in S/G2-phase in 
generation 0 at the time of medium change (Figure 4.9-1C, right). This could also 
imply that these cells had not yet seen these cytokines in G1-phase and apoptosis 
therefore was observed within G1-phase of the next generation. This assumption is 
supported by the fact that under permissive conditions, no cell-cycle specific effect on 
apoptosis can be detected (Figure 4.9-1A). 
 
4.10 HSC G1-phase enrichment can be obtained with hydroxyurea. 
 
The increased potency of G1-phase cells to produce GemM lineage under 
permissive conditions, led to the question whether this could be further enhanced by 
selective enrichment for G1-phase cells. Two different methods were used to increase 
prevalence of G1-phase cells (Figure 4.10-1). Using hypothermic culture at 33°C as 
previously established in progenitor cells (Enninga, Groenendijk et al. 1984; Mivechi 
and LI 1990), mCHERRYPSLD expressing MPPs (Lin- Ly6A/E+ CD117+ CD150- 
CD48+ CD34+ cells) were incubated and imaged using time-lapse microscopy. Due to 
cooling down and potential adaptation, cell-cycle was scored after 24 hours. This time 
period also coincides with the 24 hour time period required for viral transduction in 
HSCs. At this time point, no increase in G1-phase prevalence could be detected 
(Figure 4.10-1A, left) (data from 3 independent experiments). When looking at cell-
cycle transitions in generation 1, an increase in G1-phase could be detected (Figure 
4.10-1A, right). However, an even stronger elongation of S/G2-phase was observed 
(data from 3 independent experiments, 75 trees). The lack of G1-phase enrichment on 
the one hand and the unknown effect of increased daughter cell G1-phase and S/G2-
phase on cell fate or lineage production suggests this method is not suitable to test our 
hypothesis. 
 
Chemicals that inhibit cell-cycle progression at specific stages are well 
established for cell-cycle enrichment. However, although most inhibitors are known 
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to work in cell lines, little is known about their effect and usage in primary blood 
cells. For this purpose, MPPs (Lin- Ly6A/E+ CD117+ CD150- CD48+ CD34+ cells) 
were used and incubated with either hydroxyurea (G1-phase arrest), l-mimosine (G1-
phase arrest) or nocodazole (G2/M-phase arrest) as a negative control. Different 
incubation times and concentrations were tested. As a read-out, propidium iodide 
staining was used to detect cell-cycle distribution (data from 3 independent 
experiments, 10.000 events each) (Figure 4.10-1B, top, see also Figure 4.1-2A).  
 
 
Figure 4.10-1: Hydroxyurea treatment enriches for G1-phase cells 
A. Hypothermic culture does not increase yield of G1-phase cells and affects cell-cycle phase durations. 
Cell-cycle phase durations are depicted for dividing generation 1 cells (n=3). B. Incubation with 
hydroxyurea reduces prevalence of S/G2-phase cells. Cell-cycle distributions according to propidium 
iodide staining and FACS analysis. Percentages shown are standardized to surviving cells in control 
condition. * p-value<0.05, *** p-value<0.001. 
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From this, cell-cycle state was obtained (Figure 4.10-1B, bottom). Higher 
doses of hydroxyurea are strongly toxic, drastically reducing the number of live cells 
(not shown). An optimal G1-phase enrichment for hydroxyurea was found at 24 hours 
using 1 mM, retaining G1-phase cell numbers whilst reducing the presence of S/G2-
phase cells. The method of action for G1-phase enrichment remains unclear from this 
data. It may be that the case that S/G2-phase cells either die more or reside within G1-
phase upon their next cell-cycle, or the prolonged cell-cycle retention of G1-phase 
cells induces toxicity. However, initial experiments were performed in which cell-
cycle inhibitor-induced apoptosis was correlated with cell-cycle phase. No correlation 
or cell-cycle specific effect could be found (not shown). In contrast, l-mimosine had 
no effect on cell-cycle phase enrichment, not even when using high, non-cytotoxic 
concentrations. Nocodazole treatment on the other hand showed increased G2/M-
phase cells at the expense of G1-phase cells. For HSC G1-phase enrichment 24 hour 
pre-incubation with 1 mM hydroxyurea was chosen for further experiments. 
 
4.11 G1-phase enrichment increases multilineage production. 
 
To address the question whether G1-phase enrichment leads to an increase in 
multilineage production, clonal lineage production was again correlated with the cell-
cycle phase of generation 0 at the time of permissive cytokine addition (Figure 4.11-1, 
data from 3 independent experiments). Despite optimized hydroxyurea concentrations 
and incubation times, cytotoxicity still occurs. To verify whether cells in specific cell-
cycle phases are more prone to apoptosis, viability was assessed for both generation 0 
and generation 1 cells (Figure 4.11-1A). Both in generation 0 and generation 1, more 
cells die after being treated for 24 hours with 1mM hydroxyurea and after receiving 
permissive cytokine addition. Again, G1-phase cells are more prone to apoptosis, 
however this is not only the case in generation 0 cells but an inherited effect is also 
observed in generation 1 cells. However, since the majority of the cells were in G1-
phase after hydroxyurea treatment, this may form a bias when considering a 
correlation with apoptosis in generation 1.  
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Figure 4.11-1: G1-phase enrichment increases total GemM production 
A. Hydroxyurea treatment increases apoptosis in G1-phase cells. Cell-cycle phases indicate cell-cycle 
state in starting cells (generation 0) at the time of movie start and medium addition (n=3). B. G1-phase 
enrichment increases total yield of GemM producing cells but does not restrict lineage production. 
G=granulocytes, m=macrophages, M=megakaryocytes, e=erythrocytes. Cytokine addition in 
generation 1 occurred at 20h after movie start, giving a total of 44h. C. Correcting for cell-cycle 
prevalence and apoptosis shows increased yield of GemM producing cells after hydroxyurea treatment. 
D. Hydroxyurea prolongs G1-phase but does not affect daughter cells, G1-phase durations after 24h pre-
incubation. * p-value<0.05, ** p-value<0.01, *** p-value<0.001. Blue bars and asterisks indicate total 
levels, black asterisks show cell-cycle specific significance. 
 
Next, end-point lineage scoring was again correlated with initial cell-cycle 
phase at the time of cytokine addition (Figure 4.11-1B). Although the G1-phase 
enrichment (62% vs. 34% control) did not lead to an increase in the percentage of 
GemM lineage production, correction of the total absolute numbers (429 vs. 68, ~6.3 
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fold more) leads to a 2.2 fold increase of GemM producing cells from G1-phase cells 
after hydroxyurea enrichment even exceeding the ~1.1 fold increase in apoptosis 
(Figure 4.11-1C). As a control, S/G2-phase specific lineage production was not 
affected by hydroxyurea treatment. It may well be that the higher apoptosis in G1-
phase cells partly formed a lineage selection, causing total GemM lineage production 
to be lower. On the other hand, it has been postulated, that hydroxyurea-induced G1-
phase arrest may act too late, i.e. either late G1-phase or early S-phase, to increase 
cytokine-induced differentiation. 
 
For this reason, experiments were conducted where cells were imaged after 24 
hours and cytokines were added at 44 hours, a point at which the prevalence of G1-
phase generation 1 cells is at its peak (see also Figure 4.3-1C and Figure 4.7-1A). 
Using this technique, the effect of cytokine addition in generation 1 could be assessed 
(Figure 4.11-1B, right). By doing so, an increase of GemM lineage production from 
G1-phase cells could again be detected (data from 3 independent experiments). 
Furthermore, this was significantly higher when compared with non-enriched 
permissive control cells. In contrast, GemM lineage production from S/G2-cells was 
completely abolished. Together this points to the effective enrichment of G1-phase 
cells and the reoccurrence of GemM producing cells from G1-phase daughter cells. 
The observed longer G1-phase for GemM lineage producing cells in dividing 
generation 1 cells could not be detected for G1-phase enriched cells (Figure 4.11-1D, 
right), but a total time frame in which cytokines can act is increased by the extension 
of G1-phase in generation 0 (Figure 4.11-1D, left). 
 
4.12 p38 signaling pathway activity is reduced during G1-phase. 
 
To explore the potential signaling pathways involved with G1-phase induced 
lineage commitment, staining was performed for four different signaling pathways 
and tested for correlation with either G1-phase or S/G2-phase (Figure 4.12-1). Here 
imaging was chosen as an alternative to Western blots due to the low abundance of 
HSCs in bone marrow and correct localization was confirmed by confocal imaging 
(Figure 4.12-1A). 
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Correlation with cell-cycle was performed by scoring the amount of positive 
cells per cell-cycle phase for each signaling pathway. Scoring was performed using 
epifluorescence pictures, signals again being corrected for with controls consisting of 
only secondary antibodies. Data from three independent replicates revealed large 
variation and no cell-cycle specific activity (Figure 4.12-1B-C).  
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Figure 4.12-1: Src and p38 signaling pathway activity are reduced during G1-phase 
A. Activated signaling pathways show correct localization. Confocal images of p-p38 and p-Src (top), 
p-Akt and p-p44/p42 (middle) displayed according to secondary control (bottom). B. Background 
correction allowed for quantification of fluorescent staining for signaling pathway activity. C. G1-phase 
cells show reduced signaling pathway activity (ON/OFF) for Src and p38 compared with Akt. PSLD 
cell-cycle marker was imaged after fixation. D. G1-phase signaling intensity is weaker for P-Src P-Akt 
and P-p44. * p-value<0.05, ** p-value<0.01, *** p-value<0.001. Scale bar: A. 1 µm, B. 40 µm. 
 
Akt signaling was observed in either cell-cycle phase in almost every cell. 
Since Akt can be activated by both SCF and TPO signaling and is thought to function 
downstream of phosphoinotiside 3-kinase, which is necessary for cell-cycle 
progression, its signaling pathway activity can also be seen as a positive control. Both 
p38 and Src showed significantly reduced levels during G1-phase when compared 
with activated Akt signaling. For S/G2-phase no such effect could be observed. 
However, signaling pathway intensities were mostly found to be lower during G1-
phase (Figure 4.12-1D). 
 
4.13 NUP98-HOXA10hd represses progenitor marker expression. 
 
Ever since the groundbreaking HSC expansion through NUP89-HOXA10hd 
(NA10hd) overexpression was first published, an outstanding question has been how 
this phenomenon occurs. With recent advances using time-lapse microscopy and 
phenotyping of in vitro cultured NA10hd cells first insights have been acquired yet a 
NA10hd signatory behavior has not yet been observed or defined (Palmqvist, Pineault 
et al. 2007; Even, Bennett et al. 2011; Sekulovic, Gasparetto et al. 2011; Watts, Zhang 
et al. 2011; Sloma, Imren et al. 2013).  
 
To further understand the mechanism that drives multipotent HSCs to expand, 
NA10hd behavior was first defined on a population level (Figure 4.13-1). To ascertain 
correct expression of the NA10hd construct, the linked FLAG-domain at the N-
terminus of NA10hd was stained and imaged using confocal microscopy. With 
acquisition set to unstained controls, NA10hd cells showed nuclear expression, 
whereas mock-infected cells only expressed the nuclear membrane-tagged VENUS 
signal (not shown). Simultaneously SCA-1 was highly expressed in NA10hd cells but 
rapidly down-regulated in mock-infected cells (not shown). 
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With the proposed HSC expansion model (Sekulovic, Imren et al. 2008), 
NA10hd positive cells will expand over ~1000 fold within 6 days of culture, meaning 
a minimum of 10 divisions leading to an average cell division time of ~12-14 hours. 
For this reason, a faster proliferation and thus higher fold expansion was assumed for 
NA10hd cells when compared with mock-infected cells. When looking at early time-
points (day 1-7), total cell numbers are actually lower than mock-infected control 
cells (data from 3 independent experiments). However, in long-term culture, mock-
infected cells are depleted, whereas NA10hd cells retain the potential to proliferate 
(Figure 4.13-1A, left). Underlying reasons for this can vary from increased short-term 
apoptosis to slow-cycling subpopulations, which cannot be assessed when looking on 
a population scale. The strong repression of the progenitor marker CD48 (Figure 
4.13-1A, right) by NA10hd supports the hypothesis that NA10hd cells have not 
attained a fast proliferation rate, characteristic of multipotent progenitor cells that 
undergo lineage maturation (data from 3 independent experiments). However, a 
recent study has shown that NA10hd can introduce a fetal liver HSC phenotype 
instead, which supports the active cell-cycle while retaining multipotency. 
 
 
Figure 4.13-1: NUP98-HOXA10hd represses expression of progenitor surface markers 
A. NA10hd cells show reduced expression of CD48 in bulk population. Average of fold expansion 
standardized to day 1 (100 cells) and percentage of cells expressing CD48 (n=3). * p-value<0.05, ** p-
value<0.01. 
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4.14 NA10hd fetal liver HSC phenotype is exclusively produced by HSCs. 
 
Next, the susceptibility of different hematopoietic stem and progenitor cells to 
attain a NA10hd-induced fetal liver phenotype (Lin- Ly6A/E+ CD43+ CD11bdim) was 
assessed by sorting HSCs (LSK CD150+ CD48- CD34lo), early MPPs (LSK CD150- 
CD48- CD34+) and late MPPs (LSK CD150- CD48+ CD34+), transducing them with 
NA10hd, followed by phenotypical analysis for surface markers 12 days later (Figure 
4.14-1). At first sight, one can immediately see the strong repression of lineage 
marker expression, since ~70% of the NA10hd cells are not positive for these 
markers. This in contrast to mock-infected cells, in which the majority (>90%) lose 
their differentiation potential and express mature lineage markers (Figure 4.14-1A, 
left). This is in line with previous publications that indicate a repression of full 
maturation by NA10hd. It is conceivable that the addition of interleukin-3 and 
interleukin-6 and fetal calf serum quickly leads to loss of stemness and indeed 
acquisition of a mature phenotype, present in control cells. NA10hd cells, however, 
do not seem to be affected when it comes to lineage marker expression. 
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Figure 4.14-1: NA10hd induces a fetal liver HSC phenotype exclusively in HSCs 
A. NA10hd represses expression of surface markers for lineage commitment in HSPCs while inducing 
a fetal liver HSC phenotype only in HSCs. Rectangles and arrows indicate subsequent gating schemes. 
Analysis performed after 12 days (n=3). Fetal liver HSC phenotype is Lin- CD43+ Ly6A/E+ (CD117+) 
Cd11bdim. B. Phenotype of non-transduced cells is affected by NA10hd expressing cells in co-culture 
(n=3). * p-value<0.05, ** p-value<0.01, *** p-value<0.001). 
 
Their fast, apparently symmetric self-renewing proliferation posed the 
question whether these cells attain a fetal liver phenotype, since HSCs are quickly 
expanded within the fetal liver. To confirm transplantation data that indicated the 
presence of such a phenotype on the majority of NA10hd cells that had repopulation 
potential, presence of these cells was again assessed using flow cytometry (Figure 
4.14-1A, right). These NA10hd+ Lineage- Ly6A/E+ CD117+ CD43+ CD11bdim cells 
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were indeed present after 12 days of in vitro culture, whereas none of the control cells 
showed such a phenotype (below 1% error). Furthermore, acquisition of such a 
NA10hd phenotype was exclusive for HSCs, since early MPPs and late MPPs did not 
produce this phenotype (from 3 independent experiments). Although this does not 
imply that these cells cannot form competitive repopulating units in in vivo 
transplantations, the lack of such a phenotype caused further experiments to be 
conducted with HSCs only. 
 
After transduction, about 50% of the HSCs were successfully expressing 
NA10hd, observed through VENUSnucmem co-expression. Although for a more 
efficient workflow higher transduction rates were desirable, this allowed testing 
whether NA10hd cells can have an effect on non-transduced cells. Indeed, when 
looking at repression of lineage maturation, non-transduced showed the same effect 
(Figure 4.14-1B, left). Furthermore, the acquisition of a fetal liver HSC phenotype 
was lower than NA10hd+ cells, yet significantly distinct from control cells (p<0.01), 
in which this phenotype was barely detectable (Figure 4.14-1B, right). Together this 
shows that NA10hd can indeed have cell non-autonomous effect when it comes to 
lineage repression and marker expression. Its implications for repopulation potential 
still require further investigation. The observed NA10hd paracrine effect however is 
more likely to be accredited to secreted molecules than cell-cell contact since these 
cells were cultured in suspension with concentrations not exceeding 106 cells per mL. 
 
4.15 NA10hd retains an inheritable slow cycling cell population. 
 
NA10hd behavior was next compared with mock-infected cells and lifetimes 
for dividing cells over multiple generations were quantified (Figure 4.15-1). The 
gradual reduction of time needed for cell division over multiple generations indeed 
approaches the 12-14 hour cell-cycle, hypothesized to be required for maximal 
expansion (Figure 4.15-1A). However, NA10hd cells retain a population of slow 
cycling cells within generation 1 and 2, dividing significantly slower than mock-
infected cells (p-value<0.05 and <0.001, respectively). 
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Figure 4.15-1: NA10hd cells retain a slow-cycling compartment that is inheritable 
A. NA10hd population contains cells that have a slower cell-cycle in early generations (n=3). B. These 
slow cycling cells are derived from slow cycling ancestors. Dashed line indicates median value for 
NA10hd generation 2 dividing cells. Data points were gated accordingly (“fast” or “slow”, lower or 
higher than medium, respectively). Ratios were then calculated by dividing generation 2 lifetime by 
generation 1 lifetime for dividing cells (n=3). AB. Thick lines indicate median value. C. Expression of 
CD48 is repressed in early generations also at a clonal level. CD48 expression of all cells by live 
antibody detection in time-lapse imaging (n=3). * p-value<0.05, ** p-value<0.01, *** p-value<0.001). 
 
Although these cells also persist in generation 3, the majority of the NA10hd 
cells actually attain a faster cell-cycle when compared with mock-infected control 
cells (p-value<0.05) (from 3 independent experiments).  To verify whether slow 
cycling cells produce slow cycling progeny, lifetimes of generation 2 dividing 
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daughter cells were compared with their generation 1 dividing mothers (Figure 4.15-
1B, left).  These data points were subdivided according to the NA10hd median value 
for generation 2, leading to a “fast” and “slow” cycling compartment.  When now 
comparing their cell lifetime ratios with their generation 1 lifetime, one finds that 
slow dividing NA10hd cells indeed give rise to slow dividing progeny (p-
value<0.05). The same phenomenon is true for fast dividing NA10hd cells that 
produce faster dividing progeny (from 3 independent experiments). This leads to an 
overall gradual dilution of the slow cycling compartment, therefore absent in later 
generations. Mock-infected control cells did not show a significant difference albeit 
the majority of the cells are derived from already fast dividing cells.    
The absence of CD48 expression on NA10hd cells reported by others was also 
confirmed in time-lapse imaging (Figure 4.15-1C). 
 
4.16 Thrombopoietin alters the NA10hd-induced phenotype 
 
Addition of thrombopoietin (TPO) abolishes NA10hd-induced HSC expansion 
(Sekulovic, Gasparetto et al. 2011). To test whether this has an effect on marker 
expression, NA10hd HSCs were cultured with or without TPO addition and were 
analyzed after 12 days of culture (Figure 4.16-1, data from 3 independent 
experiments).  Indeed, the percentage of cells with a fetal liver HSC phenotype was 
greatly reduced after TPO addition (p-value<0.05) (Figure 4.16-1A). However, one 
cannot exclude that TPO addition alters marker expression whilst retaining 
repopulation potential or indeed, cells with repopulation potential adopt a different 
phenotype when cultured with TPO addition.  
 
To explore potential differences in NA10hd behavior, cell lifetimes were again 
compared over multiple generations (Figure 4.16-1B). TPO strongly increases 
lifetime of NA10hd dividing cells (p-value<0.001). This could imply that the 
previously found dividing cellular subsets with longer cell lifetime are cells that are 
no longer or not yet having induced self-renewal divisions. To support this 
hypothesis, further transplantations are required with isolated cells from time-lapse 
imaging. 
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Figure 4.16-1: Thrombopoietin addition reduces fetal liver HSC phenotype in NA10hd 
cells 
A. TPO addition reduces NA10hd fetal liver HSC phenotype. B. NA10hd cell-cycle is altered upon 
TPO addition. Thick lines indicate median value. Cells were imaged after 24h pre-incubation. 
TPO=thrombopoietin, * p-value<0.05, ** p-value<0.01, *** p-value<0.001). 
 
4.17 Stroma interactions increase NA10hd lifetime and motility 
 
The loss of the highly proliferative character of in vitro NA10hd cells upon 
transplantation in vivo as well as the in vivo establishment of mature lineage subsets 
derived from NA10hd cells is of great clinical interest, yet its method of action has 
not yet been unraveled. When HSCs home into their in vivo niche, cell-cell 
interactions are re-established. This interaction has been shown to be crucial for 
maintenance of quiescence and simultaneously controls differentiation. Here, a PA6 
stromal co-culture was established to identify whether NA10hd behavior is distinct 
from mock-infected cells when cell-cell interactions are introduced with stroma 
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capable of short-term stem cell maintenance (Figure 4.17-1, data from 5 independent 
experiments).  
 
 
Figure 4.17-1: NA10hd cells have longer cell lifetimes in PA6 co-culture 
NA10hd cell lifetimes for dividing cells are longer in late generations. n=5, * p-value<0.05, ** p-
value<0.01, *** p-value<0.001. Thick horizontal lines indicate median value. 
 
When comparing generations, initial cell lifetimes (generation 1-3) are highly 
heterogeneous. In later generations (i.e. 4 and 5), it becomes apparent that NA10hd 
have a much longer (~1.5 fold) lifetime when compared with mock-infected control 
cells. To check whether this correlates with cell-cell interactions, determined by 
adherence underneath the stroma, the percentage of adherence per cell lifetime was 
measured (Figure 4.17-2A, left). Large heterogeneity exists in early generations (1-3), 
in which cells are frequently free floating and do not fully reside underneath the 
stroma during their lifetime. Although NA10hd cells have subsets that have less 
stroma residency during generation 3 and 4, the majority of these cells are more than 
90% of their lifetime underneath the stroma. Indeed, for generation 5, in which 
NA10hd cells have a longer cell lifetime, all cells were underneath the stroma for the 
complete duration of their cell-cycle.  
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Figure 4.17-2: NA10hd specific behavior correlates with cell-cell contact 
A. NA10hd adherent cells have longer cell lifetimes than non-adherent and control cells in early 
generations. Cell lifetimes for generation 1-3 were pooled and subsets were created depending on 
percentage of stroma residency. B. NA10hd cells show increased motility and repress CD48 expression 
in co-culture with PA6 stroma. Motility of dividing cells with 100% stroma residency was compared. 
n=5, * p-value<0.05, ** p-value<0.01, *** p-value<0.001. Thick horizontal lines indicate median 
value. 
 
For more in-depth analysis of earlier generations, cells were subdivided 
according to their stroma residency. For this purpose, cells were pooled from 
generation 1-3 and subsets containing >90% of stroma residency were compared with 
subsets containing <90% of stroma residency. By doing so, NA10hd cells with higher 
stroma residency were found to have longer lifetimes, compared both with NA10hd 
cells with less stroma residency and mock-infected control cells, independent of 
stroma residency (Figure 4.17-2A, right). This shows, that the longer lifetime found 
for NA10hd cells is either cell-contact specific and not caused by soluble factors or 
slow dividing NA10hd cells have a better adherence. Together this shows that through 
all generations, NA10hd have a longer lifetime when in direct contact with PA6 cells.  
 
Not only does PA6 co-culture allow quantification of adherent state, other 
attributes such as cell-size, nucleus size and migration can be measured as well. 
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Perhaps most interesting is the ability to quantify motility, which under liquid culture 
conditions difficult to measure due to high variations, gradient differences and flux of 
cells towards certain areas of culture plates due to tilting, motorized stage movement 
or non-uniform heating. To reduce heterogeneity, cell motility was quantified for cells 
that were underneath the stroma for the full duration of their cell-cycle (Figure 4.17-
2B, left). NA10hd cells in generation 4 and 5 show an almost 2-fold increase in 
motility when compared to mock-infected control cells.  
 
The NA10hd-induced repression of CD48 also occurs in stroma co-culture 
(Figure 4.17-2B, right). Further experiments are required to test whether the 
expression of CD48 on mock-infected control cells correlates with their reduced 
motility and cell lifetime.  
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5 Discussion 
 
5.1 Optimization of a clonal read-out  
 
Despite the tremendous amount of work in the last decades on optimization of 
HSCs purification schemes and defining their phenotypical identity, a uniform 
consensus or methodology has not yet been achieved. In this work, a sorting scheme 
using expression of surface markers was adapted (Kiel, Yilmaz et al. 2005; Raval, 
Kusler et al. 2012) and used for HSC purification. Previous work on HSCs that 
explored the susceptibility of different cell-cycle phases to induce lineage production 
upon cytokine addition has also been performed using purification methods based on 
dye efflux (Goodell, Brose et al. 1996; Matsuzaki, Kinjo et al. 2004). Although dye 
efflux has been proven useful to increase the yield of quiescent cells, the addition of 
CD34 to SLAM markers in order to further distinguish quiescent cells from activated 
cycling cells (Sato, Laver et al. 1999; Tajima, Sato et al. 2000; Ogawa, Tajima et al. 
2001) also results in highly efficient retrieval of quiescent HSC populations. The HSC 
populations used in this work, however, may differ from other published work in 
terms of pre-sorting lineage bias or quiescent state and comparison of results thereof 
need to be interpreted with care. Although single-cell transplantations were not 
performed in the course of this work, preliminary experiments using limiting dilution 
assays in c-kit deficient mice were performed, confirming high HSC purification 
levels of the isolated cells (not shown). Furthermore, the purity and quiescent state of 
these cells was confirmed by the time necessary for the first in vitro cell division and 
comparison with multipotent progenitors, which correlates with the in vivo 
repopulation capacity as previously described (Dykstra, Ramunas et al. 2006; Nygren, 
D et al. 2006; Benveniste, Frelin et al. 2010).  
 
The lack of robust and reliable live cell-cycle markers made continuous cell-
cycle quantification difficult to perform. With the coming of a cell-cycle reporter 
mouse expressing FUCCI, S/G2 phase can be visualized by onset of fluorescence. 
However, the signal was not always detectable and cumbersome post-processing was 
required in order to quantify cell-cycle state. The combination with another 
fluorescent protein knock-in to visualize G1-phase made this process more reliable 
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and workable in in vivo setting, yet still required post-processing and the use of 
another fluorescent protein reduced the potential use of fluorescent antibody 
combinations or demanded even higher optical resolution thereby challenging 
temporal resolution. Furthermore, FUCCI expression was found to be non-ubiquitous 
and indeed time-lapse imaging of isolated in vitro cultivated HSCs showed too low 
expression to conduct any further experiments (not shown). Very recently the authors 
confirmed this observation and developed different mouse lines for this purpose 
(Sakaue-Sawano, Hoshida et al. 2013). To circumvent this problem, PSLD was virally 
transduced into HSCs resulting in a robust expression of a valid cell-cycle reporter. 
During 24 hour pre-incubation, >95% of the cells still reside within their first in vitro 
cell-cycle and although cells may have lost their HSC potential, the majority of the 
cells had not lost their multipotency, due to their cultivation in a previously described 
medium that can maintain HSCs (Ema, Takano et al. 2000). This is in line with other 
purification methods and the late cell-cycle entry found in population-based data 
(Reddy, CY et al. 1997; Colvin, Dooner et al. 2007). With this system, it was possible 
to quantify and show how HSCs transit through different cell-cycle phases over 
multiple generations in a heterogeneous fashion for the first time, while 
simultaneously assessing their in vitro lineage production. Future work, however, 
should profit from new robust methods allowing live continuous cell-cycle 
assessment directly after isolation without applying invasive techniques. 
 
The problem with many published population-based data is the loss of cellular 
genealogy. To be able to identify cell-specific behavior and compare kinship not only 
requires continuous time-lapse imaging on a single-cell resolution, but in order to 
exclude a direct (e.g. cell-cell) or indirect (e.g. secreted molecules) interaction 
potentially influencing cell fate, such an analysis must be performed clonally, e.g. 1 
well containing 1 cell. Of course, one could argue that once cells proliferate, cell 
density increases accordingly, especially in static cultures where cells only reside on 
the bottom surface area. Soluble and secreted molecules produced may then again 
affect the fate of other cells, however since all cells are ultimately derived from one 
starting cell the decision to do so consequently has been made up in the hierarchy. In 
addition, analysis of bulk populations leaves uncertainties about the existing of 
subpopulations that may mask the overall observed effect. As is the case with many in 
vivo studies, bulk culture could furthermore provide compensatory mechanisms, e.g. 
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the large amount of different secreted molecules by various cells may lead to variable, 
even false conclusions. Clonal assays abolish most of these problems. Today such 
clonal assays have been optimized with help of lab-on-a-chip microfluidic culture 
devices that allow continuous observation (Faley, Copland et al. 2009; Wlodkowic, 
Skommer et al. 2009; Lecault, Vaninsberghe et al. 2011) yet the number of off-the-
shelve products is limited.  
 
The problem with many scaled-down bioreactors lies in the fact that upon 
proliferation cell density increases. This not only prevents long-term single-cell 
tracking but may also influence cell fate as known for many primary cell types 
(Baksh, Zandstra et al. 2007; Kirouac, Madlambayan et al. 2009; Lee, Kim et al. 
2013; Vaquette, Ivanovski et al. 2013). For this project a gas-perfusable clonal read-
out was established that provided both high-throughput imaging on single-cell 
resolution and long-term cultivation without reaching confluence. However, in order 
to study cell-cell interactions, culture devices still require improvement. Perfusion 
culture by membrane separation (Lecault, Vaninsberghe et al. 2011; Ratcliffe, Glen et 
al. 2012) ensures continuous availability of fresh media and other than static 
conditions or serial dilutions reduces accumulation of cytokines and medium 
degradation products that may selectively affect cell fate. The rather static conditions 
used in this work therefore could show different results when compared with dynamic 
culture conditions. Such work is required to rule out cell extrinsic factors produced by 
other cells and simultaneously study the effect of self-produced cytokines or 
extracellular matrix proteins to create a local environment.  
 
On the other hand, increasing cell density is another problem, which needs 
further strategic development in order to study the influence of cell-cell interactions in 
suspension culture. The fact that clinical studies focusing on human HSPC expansion 
showed a positive correlation of HSPC expansion with increasing cell density 
(Zandstra, Eaves et al. 1994), shows low density suspension culture and can even 
prove beneficial. The accompanied reduction of oxidative stress may also play a role 
in selective apoptosis or lineage production. Recent developments in protein stamping 
(Rottgermann, Alberola et al. 2014) and microwell structures by soft lithography 
(Chen, Li et al. 2011) could be of interest in studying cell-cell interactions, permitting 
or inducing migration with their effect on maturation and specialization. Combining 
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this with titrated perfusion and cytokine addition would encompass many 
requirements to study both cell intrinsic and extrinsic factors. Such a device has 
recently been developed and not only enables these features but also could be used to 
follow up development of genealogy and perform daughter separation by cell trapping 
(Frank and Tay 2013). Although so far no work on primary cells has been published, 
preliminary results obtained with cell lines show robust methodology and should be 
of interest to study HSC fate and function. 
 
Different media conditions allow for different lineage production and 
maturation. Testing of different media conditions in this work led to different 
outcome in terms of apoptosis, survival and lineage production. Although not the 
main focus in this thesis, these results proved reproducible and could be of future 
interest to study potential selective effects of cytokines. However, to increase 
efficiency in high-throughput screening, reduction of high numbers of apoptotic 
events was desirable. Simultaneously, high apoptosis rates as well as exclusion of 
development of certain lineage subsets could indicate a selective mechanism (Enver, 
Heyworth et al. 1998; Josefsen, Blomhoff et al. 1999; Rieger, Hoppe et al. 2009; 
Mossadegh-Keller, Sarrazin et al. 2013) and the development of pre-biased cells 
would not be read out. To reduce this occurrence and its complexity when it comes to 
cell-cycle specific lineage production, medium supplements were chosen that were 
permissive for the development of all mature lineage subsets and had an overall low 
occurrence of apoptosis. Furthermore, media conditions that resulted in early 
detection of lineage subsets were favored because 1) this drastically reduced workload 
by avoiding media refreshment, which on itself could also affect lineage production 
and 2) an earlier observed effect on differentiation could be better correlated with 
initial cell-cycle phase. For these reasons, media supplements were chosen, based on 
previously published methods that allowed high and early prevalence of all mature 
myeloid lineage subsets (Takano, Ema et al. 2004). Again, comparison of results in 
perfusion culture to ensure optimal medium conditions will need to be performed and 
used concentrations require further titrations to point out efficiency and validity of 
cytokine function. 
  
 Culture conditions without co-culture with stromal cells were chosen to 1) 
relate lineage production to added rather than secreted cytokines and molecules and 2) 
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improve optical quality and ability to follow HSC behavior and cell-cycle durations 
over time. However, the lack of lymphoid maturation poses the question whether 
culture conditions could be further optimized to read-out lineage potential. Addition 
of interleukin-7 would most likely ensure that lymphoid cells could be produced. 
However, lymphoid cells require much longer developing and detection of these cells 
only occurs at later stages, similar to in vivo repopulation kinetics. The strong 
proliferation observed under these media conditions in in vitro culture (104 to 105 
cells after 14 days), points to the necessity of multiple instances of media refreshment 
and usage of large incubation devices. Since the aim was to explore multilineage 
production in relation to cell-cycle, lymphoid reconstitution was omitted from the 
scope of this thesis. Nevertheless, the detection of all myeloid lineage subsets in vitro 
has been correlated with in vivo multilineage (including lymphoid) reconstitution 
potential (Takano, Ema et al. 2004), allowing a bridge to HSC functionality, although 
ultimately transplants would be required to prove this point. 
 
 The data presented in this thesis shows lower clonal multilineage production 
when compared with published data. On one hand, this could be explained by the fact 
that certain media supplements such as insulin or transferrin were not added since this 
reduced the amount of variables that could influence cell fate. On the other hand, in 
this work cells were pre-incubated for 24 hours and cytokines were added then rather 
than immediately after isolation. Although the pre-incubation medium should 
maintain multipotency for the majority of the cells, it could well be that this affected 
lineage potential after further addition of permissive cytokines. Taking into 
consideration however that the majority of the cells at 24 hours no longer reside 
within G1-phase (>70%), cytokine addition may have different effects when compared 
to freshly isolated cells that all pass G1-phase when receiving permissive cytokines. 
Together, this might explain the reduced potential but for the scope of this work this 
effect was less relevant since comparisons were made with control cells not receiving 
permissive cytokine addition. Furthermore, the megakaryocyte producing potential 
was not undermined by pre-incubation. 
 
 The time-point at which end-point lineage production was assessed is derived 
from LTC-IC data, both published (Kerst, Slaper-Cortenbach et al. 1992; Verfaillie 
1992; Smith, Bender et al. 1993; Verfaillie 1993; Henschler, Brugger et al. 1994; 
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Petzer, Hogge et al. 1996) and established in this lab. Considering the in vivo 
longevity of lineage subsets (~5-6 days for neutrophils/granulocytes, 100-120 days for 
erythrocytes, ~60 days for macrophages and 7-10 days for megakaryocytes) this 
however does not mean that in vitro lifespan compare. Optimal detection for all 
lineages including erythrocytes was found between day 12 and 14 for freshly isolated 
HSCs. Including pre-incubation time of 24 hours, cells were therefore analyzed 13 
days after permissive cytokine addition, i.e. 14 days after isolation. This work offers a 
comparison after 14 days of culture. It must be said that earlier lineage commitment, 
maturation and even apoptosis of different lineage subsets cannot be excluded, as well 
as lineage production after this time-point. Ideally, multiple time-points or continuous 
time-lapse imaging would provide such more in-depth information about proliferation 
kinetics and dynamics of lineage production. This would also shed light on lineage 
potency at different stages in genealogy, yet the exact point of lineage decision was 
beyond the scope of this thesis. 
 
5.2 Cell-cycle and its role in lineage production 
 
The quest of inducing specific lineage subsets has been an equal struggle as the 
quest to understand how it occurs. Indeed, with in-depth knowledge about the 
mechanism, lineage decision can be orchestrated with higher efficiency. For a long 
time it has been hypothesized and assumed that cytokines can induce different cell 
fates, depending on the cell-cycle phase they act on. Moreover, it has been postulated 
that certain cytokines might only function within certain cell-cycle phases. This thesis 
provides evidence that such relations indeed exist and simultaneously provides a 
robust method for future research that allows direct quantitation of cytokine-specific 
and cell-cycle phase-specific effects. 
 
Many cells that undergo differentiation reside within G1 phase, based upon their 
DNA content. Furthermore, forced cell-cycle inhibition through ectopic expression of 
CKI, was found to not only lead to up-regulation of differentiation markers but also 
induce differentiation into muscle cells (Shih, Tevosian et al. 1998), shown to 
enhance nerve growth (Erhardt and Pittman 1998) and was shown to be essential for 
erythroid differentiation (Tamir 2000). In these studies, however, cells were already 
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within a mature, less potent stage and thereby could not show that cytokine induced 
lineage production was related to cell-cycle phase earlier in genealogy and hierarchy. 
To be able to link lineage production to cell-cycle, clonal identity needs to be 
preserved and visualization of cell-cycle is required. This is challenging in many 
vertebrate systems, in which in vivo imaging resolution is limited and the number of 
possible serial time-points is often restricted. Recently, the successful FUCCI-based 
mouse model has been translated to zebrafish, which due to its optical clarity may 
facilitate continuous cell-cycle quantification in vivo (Sugiyama, Sakaue-Sawano et 
al. 2009). 
 
Studies on astrocyte function, proliferation and function have revealed that 
niche-specific interaction and location during cell-cycle are essential for future cell 
fate in terms of differentiation (Pilz, Shitamukai et al. 2013). In addition, cell-cycle 
specific up-regulation of different genes were found to be correlating with and 
directing differentiation (Robel, Bardehle et al. 2011; Bardehle, Kruger et al. 2013). 
Yet the in vivo abundance of extracellular signaling pathways often form 
compensatory mechanisms that make it hard to relate cytokine function and cell-cycle 
to cell fate. For most of these cell types, controlled cultivation in an in vitro setting is 
difficult and results are often skeptically interpreted as artifacts. Since the majority of 
the in vivo hematopoietic system has a non-adherent character, in vitro cultivation has 
been very well established and media supplements such as cytokine concentrations 
have been optimized to ensure optimal culture conditions. Despite studies on gene 
profiling during proliferation in HSPCs (Passegue, Wagers et al. 2005), to date still 
little is known about cytokine function in various cell-cycle phases and how this 
relates to cell fate. 
 
The observation described in this thesis that GemM lineage production is 
mainly derived from G1-phase cells at the time of permissive cytokine addition 
whereas megakaryocytes are mostly produced from S/G2-phase cells is the first direct 
evidence on a clonal basis that cytokines added at different cell-cycle phases can 
induce diverging cell fates. However, this does not occur with 100% penetrance, i.e. 
lineage production is not cell-cycle exclusive. One reason previous work could not 
show the same results on a clonal basis, might be that cell-cycle phases were based on 
population-based distributions and could not be assessed live on a single-cell 
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resolution (Colvin, Dooner et al. 2007). S/G2-phase cells also produce granulocytes, 
macrophages and indeed full GemM lineage albeit to a much lower extent. Hence the 
question arises whether these occurrences are really cytokine and cell-cycle 
dependent or if they are cell-intrinsic features, e.g. cells with a longer G1-phase have a 
higher probability of receiving permissive cytokine addition in G1-phase whilst 
having an increased intrinsic potential to develop full GemM lineage. Quantification 
of G1 phase duration during which the cells received cytokine signaling, an advantage 
of using time-lapse imaging, did not reveal a dependency on G1 phase duration and 
excluded such an effect to be caused by probability. The fact that the same effect can 
be observed when adding cytokines to daughter (generation 1) cells, independent of 
mother (generation 0) cell-cycle durations shows that this is a reversible feature that is 
maintained in progeny, yet does not prove or disprove a cell-intrinsic effect. To 
further explore this possibility, cells were forcefully pushed or retained in G1-phase 
using cell-cycle inhibitors. Although percentages of GemM production from G1-phase 
cells were not increased, strikingly, the absolute number of GemM colonies was 
indeed found higher after G1-phase enrichment, since the number of G1-phase cells 
was increased (~2 fold more) and G1-phase specific apoptosis was found to be only 
slightly higher (~10%). As a negative control, S/G2-phase cells show no effect of G1-
phase enrichment.  
 
The general higher occurrence of apoptosis in cells in G1-phase in generation 0 
could point to a potential selective lineage production, i.e. certain HSC subsets in G1-
phase that could be primed for specific lineages would not survive and hence the 
percentage of GemM lineage production could be an artifact. However, since GemM 
lineage production is actually increased for G1-phase cells, the loss of G1-phase cells 
could simultaneously indicate a loss of GemM lineage production. To circumvent this 
problem and study this theory, experiments should be performed in which apoptosis is 
abolished. Further directions could therefore be pointed towards use of purified HSCs 
from constitutively active bcl-2+/+ mice as a control, in which cells are no longer 
undergoing apoptosis. Furthermore, the stressful isolation steps and re-sorting of 
HSCs after 24 hours do not allow thorough adaptation to change of environment and 
it may be that G0 or G1 phase HSCs are more sensitive to signaling disruption. This 
has been shown in leukemic cell lines (Jedema, Barge et al. 2003) but remains 
inconclusive for primary HSCs. 
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When cytokines were added to daughter cells (generation 1) derived from G1-
phase enriched mother cells (generation 0), GemM production was again increased 
for G1-phase daughter cells. Although the observed effect is even stronger when 
compared with non-enriched control cells, the occurrence of apoptosis in generation 1 
is also increased, which could again point to potential selectivity. This data supports 
the hypothesis that indeed hydroxyurea treatment may push the cells in G1-phase, but 
the actual effect takes place during its next cell-cycle where it passes the G1-phase 
related different retinoblastoma phosphorylation stages. Previous studies have 
postulated that hydroxyurea arrests cell-cycle transition at a later G1-phase stage or 
indeed when early S-phase has already begun (Murciano, Zamora et al. 2002). If this 
is true, it could be that the G1-phase specific restriction point had already been passed, 
resulting in a potential lower frequency of GemM lineage production. After division 
of these cells their daughter cells can receive cytokine addition in G1-phase, which 
may occur at other stages that were no longer accessible due to hydroxyurea 
treatment. This is supported by data showing that protein-DNA interactions are lost 
upon S-phase specific dissociation and are re-established during G1-phase in which 
transcription factors and proteins controlling epigenetic mechanisms are re-associated 
(Blomen and Boonstra 2011). On the other hand, clinical studies that use hydroxyurea 
to induce erythroid differentiation have also shown that subpopulations undergoing 
stress response adaptation are less prone for apoptosis while having a higher potential 
to develop mature erythrocytes (Pourfarzad, von Lindern et al. 2013). GemM lineage 
production would still be more efficient when using hydroxyurea for G1-phase 
enrichment but experiments with use of a constitutively active bcl-2+/+ mouse model, 
which would reduce the hydroxyurea induced apoptosis (Liu, Aiello et al. 2012), are 
required to study a potential selective effect. 
 
G1-phase transition is mainly controlled by the phosphorylation state of 
retinoblastoma in which p18 and to a lower extent p16 are normally involved in 
inhibition of the cyclin D / CDK4-6 activity. First experiments with a p16 double 
knockout model in C57Bl/6 mice yielded no ablation of GemM lineage production, in 
fact no effect on lineage detection could be observed (not shown). This again 
demonstrates that the G1-phase stage in which cytokines are received and act upon in 
order to make lineage decision may not be within early G1-phase in which cell-cycle 
entry takes place. In line with this is the fact that multipotent progenitor cells are also 
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capable of producing GemM lineage, albeit to a lower extent. Since these cells 
generally have a faster cell-cycle, it does not seem farfetched that the time-frame in 
which the cytokines can act is shorter and this causes a lower yield of GemM 
colonies.   
 
An in vitro read-out that could predict lineage production and multipotency 
would facilitate both clinical therapies as well as many other scientific approaches 
such as daughter cell comparison, studying stem cell maintenance and expansion, 
asymmetric cell divisions and gene profiling. Current read-outs such as cobblestone 
formation or colony assays provide end-point information about potency but do not 
allow usage of cells before lineage commitment. To date many models exist; 
however, a prediction model on the HSC level has not yet been succeeded (Glauche, 
Cross et al. 2007; Loose, Swiers et al. 2007; Kirouac, Madlambayan et al. 2009; Marr, 
Strasser et al. 2012; Teles, Pina et al. 2013). Prediction of cell fate through cell-cycle 
phase progression has been successful in pluripotent cell lines that could show a 
correlation of G1-phase elongation with development into neural stem- and progenitor 
cells (Roccio, Schmitter et al. 2013) or G2-phase elongation to be essential for in vivo 
neurulation (Ogura, Sakaue-Sawano et al. 2011). In general differentiation and 
purification of pluripotent stem cells can be achieved by selection and manipulation 
of G1-phase durations (Calder, Roth-Albin et al. 2013; Coronado, Godet et al. 2013; 
Pauklin and Vallier 2013). Although differentiation into specific lineages in the 
hematopoietic system has also been correlated with G1-phase elongation (Furukawa, 
Kikuchi et al. 2000; Hsieh 2000; Tamir 2000; Munoz-Alonso, Ceballos et al. 2012), 
this has never been shown in multipotent cells upstream in the hierarchy. In this study 
not only does initial cell-cycle phase seem to correlate with end-point lineage output, 
continuous time-lapse imaging also revealed lineage-specific cell-cycle phase 
durations and cell division times. Although not providing a prediction model on itself, 
when combining different features, lineage-specific behavior could in the future prove 
to be mutually exclusive. The GemM specific longer G1-phase in daughter cells 
(generation 1) together with the overall symmetric division times for kinship and the 
higher prevalence of G1-phase in their ancestry (generation 0) would with the current 
status already exclude the development of granulocytes which ancestors have an 
overall shorter G1-phase and S/G2-phase while having a higher occurrence of 
asymmetric daughter cell lifetimes. Megakaryocytes on the other hand have highly 
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symmetric daughter cell lifetimes while having significantly shorter G1-phase 
durations and are more prevalent in S/G2 phase during generation 0. With more in-
depth cell-cycle analysis of these characteristics, e.g. with another cell-cycle reporter 
such as PCNA that allows a more qualitative cell-cycle analysis, combined with 
morphological features and with higher temporal resolution, these results provide 
future directions that could ultimately predict lineage commitment in early in vitro 
cell divisions.  
 
The effect of GM-CSF on megakaryocyte development has been contradictory. 
Here, addition of GM-CSF reduced GemM lineage production whilst increasing 
megakaryocyte production from S/G2-phase cells. However, apoptosis was 
significantly increased for G1-phase cells when compared to control cells without 
GM-CSF addition. The fact that changing of media conditions towards GM-CSF 
resulted in much higher apoptosis indicates the beneficial permissive conditions, 
albeit even under these culture conditions selective apoptosis cannot be excluded. 
Furthermore, GM-CSF on itself increased apoptosis in S/G2-phase cells, in contrast to 
addition to permissive conditions. Together this hints towards a potential synergistic 
effect with other cytokines. The mixture of cytokines present in permissive conditions 
could provide stronger competition when considering binding affinity and could 
potentially have a conflicting effect in signaling pathway activation. More work is 
still required to unravel the complex signaling network topology involved. 
 
Following in vivo studies (Asami, Pilz et al. 2011) and work on leukemic cell 
lines (Matsumura, Ishikawa et al. 1997) that correlated cell-cycle specific gene up-
regulation to be essential for differentiation in progeny, signaling pathway activation 
in in vitro cultivated HSCs was quantified. Initial experiments showed cell-cycle 
phase heterogeneity in the activity of four different signaling pathways. PI3K had 
been previously described to be necessary to transit through cell-cycle and indeed was 
found to be active in >90% of the cells. With the prospect of exploring cell-cycle 
specific activity, mCHERRYPSLD expressing cells were fixed and imaged before 
staining with antibodies specific for phosphorylated signaling pathways. This 
experimental setup was not ideal since fixation caused a significant drop in cell-cycle 
reporter levels, which hampered clear detection and quantification. Imaging of cells 
prior to fixation led to loss of cell identity after staining of activated signaling 
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pathways. Although ambiguous cells and cell-cycle states were not counted, future 
work should further improve this method, preferably using live biosensors. Such work 
has already been performed in cell lines and progenitor populations but not in HSCs 
and is further complicated by the need of serum starvation (Haugh, Codazzi et al. 
2000). Live methods would furthermore facilitate correlation with future cell fate. 
Overall, none of the signaling pathways showed cell-cycle phase-specific activity. 
When comparing absolute levels however, both p38 and Src had reduced activity in 
G1-phase when compared with PI3K. p38 is known to be important for 
megakaryocyte development, whereas Src has been implied to be essential for 
macrophage development (Melemed, JW et al. 1997; Whalen, SC et al. 1997; 
Fichelson and Freyssinier JM 1999; Jacquel, Herrant et al. 2006; Bourgin-Hierle, 
Gobert-Gosse et al. 2008; Kaminska, Klimczak-Jajor et al. 2008; Severin, Ghevaert et 
al. 2010). Despite these first hints for correlation with potential lineage commitment, 
no clear pattern could be observed yet.  
 
The capacity to induce more than a 10,000 fold increase in HSC numbers within 
2 weeks of culture without a potential risk of leukemia made NA10hd revolutionary 
in the field of blood stem cell biology. Both the necessary proliferation rate as well as 
the co-localization of NA10hd with p300 led to the hypothesis that NA10hd may have 
an impact on cell-cycle and cell lifetime. To date, little is known about the in vitro 
NA10hd-specific behavior, and even proliferation rates on a clonal level did not shed 
light onto the potential mechanism of NA10hd-induced in vitro HSC expansion. Here, 
evidence is presented for the first time that different subsets within the NA10hd+ 
compartment exist and can be separated according to cell lifetime: cells with longer 
lifetimes are more abundant in NA10hd+ populations compared with mock-infected 
control cells. Furthermore, by comparing progeny with ancestry over multiple 
generations, these features were shown to be inheritable. Simultaneously however, 
NA10hd+ cells with a faster cell-cycle were equally derived from mother cells with a 
faster cell cycle, together pointing to the gradual exhaustion of slow cycling 
NA10hd+ cells. Indeed, after several days, these differences are no longer detectable. 
This shows again the strength of single-cell continuous time-lapse observation and 
that read-out of created pedigree-based data provides much more information when 
compared with bulk population-derived data.  
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Recently, NA10hd has been found to induce a fetal liver HSC phenotype. This 
lineage- Ly6A/E+ CD117+ CD43+ CD11bdim population contained the majority (25-
50%) of in vitro expanded HSCs with in vivo repopulation capacity. Since original 
studies were performed with bulk populations containing ~1% HSCs and recent 
published data has shown a higher number of CRU containing wells than initially 
purified and clonally seeded, the potential of early multipotent progenitor cells to 
induce such a phenotype was assessed in this study. Surprisingly, only HSCs were 
susceptible to acquire such a phenotype. This however does not mean that none of the 
multipotent progenitors were capable of forming in vivo CRUs; it may well be the 
case that they attain a different phenotype. Indeed, not all cells possessing a fetal liver 
phenotype were capable of in vivo repopulation, neither did all HSCs express such a 
phenotype (Sekulovic, Gasparetto et al. 2011). Furthermore, suggested by their data, 
the NA10hd mechanism to induce HSC expansion may even be caused by an induced 
self-renewing and repressed differentiation onset in multipotent progenitors. The fact 
that addition of thrombopoietin drastically reduces such a phenotype whilst 
simultaneously abolishing repopulation potential makes it of future interest to 
compare these populations and quantify their dynamics of marker expression, ideally 
through time-lapse imaging, in order to define their behavior. 
So far, only Sca-1 was observed to be strongly retained on NA10hd+ cells in 
comparison with mock-infected control cells. Nevertheless, expression levels through 
quantification did not show any correlation with NA10hd expression nor with cell 
lifetime of these cells (not shown). 
 
This data is derived from liquid culture in which many cells were not 
effectively transduced with NA10hd. The lineage marker repression and the 
acquisition of a fetal liver phenotype in many of the non-transduced cells points to a 
paracrine effect, either through cell-cell signaling or by secretion of extracellular 
proteins and soluble molecules. This effect has not been previously described, 
possibly due to the different and highly efficient transduction protocols used by other 
labs that reach >95% transduction efficiency. Although this paracrine effect can be of 
interest on itself, one may not exclude the effect of non-transduced cells on NA10hd+ 
cells: HSC expansion may be effectively altered by cells producing mature lineage 
subsets or secreting and expressing different molecules than NA10hd+ cells. Initial 
colony assays after 2 weeks of in vitro culture however showed a high prevalence of 
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blast and GemM lineage producing cells, indicating their immature nature and 
multipotency, respectively (not shown).  
 
To further investigate the influence of environment and cell-cell contact as well 
as to mimic the in vivo niche influence on NA10hd cells, a stromal co-culture was 
established with PA6 cells. These cells are known to be able to maintain stemness in a 
proportion of cells (Kodama, Amagai et al. 1982; Kodama, Nose et al. 1992) and due 
to their optical clarity and contact inhibition, offer a good platform to study NA10hd+ 
cells behavior. Interestingly, NA10hd cells were shown to have a much longer cell 
lifetime for dividing cells in both early and late generations which was dependent on 
their adherent state: cells that were underneath the stroma had a longer cell-cycle 
when compared with cells that had a shorter stromal residency. This indicates that a 
NA10hd+ cell-PA6 interaction rather than secreted molecules causes the extension of 
cell lifetime. Whereas mock-infected control cells contain a subpopulation retaining 
this long lifetime in early generations, these are no longer present in later generations. 
Since PA6 cells can maintain stemness over multiple days, it could well be that this 
property is lost after multiple days of culture. This is supported with the faster onset 
of CD48, an in vitro progenitor marker in mock-infected control cells when compared 
with NA10hd cells. In later generations, however, a proportion of NA10hd+ cells also 
expresses CD48.  
 
PA6 cells express CXCL5 ligand, which functions as a chemoattractant. 
CXCL5 binding is known to repress megakaryocyte development. After 6-7 days of 
PA6 co-culture, mock-infected control cells produce megakaryocytes (Supplemental 
movie 3 and 4). After 7 days of culture, NA10hd cells had not developed any 
megakaryocytes. If their increased motility when underneath PA6 stroma is indeed 
caused by increased binding of the chemoattractant CXCL5, this would support this 
finding and is in line with improved homing of HSCs in vivo (Yoon, Cho et al. 2012). 
Preliminary marker screens performed prior to these observations indicated an 
increased expression of CXCR4, which belongs to the same family of proteins. 
Further experiments to support and test this hypothesis will need to be performed in 
future work as well as transplantations to correlate to HSC functionality. On the same 
line this could imply that these cells favor stroma residency whilst up-regulating 
integrin expression that allows for the higher motility found in NA10hd cells. On the 
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other hand, these cells may in fact seek ways to exit cell-cell contact. This, however, 
is unlikely since all cells gradually favor to be underneath stroma, even when cultured 
in lower stroma co-culture densities. 
 
The two different environments covered by this thesis thus provide two 
different read-outs. Whereas longer cell lifetime for dividing cells in liquid culture 
could indicate a less active NA10hd-induced fetal liver HSC cycling, the longer 
lifetime found when cultured on PA6 stroma could indicate retention of stemness or 
repression of differentiation. Transplantations after clonal PA6 stromal co-culture 
combined with time-lapse imaging could test these hypotheses.  
 
5.3 Scientific contribution 
 
In this thesis, I have provided new discoveries on two different subjects that 
both involve definition of in vitro HSC behavior. Live quantification of cell-cycle 
phase duration in HSCs showed that even highly purified stem cells transit through 
cell-cycle in a highly heterogeneous fashion over multiple generations when receiving 
the same media supplements. Furthermore, the discovery of lineage-choice behavior 
with respect to cell-cycle stage on a single-cell resolution had not yet been achieved 
and here I showed concrete evidence that such a correlation can exist. This could have 
both clinical and scientific implications when HSC expansion without multilineage 
potential loss is required. On one hand HLA competent cells could be more 
specifically directed to increase specific lineages ex vivo or purification could be 
enhanced through selection in short-term culture. This could be of interest for 
potential clinical applications where patients are depleted with certain mature lineage 
subsets or require long-term contribution for all lineages, as is the case with HSC 
transplantations. With future work still required, this would also provide new insight 
in the underlying mechanisms and factors that influence cell fate decisions and could 
be useful for therapies that cope with disruption of these mechanisms in 
hematological diseases. On the other hand, scientific research could benefit from the 
results provided in this thesis, not only because HSC and lineage-specific behavior 
could be determined but also because this assists future predictive models regarding 
lineage potential that, when functional, could reduce workload and necessity of long-
! 107!
term in vitro assays. In fact, the robust read-out provided, using continuous cell-cycle 
quantification and clonal multilineage production, can easily be translated to other 
long outstanding questions such as asymmetric cell division, cell type specific 
morphological and behavioral characteristics, HSC maintenance under co-culture or 
cytokine instructed differentiation, allowing a deeper in-sight towards cell-cycle 
dynamics of these cells and provide a stepping stone to fully understand HSC biology.  
 
The results I’ve provided here from the NA10hd project show for the first time 
that different NA10hd+ subsets exist with respect to cell lifetime and that to a certain 
extent these properties are inheritable, yet only become visible when using time-lapse 
imaging that allows following their cellular genealogy and inferring inheritable 
properties and their relation to their ancestry. The improved motility of these cells as 
well as the influence of NA10h cell-PA6 cell interactions furthermore provide new 
insights in NA10hd behavior and forms first steps towards in vivo translation and a 
deeper understanding of the requirements of HSC expansion. 
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7 Supplemental movie legends 
 
 
Supplemental movie 1. Live cell-cycle time-lapse imaging in transduced NIH3T3 cells 
after 48 hour pre-incubation. 10x Fluar objective and 0.63x Tv adapter. 
 
Supplemental movie 2. Live cell-cycle time-lapse imaging in transduced primary 
HSCs after 24 hour pre-incubation. 10x Fluar objective and 0.63x Tv adapter. 
 
Supplemental movie 3. Live cell-cycle time-lapse imaging in transduced primary 
HSCs after 24 hour pre-incubation in PA6 stroma co-culture. Zoomed in to single-cell 
resolution in slow-motion and using fast-forward to indicate colony formation during 
1 week of in vitro culture. Wavelength 1 (middle) shows VENUSnucmem signal and 
Wavelength 2 (right) shows onset and detection of CD48 by antibody staining. 10x 
Fluar objective and 0.63x Tv adapter. 
 
Supplemental movie 4. Live cell-cycle time-lapse imaging in transduced primary 
HSCs after 24 hour pre-incubation in PA6 stroma co-culture. Zoomed in to single-cell 
resolution showing megakaryopoiesis during 1 week of in vitro culture. Wavelength 1 
(middle) shows VENUSnucmem signal and Wavelength 2 (right) shows onset and 
detection of CD48 by antibody staining (negative). 10x Fluar objective and 0.63x Tv 
adapter. 
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